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8Chapter 1
AN INTRODUCTION TO CANCER
The first description of cancer dates back to around 3000 BC and consisted of a papyrus 
describing different kinds of tumors and ulcers of the breast for which no treatment existed. 
At that time, though, it was not called cancer. The Greek physician Hippocrates (460-370 
BC) coined the word carcinos – meaning crab – to describe tumors, which has later been 
replaced by the Latin word for crab: cancer. Tumors, which are basically lumps of cells in 
the body, can be benign or malignant. Nowadays, the word cancer is no longer used to 
describe all tumors; only malignant tumors are defined as cancer.
Hallmarks of cancer
Various types of cancer exist, depending on the cell of origin. Hanahan and Weinberg in 
2000 described six hallmarks of cancer; these were hallmarks that all types of cancer had 
in common. These included sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis [1]. Progressing knowledge has led to a revision of the hallmarks 
of cancer and four new hallmarks were added in 2011: deregulating cellular energetics, 
avoiding immune destruction, genome instability and mutation, and tumor-promoting 
inflammation [2], see figure 1. Together, these hallmarks lead to the development and 
progression of cancer.
Figure 1. The ten hallmarks as defined by Hanahan and Weinberg. Figure adapted from Hanahan & 
Weinberg, Cell 2011. The six hallmarks depicted in black are the hallmarks described in 2000. In 2011, 
the hallmarks were revisited and four additional hallmarks (depicted in blue) were added.
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Cancer-driving mutations
Normal cells can transform into tumor cells by accumulating several mutations. Examples 
are mutations in proto-oncogenes and tumor suppressor genes. Proto-oncogenes drive 
cell proliferation, and upon altered or constitutive activity (gain of function) they become 
oncogenes and may lead to tumor development (hallmark: sustaining proliferative 
signaling). Examples of oncogenes are MYC, a transcription factor inducting cell proliferation, 
mutated tyrosine kinases of the Ras signaling pathway such as HRAS, KRAS, and BRAF, and 
growth factor receptors such as epidermal growth factor receptor (EGFR) and vascular 
endothelial growth factor receptor (VEGFR). Tumor suppressor genes on the other hand 
prevent cell growth and division, so inactivation or deletion (loss of function) of both copies 
of the tumor suppressor gene can lead to uncontrolled cell division (hallmark: evading 
growth suppressors). Frequently mutated tumor suppressor genes include RB1, encoding 
retinoblastoma 1, and TP53, encoding tumor protein 53. Rb and p53 are both regulators 
of the cell cycle, preventing the cell from entering the S phase until it is ready to divide [3].
Stages of cancer
In the early stages of cancer, the tumor is confi ned to one local site. It becomes malignant 
once it starts to invade surrounding tissue. When the tumor progresses, individual tumor 
cells may travel via the lymphatic system to the lymph node and develop into regional a 
metastasis or travel further to develop metastases at distant organs. These diff erent stages 
of tumor progression are classifi ed as stage I-IV, in which in general stage I-II represent 
localized cancer, stage III includes regional metastases and stage IV distant metastases. 
Survival rates - although greatly varying between cancer types - decrease with each stage, 
with most cancer patients dying from metastatic disease.
Cancer treatment
Various cancer treatments have been developed over the years, and the type of treatment 
depends amongst others on the stage of cancer. When the tumor is locally confi ned, the 
tumor is often surgically removed. Radiotherapy is the second treatment option which is 
often used in early stage tumors, for example when a patient is unfi t for surgical treatment 
or the tumor is in a location that is diffi  cult to reach. Radiotherapy acts via the induction 
of DNA damage, eventually leading to death of tumor cells. Another class of cancer drugs 
are chemotherapeutic agents that have been developed since the 1950s and are usually 
administered systemically to treat cancers that have already spread to lymph nodes or 
other organs. Chemotherapy aff ects all dividing cells in the body, and hence has signifi cant 
side eff ects. Increased understanding of the molecular changes in cancer cells has led to 
the development of targeted therapies since the 1970s. These therapies specifi cally target 
certain genomic alterations or pathways, such as the oncogene EGFR which is frequently 
1
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mutated in lung cancer and thereby driving cancer growth. Inhibiting aberrant EGFR 
signaling by small molecules can inhibit tumor growth [4]. Lastly, next to direct tumor cell 
killing as induced by the previously mentioned strategies, immunotherapy has emerged as 
a new treatment modality over the last decades. Immunotherapy focuses on activating the 
patient’s own immune system to eradicate the tumor, aiming to reverse the hallmarks of 
evading immune destruction and tumor-promoting inflammation. This treatment strategy 
is discussed in more detail later in this chapter.
THORACIC MALIGNANCIES
This thesis focuses on thoracic malignancies, which include lung cancer and mesothelioma. 
Lung cancer has the highest cancer mortality worldwide, with an estimated number of 1.6 
million deaths in 2012 [5]. Two main classes of lung cancer are identified: small cell lung 
cancer, and non-small cell lung cancer. Below, the etiology, prevalence, prognosis and 
treatment of the two lung cancer subtypes and mesothelioma are discussed.
Small cell lung cancer
Small-cell lung cancer (SCLC) – also referred to as oat-cell carcinoma – was first discovered as 
being a type of lung cancer in 1926 [6]. It is a specific type of lung cancer with neuroendocrine 
properties and relatively poorly differentiated cells. This type of lung cancer accounts for 
12-15% of all lung cancer cases and is – compared to other subtypes – most strongly 
associated with smoking. The tumor suppressor genes RB1 and TP53 are inactivated in 
most SCLC cancers. SCLC is characterized by a high mutational burden and minor immune 
infiltrates. It is highly proliferative and metastasis generally occurs at an early stage, making 
it a particularly aggressive cancer. The five-year survival rate is around 1-5% [7]. Treatment 
opportunities have remained equal for several decades, but with increasing insights in the 
biology and a renewed interest in SCLC research over the last years, it is believed that clinical 
advancements will be achieved in the coming decade [6].
Non-small cell lung cancer
Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases, and can be 
divided in the subtypes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, 
depending on the originating cell type. As for SCLC, the main risk factor for NSCLC is 
smoking, with an estimated ~80% of cases to be caused by smoking. However, a growing 
proportion of non-smoking NSCLC cases is observed [8]. Treatment of NSCLC depends 
mainly on cancer stage. In early stage, localized NSCLC, most cancers are either surgically 
removed, or treated by stereotactic ablative body radiation (SABR), also called stereotactic 
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body radiation therapy (SBRT). The choice for either of these two treatments is made by 
the treating physician and the patient and is usually dependent on the overall fi tness of the 
patient and the location of the tumor. Despite the curative intent of these treatments, the 
majority of patients face a recurrence of the disease, often subsequently progressing to an 
advanced stage. The majority of patients are diagnosed with an advanced stage disease, 
when the tumor has already spread to the lymph nodes (regional spread, 22%) or other 
organs such as liver, bone or brain (distant spread, 57%) [9]. In these advanced stages of 
NSCLC, patients with specifi c gene mutations can be treated with targeted therapy (e.g. 
EGFR, anaplastic lymphoma kinase [ALK] or BRAF inhibitors), but most patients are treated 
with chemotherapy. In 2015, the fi rst immunotherapy for second-line treatment of NSCLC, 
the anti-PD1 checkpoint inhibitor pembrolizumab (see below) was approved by the FDA, and 
approval and use of this and other PD-1/PD-L1 inhibitors has been greatly expanded over 
the following years. Currently, in 2019, combination of chemotherapy + checkpoint inhibition 
is the standard fi rst-line treatment for advanced stage NSCLC patients without specifi c 
mutations, with low PD-L1 expression. In patients with high PD-L1 expression, either this 
combination or pembrolizumab monotherapy can be chosen as the preferred treatment.
Pleural mesothelioma
Pleural mesothelioma is a much rarer type of cancer than lung cancer and aff ects the 
pleural lining of the lungs. The yearly death rate is 3000 in the US and 5000 in Europe 
[10]. Mesothelioma is almost exclusively caused by asbestos exposure, with in general a 
lag time of 20-50 years between exposure and diagnosis. Asbestos use has been banned 
in many countries, but due to this long incubation time, the incidence is still increasing 
in most countries. Also, asbestos is still redundantly present in the western world as it is 
incorporated in buildings, water pipes, etc. Moreover, asbestos is still frequently used in 
for example Russia, China, Brazil and Kazakhstan [11]. Treatment options for mesothelioma 
are very limited, and median survival after diagnosis is less than one year [10]. As no 
known therapeutic targets are present in mesothelioma, patients are usually treated 
with chemotherapy but with modest improvement of survival. Mesothelioma can also 
develop from the peritoneum, in which case it is referred to as peritoneal mesothelioma 
or abdominal mesothelioma.
AN INTRODUCTION TO THE IMMUNE SYSTEM
The immune system protects our body from invading pathogens by distinguishing “self” 
from “non-self” and triggering immune responses when needed, but is also equipped to fi ght 
tumor development and progression. The innate arm of immunity is quick and less specifi c, 
1
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whereas adaptive immunity is slower, highly specific and able to induce ‘memory’, allowing 
a stronger and quicker response if the same pathogen is encountered again. Different types 
of immune cells exist and collaborate to induce an effective immune response, to inhibit 
immune responses if not needed, and to facilitate tissue repair. Immune cells of the myeloid 
lineage are mainly involved in innate immunity. These include granulocytes, monocytes and 
macrophages. Dendritic cells (DC), also from the myeloid lineage, form the bridge between 
innate and adaptive immunity by sampling from their environment and presenting antigens 
to T cells. Lymphoid cells include NK cells, T cells, B cells and innate lymphoid cells (ILCs). 
B cells and T cells are part of adaptive immunity and each cell is specific for one antigen. B 
cells produce antibodies recognizing the specific antigen (humoral response), while T cells 
use their T cell receptor to recognize specific antigens presented on major histocompatibility 
complexes (MHC) of a cell. Cytotoxic T cells (expressing CD8) kill infected or transformed 
cells presenting the specific antigen that the T cells recognize. T helper cells (expressing CD4) 
are needed to fully activate and differentiate B cells and cytotoxic T cells. Regulatory T cells 
on the other hand are suppressing immune responses. T cells are able to greatly expand in 
numbers once they are activated. They will differentiate from naïve to effector and memory 
T cell subsets. After the immune response subsides, part of the memory T cells will remain 
present, ready to respond quickly when the antigen reoccurs [12].
THE ROLE OF THE IMMUNE SYSTEM IN CANCER
Instead of just malignant cells, the tumor consists of a mix of different cell types, apart 
from tumor cells including stromal cells and immune cells. Together these cells create the 
tumor microenvironment (TME), of which the composition can greatly influence cancer 
progression and response to treatment [13]. In the updated version from Hanahan and 
Weinberg’s Hallmarks of cancer in 2011, two hallmarks were added indicating the role of the 
immune system in the development of cancer: the enabling characteristic of inflammation 
and the emerging hallmark of evading immune destruction [2]. These hallmarks show 
the paradoxical role of the immune system in cancer: inflammation enables the tumor to 
develop (pro-tumor immunity), while the tumor has to evade recognition and killing by the 
immune system (anti-tumor immunity). Indeed, different immune cells have been known to 
play opposing roles in relation to cancer. In Table 1, the effect of the presence/ number of 
various immune cells in the tumor or peripheral blood on the overall or progression free 
survival of cancer patients are summarized. While for some cell types their effects are clearly 
positive or negative, for some other cell types some controversy still exists in literature or 
their effect is dependent on cancer type. This list comprises a summary of meta-analyses 
and is by all means not complete, as there are many more individual studies describing 
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links between immune cells and clinical outcome in cancer. An example is innate lymphoid 
cells (ILCs), which are found to be present in the tumor environment and may contribute to 
both tumor growth and metastasis as well as anti-tumor immunity [14].
Table 1. Eff ect of immune cells on outcome of cancer patients, summary of meta-analyses
Immune cell eﬀ ect on 
outcome
tumor type blood/
tumor
reference
CD3 T cells positive various cancers 
(overall eff ect)
tumor Gooden et al. BJC 2011 [15]
positive NSCLC tumor Zeng et al. Oncotarget 2016 [16]; 
Soo et al. Oncotarget 2018 [17]
positive HNSCC tumor De Ruiter et al. 
OncoImmunology 2017 [18]
positive gastric cancer tumor Zheng et al. Oncotarget 2017 [19]
positive hepatocellular 
carcinoma
tumor Yao et al. Sci Rep. 2017 [20]
no eff ect esophageal cancer tumor Zheng et al. Cell Phys Biochem 
2018 [21]
CD4 T cells positive NSCLC tumor Zeng et al. Oncotarget 2016 [16]
no eff ect; 
stromal cells 
positive 
eff ect
NSCLC tumor Soo et al. Oncotarget 2018 [17]
questionable 
/ ambiguous
HNSCC tumor De Ruiter et al. 
OncoImmunology 2017 [18]
no eff ect gastric cancer tumor Zheng et al. Oncotarget 2017 [19]
no eff ect on 
OS; positive 
on RFS
hepatocellular 
carcinoma
tumor Yao et al. Sci Rep. 2017 [20]
no eff ect esophageal cancer tumor Zheng et al. Cell Phys Biochem 
2018 [21]
CD8 T cells positive various cancers 
(overall eff ect)
tumor Gooden et al. BJC 2011 [15]
positive triple negative 
breast cancer
tumor Ibrahim et al. Breast Cancer Res 
Treat 2014 [22]
positive NSCLC tumor Zeng et al. Oncotarget 2016 [16]
positive HNSCC tumor De Ruiter et al. 
OncoImmunology 2017 [18]
positive gastric cancer tumor Zheng et al. Oncotarget 2017 [19]
positive hepatocellular 
carcinoma
tumor Yao et al. Sci Rep. 2017 [20]
positive esophageal cancer tumor Zheng et al. Cell Phys Biochem 
2018 [21]
1
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regulatory T 
cells
negative breast cancer 
(overall)
tumor Jiang et al. BMC Cancer 2015 
[23]; Shou et al BMC Cancer. 
2016 [24]
negative cervical, renal, 
melanoma, breast, 
lung
tumor Shang et al. Sci Rep. 2015 [25]
negative NSCLC tumor Zeng et al. Oncotarget 2016 [16]
negative various cancers 
(overall effect)
tumor Shang et al. Sci Rep. 2015 [25]
negative hepatocellular 
carcinoma
tumor Yao et al. Sci Rep. 2017 [20]
no effect various cancers 
(overall effect)
tumor Gooden et al. BJC 2011 [15]
positive triple negative 
breast cancer
tumor Jiang et al. BMC Cancer 2015 [23]
positive colorectal, head and 
neck, esophageal
tumor Shang et al. Sci Rep. 2015 [25]
positive HNSCC tumor De Ruiter et al. 
OncoImmunology 2017 [18]
B cells positive NSCLC tumor Soo et al. Oncotarget 2018 [17]
positive gastric cancer tumor Zheng et al. Oncotarget 2017 [19]
NK cells positive NSCLC tumor Soo et al. Oncotarget 2018 [17]
positive gastric cancer tumor Zheng et al. Oncotarget 2017 [19]
positive esophageal cancer tumor Zheng et al. Cell Phys Biochem 
2018 [21]
TAM negative NSCLC tumor Soo et al. Oncotarget 2018 [17]
M1 macrophages positive lung cancer tumor Wu et al. Oncotarget 2016 [26]; 
Soo et al. Oncotarget 2018 [17]
M2 macrophages negative lung cancer tumor Wu et al. Oncotarget 2016 [26]
dendritic cells positive NSCLC tumor Soo et al. Oncotarget 2018 [17]
neutrophils negative various cancers 
(overall effect)
tumor Shen et al. PLoS ONE 2014 [27]
MDSC negative various cancers 
(overall effect)
blood Wang et al. OncoImmunology 
2018 [28]
NLR negative NSCLC blood Gu et al. Sci Rep. 2015 [29]; Yin et 
al. Clinics 2015 [30]
negative renal cell carcinoma blood Hu et al. BMJ open 2014 [31]
negative pancreatic cancer blood Yang et al. World J Gastroenterol 
2015 [32]
negative colorectal cancer blood Li et al. Int J Cancer 2013 [33]
negative various cancers 
(overall effect)
blood Templeton et al. J Natl Cancer 
Inst 2014 [34]
negative urinary cancers blood Wei et al. PLoS ONE 2014 [35]
PLR negative various cancers 
(overall effect)
blood Zhou et al. PLoS ONE 2014 [36]
LMR positive various cancers 
(overall effect)
blood Nishijima et al. Cancer Treatment 
Rev 2015 [37]
TAM = tumor associated macrophage; NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte 
ratio; LMR = lymphocyte-monocyte ratio; MDSC = myeloid-derived suppressor cell; NSCLC = non-
small cell lung carcinoma; HNSCC = head and neck squamous cell carcinoma
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The cancer immunity cycle
Besides protecting our bodies against invading pathogens, our immune system also 
recognizes transformed cells and prevents them from developing into a tumor. This has 
been described in a model posed by Chen and Mellman in 2013: the cancer immunity 
cycle (Figure 2) [38]. Cancer cells harbor various alterations compared to their healthy 
counterparts, which leads to tumor-specifi c or tumor-associated antigens. These antigens 
can be picked up by DCs, which upon activation travel to the tumor draining lymph node 
where they can activate T cells that are specifi c for that antigen, leading to proliferation and 
diff erentiation of T cells. Subsequently the T cell migrates via the blood to the tumor, where 
the cytotoxic T cells can recognize and kill the tumor cells. On the other hand, tumor cells 
may also accumulate mutations that increase their capacity to evade recognition by the 
immune system. They for example downregulate expression of tumor antigens to prevent 
recognition by the immune system or recruit immune suppressive cells such as regulatory 
T cells and myeloid-derived suppressor cells (MDSCs) [39] that are able to dampen the 
immune response.
Figure 2. The Cancer Immunity Cycle. Reprinted from Immunity, Volume 39 issue 1, Chen DS and 
Mellman I, Oncology Meets Immunology: The Cancer-Immunity Cycle, Pages 1-10, Copyright (2013), 
with permission from Elsevier.
1
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Immune surveillance
The recognition and destruction of transformed cells by our immune system is called 
immune surveillance. Three different stages of immune surveillance are described, the three 
E’s: elimination, equilibrium and escape. When the immune system recognizes and kills the 
transformed cells, the tumor is eliminated. However, if some tumor cells remain, they can 
accumulate additional mutations or other modifications to evade the immune response. 
In this equilibrium phase, there is a balance between the anti-tumor immune response 
and the evading capacity of the tumor cells. Over time, tumor cells with a survival benefit 
will grow out, which eventually may lead to escape, in which the tumor has overcome 
immune destruction and is able to grow and/or metastasize. Tumors may employ various 
mechanisms to escape immune destruction. Immune-deserted tumors for example, have 
prevented induction of a proper anti-tumor immune response by preventing priming 
or inducing tolerance or immune ignorance. Immune-excluded tumors have created an 
impenetrable or hostile tumor microenvironment, in which tumor-reactive immune cells 
cannot infiltrate. Lastly, if immune cells are able to infiltrate the tumor (inflamed tumor), 
they might be hampered or suppressed by a very immune suppressive microenvironment, 
caused by the presence of immune suppressive cells or the secretion or expression of 
various immune suppressive factors such as immune suppressive cytokines or inhibitory 
ligands.
IMMUNOTHERAPIES
Over the last years, scientific knowledge and interest in the role of the immune system 
in cancer has greatly expanded. These increasing insights have led to several treatment 
strategies actively targeting the immune system to combat cancer. Immunotherapeutic 
strategies can be divided in the following classes: monoclonal antibodies, checkpoint 
inhibitors, adoptive cell transfer, therapeutic vaccines, and other immunomodulatory 
compounds such as cytokines.
Monoclonal antibodies can be targeted against specific tumor antigens and induce tumor 
killing via several mechanisms. For example, they may induce antibody-dependent cellular 
toxicity (ADCC) or deliver an anti-cancer drug specifically to the tumor (antibody-drug 
conjugate; ADC). Furthermore, monoclonal antibodies might target components of the 
immune system that may in turn be activated, suppressed or recruited, thereby indirectly 
targeting the tumor.
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Checkpoint inhibitors are a class of compounds, which may also be monoclonal 
antibodies, that inhibit checkpoint molecules on T cells. These checkpoint molecules confer 
inhibitory signals to the T cell and hence act as a break on their activation. By inhibiting 
these receptors, T cells can be reinvigorated and thereby enhancing the anti-tumor immune 
response. Checkpoint inhibitors against cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4) and programmed death receptor (PD)-1 were the fi rst to be approved by the FDA and 
have revolutionized cancer treatment [40-42]. These checkpoint inhibitors are most eff ective 
in tumors with a high mutational burden and strong immune infi ltration (so called ‘hot’ 
tumors) [43-46].
Adoptive cell transfer uses immune cells – usually T cells – from a cancer patient, which 
are expanded and/or modulated ex vivo and subsequently transferred back into the patient 
to boost the immune response. For this treatment strategy, tumor-infi ltrating T lymphocytes 
(TILs) can be used, or T cells with a modifi ed T cell receptor to recognize a certain tumor 
antigen. Chimeric antigen receptors (CARs) are an example of such modifi ed receptor. These 
receptors consist of an antigen recognition domain and domains needed for the activation 
of the T cell. CAR T cells have been very successful in hematological cancers [47, 48].
The strategy of therapeutic vaccination aims to induce or boost the immune response 
against the tumor by exposing the immune system to tumor antigens. For vaccination 
purposes, whole tumor lysate, peptides or DCs can be used. DCs are the main antigen-
presenting cells and can be isolated from blood or cultured ex vivo from peripheral blood 
monocytes. They can be pulsed with peptides, proteins or whole tumor lysate, to present 
certain antigens on MHC class II or I, the latter via cross-presentation. Our research group 
has developed a DC vaccination strategy for malignant pleural mesothelioma using 
monocyte-derived DC pulsed with autologous mesothelioma tumor lysate. As only low 
numbers of T cells are present in most mesothelioma tumor tissues [49], and DCs are 
described to be reduced in numbers and functionality in mesothelioma patients [50], this 
strategy aimed to prime an anti-tumor immune response by delivering activated DCs pulsed 
with tumor cell lysate. This treatment has been shown to be eff ective in in vivo models [51], 
and has been shown to be safe in patients [52, 53]. In melanoma and other cancer types 
DC vaccination has shown promise as well, with strategies employing monocyte-derived 
DC or blood-derived DC [54-56].
Other immunomodulatory compounds include cytokines, for example IL-2 to enhance 
anti-tumor immune responses in melanoma and renal cell carcinoma [57, 58] and the use 
of oncolytic viruses that selectively replicate in and kill tumor cells [59].
1
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PRECISION MEDICINE AND COMBINATION STRATEGIES
Immunotherapy has been considered a major breakthrough in the treatment of cancer, 
with unprecedented responses [40-42]. However, despite long-lasting responses for some 
patients, the majority of cancer patients does not benefit from treatment with a single 
checkpoint inhibitor. Due to the heterogeneity and the adaptive ability of cancer, we should 
aim to target the tumor via multiple hits, sequentially or simultaneously, to further improve 
response rates and durability of responses. Combination treatment has received a lot of 
attention recently as becomes evident from published literature [60-64]. Furthermore, there 
is a dire need for reliable biomarkers that predict response to treatment, which will allow for 
a better choice of treatment for individual patients. Currently, treatment choices are mostly 
based on the patient’s tumor stage: radiotherapy and surgery for early stage cancers and 
systemic treatments in advanced stage cancer. The development of targeted therapies 
has introduced molecular characterization of the tumor to guide treatment strategies: 
the target mutation or target receptor should be present on the tumor subtype for the 
treatment to have its effect. For some checkpoint inhibitors, expression of PD-L1 acts as 
a biomarker, although its clinical value is still debatable [65]. Despite the efforts to find 
predictive biomarkers in recent years, most treatments are still prescribed with a ‘trial-and-
error’ approach, leading to potentially unnecessary treatments with accompanying side 
effects. Precision medicine aims to give the right treatment to the right patient, steered by 
an individual patient’s (disease) characteristics. Moreover, as the field moves more and more 
towards combinatorial treatment strategies, a better understanding of treatment effects 
and mechanisms of actions is needed to rationally design the most optimal combinations.
AIMS AND OUTLINE OF THIS THESIS
As new medicines are being developed, the number of potential combinations drastically 
increases. To test all potential combinations in clinical trials is not feasible, and therefore 
should be guided by solid preclinical data. In this thesis we aimed to increase our 
understanding of the role of the immune system and its clinical value in patients with 
thoracic malignancies during treatment. We monitored the effects of several conventional 
and experimental treatments on the immune profile of patients, and actively exploited the 
immune system to treat malignant pleural mesothelioma.
To monitor immune modulation by cancer treatment, either tumor or peripheral blood 
material can be used. Here, we mainly focused on immune cells from peripheral blood, for 
the following reasons. First, blood samples can be obtained from patients in a minimally 
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invasive way. This allows for serial collection of patient samples for monitoring responses 
over time. Blood samples can be obtained even if the tumor is macroscopically absent 
after treatment. Second, as cancer progresses and metastasizes, it can be regarded as a 
systemic disease. While tumor biopsies provide information on the local immune response, 
they are not able to capture the heterogeneity of the tumor and its metastasis, which may 
diff erentially respond to treatment [66]. We therefore believe that the peripheral blood 
represents the general immunological state of a patient and can provide valuable insights 
into the immune response.
In this thesis, we aimed to increase our understanding of the functional role and clinical 
value of the immune system and its dynamics in patients with thoracic malignancies, by 
monitoring immune populations in peripheral blood during treatment.
In chapter 2, we focused on an important immune suppressive population present in 
peripheral blood of cancer patients, of which their function is still largely unknown: MDSC. 
We studied their clinical value in advanced stage NSCLC patients treated with chemotherapy. 
Moreover, we further explored potential immune suppressive mechanisms by focusing on 
the inhibitory receptor immunoglobulin-like transcript (ILT) 3, known for its tolerogenic 
properties on DC. We assessed expression of ILT3 on MDSC in lung cancer patients with 
advanced disease before the start of chemotherapy and evaluated its eff ect on clinical 
outcome.
In chapter 3 and 4 we aimed to study the eff ect of conventional cancer therapies on the 
peripheral blood immune profi le, to address whether these therapies are able to activate 
or suppress systemic immune activation which may contribute to treatment response. We 
investigated both activation of T cells, as well as immune-suppressive cell populations. In 
chapter 3, we focused on NSCLC patients with an early stage of disease, who were treated 
with either surgery or radiotherapy, and assessed treatment eff ects on the induction of 
T-cell activation in the early post-treatment period. In chapter 4 we studied the immune 
modulatory eff ects of a chemotherapy/ anti-angiogenesis combination in NSCLC patients 
with advanced disease and examined whether these were related to clinical outcome.
With advancing techniques such as the increasing number of parameters that can 
be measured with fl ow cytometry novel immune cell subpopulations can be identifi ed 
and cell characteristics, including activation or exhaustion markers, can be analyzed in 
unprecedented detail. However, the amount of acquired data causes challenges for data 
analysis. In chapter 5 we evaluated the use of a novel computational method for the 
analysis of fl ow cytometry data for survival prediction, in our cancer immunology setting.
1
Pauline_Proefschrift.indd   19 29/11/2019   09:09:51
20
Chapter 1
Besides the role of the immune system in responses to conventional therapies, the immune 
system can be an active target for cancer therapy in emerging immunotherapy strategies. 
To boost an anti-tumor immune response, DCs can be cultured ex vivo and pulsed with 
tumor lysate. When administered to patients, these activated and mature DCs can induce 
an anti-tumor immune response. Earlier work by our group on DC vaccination has shown 
promise as a treatment for mesothelioma. However, the main limitation for scaling up this 
treatment was the use of autologous tumor material that not always provided sufficient 
material to pulse the DCs. Chapter 6 describes a first-in-human trial in which we designed 
an improved DC immunotherapy for patients with mesothelioma, overcoming this limitation 
by using allogeneic mesothelioma cell lines. We studied efficacy of this method in mice and 
assessed safety and feasibility of this therapy in patients.
In chapter 7 we further investigated the DC immunotherapy approach introduced in 
chapter 6, by studying immunological changes induced in these patients by treatment, to 
shed light on the mechanism of action of DC immunotherapy and to identify markers that 
are suitable for immune monitoring in upcoming DC immunotherapy trials. We asked which 
immune cell populations alter upon treatment and whether they are related to treatment 
response. In this study, we aimed to address both broad immune activation, as well as the 
specificity of the T cells.
The results of chapters 2-7 are summarized and discussed in the context of current literature 
in chapter 8. Furthermore, (clinical) implications and future directions of this research are 
discussed.
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IMMUNOGLOBULIN-LIKE TRANSCRIPT 
3 IS EXPRESSED BY MYELOID-DERIVED 
SUPPRESSOR CELLS AND CORRELATES 
WITH SURVIVAL IN PATIENTS WITH 
NON-SMALL CELL LUNG CANCER
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ABSTRACT
Myeloid-derived suppressor cells (MDSC) play an important role in immune suppression 
and are elevated under pathological conditions such as cancer and chronic inflammation. 
They comprise a heterogeneous population of immature myeloid cells that exert their 
immune suppressive function via a variety of mechanisms. Immunoglobulin-like transcript 
3 (ILT3) is a receptor bearing immunoreceptor tyrosine-based inhibition motifs (ITIM), that 
can be expressed on antigen presenting cells and is an important regulator of dendritic cell 
tolerance. ILT3 exists in a membrane-bound and a soluble form and can interact with a still 
unidentified ligand on T cells and thereby induce T cell anergy, Tregs or T suppressor cells. 
In this report, we analyzed freshly isolated mononuclear cell fraction from peripheral blood 
of 105 patients with non-small cell lung cancer and 20 healthy controls and demonstrate for 
the first time that ILT3 is expressed on MDSC. We show that increased levels of circulating 
monocytic MDSC and polymorphonuclear MDSC correlate with reduced survival. On the 
basis of ILT3 cell surface expression, an ILT3low and ILT3high population of PMN-MDSC could 
be distinguished. Interestingly, in line with the immune suppressive function of ILT3 on 
dendritic cells, patients with increased proportions of PMN-MDSC and an increased fraction 
of the ILT3high subset had a shorter median survival than patients with elevated PMN-MDSC 
and a smaller ILT3high fraction. ILT3 expressed on MDSC might reflect a previously unknown 
mechanism by which this cell population induces immune suppression and could therefore 
be an attractive target for immune intervention.
26
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INTRODUCTION
The immune system infl uences lung cancer pathogenesis, progression, and response to 
therapy and thereby strongly contributes to the prognosis of the disease [1]. The infl uence of 
the immune system is, however, paradoxical, as the diff erent components can either inhibit 
tumor growth or promote immune evasion and cancer progression [2]. In the latter process, 
myeloid-derived suppressor cells (MDSC) are an important contributor [3].
MDSC are a heterogeneous population of immature myeloid cells that accumulate in blood, 
lymphoid organs and tumor tissue under several pathologic conditions, including cancer [3, 
4]. MDSC are generally characterized by being CD33 and CD11b positive and HLA-DR low or 
negative [5]. This population can be divided in two subgroups with diff erent morphology. 
Monocytic (MO-)MDSC are mononuclear and CD14 positive, whereas granulocytic or 
polymorphonuclear (PMN-)MDSC are CD14 negative [3, 5]. Both populations contribute to 
tumor immune escape by inducing immune suppression and tolerance through a variety 
of mechanisms, such as production of nitric oxide and reactive oxygen species, arginine 
and cysteine depletion and induction of regulatory T cells [6-9]. However, their regulation 
and dynamics are poorly understood, especially in humans [10].
An important mediator in the induction of immune tolerance is the immunoglobulin-like 
transcript (ILT) 3 (also described as LILRB4, CD85k, LIR-5), which is expressed on monocytes 
and antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs) [11, 12]. 
ILT3 expression marks tolerogenic DCs and has been reported to be elevated in APCs of 
cancer patients [13, 14] and decreased in autoimmune diseases [15, 16]. ILT3 is believed 
to signal via its immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs 
are known to inhibit NF-κB activation and transcription of costimulatory molecules and 
thereby render the cell tolerogenic [17]. The two extracellular Ig-like domains of ILT3 most 
likely contain ligand binding sites; however, the nature of the ligand is still unknown [12, 
17-19]. Membrane-bound ILT3 interacts with T cells in a cell-to-cell contact dependent 
manner and induces immune suppression or tolerance by inducing anergy in CD4+ T cells, 
suppressing the diff erentiation of IFN-γ producing CD8+ T cells, inhibiting T cell proliferation 
and induction of regulatory T cells (Tregs) and alloantigen-specifi c CD8+ T suppressor cells 
(Ts) [17, 20]. Moreover, a soluble form of ILT3 (sILT3) resulting from alternative splicing, has 
been described to interact with T cells and induce anergy [21]. CD68+ tumor associated 
macrophages are the major source of sILT3 [21, 22].
Earlier we have shown that MDSC are elevated in treatment-naïve stage IV non-small cell 
lung carcinoma (NSCLC) patients [23]. Because MDSC have the ability to induce immune 
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suppression, we hypothesized that ILT3 expression could be part of a yet unidentified 
mechanism by which MDSCs mediate immune escape. Therefore, we aimed to assess 
expression of ILT3 on MDSC in lung cancer patients with advanced disease before the start 
of chemotherapy and evaluate its effect on clinical outcome.
RESULTS
Characteristics of study subjects
In this study, 118 stage IV NSCLC patients participating in the NVALT12 study were 
included. Of 13 patients, blood samples were not available for processing within 6 hours 
after the samples were taken and were excluded from further analysis. Table 1 shows the 
characteristics of the 105 NSCLC study participants and 20 healthy controls (HC) that were 
included in our analyses. The patient characteristics of this study cohort were similar to the 
total NVALT12 population [23], therefore no selection bias was introduced.
Table 1. characteristics of study subjects
Healthy controls NSCLC patients
Number of subjects 20 105
Age (years) (Mean ± SD) 54 ± 7.5 61 ± 8.3
Gender (%)
Male 4 (20) 53 (50.5)
Female 16 (80) 52 (49.5)
WHO performance score (%)
0 20 (100) 51 (49)
1 50 (48)
2 3 (3)
Histologic subtype (%)
Adenocarcinoma 87 (84)
Large cell carcinoma 17 (16)
Both MO-MDSC and PMN-MDSC are elevated in stage IV NSCLC patients
The two MDSC subsets - MO-MDSC and PMN-MDSC - were assessed in the peripheral 
blood of stage IV NSCLC patients and healthy controls by flow cytometric analysis of freshly 
obtained peripheral blood mononuclear cells (PBMC). The gating strategy for the two 
populations is presented in Figure 1A and was performed as previously described [23]. First, 
mature granulocytes were excluded based on their CD16++ expression [5, 24]. Then, MO-
MDSC were characterized as CD11b+ CD14+ HLA-DR- CD33+ CD15+, whereas PMN-MDSC 
were characterized as CD11b+ CD14- HLA-DR- CD33+ CD15+.
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As reported earlier by our group, MDSC are elevated in NSCLC patients [23]. Accordingly, 
in the cohort used in this study, the frequencies of both MO-MDSC and PMN-MDSC in 
peripheral blood were signifi cantly higher in patients than in healthy controls, as shown in 
Figure 1B.
Figure 1. Circulating MO-MDSC and PMN-MDSC are increased in NSCLC patients. A. Flow cytometry 
was performed on freshly isolated PBMC from NSCLC patients and healthy controls. Gating strategy 
for determination of circulating MO-MDSC and PMN-MDSC is depicted in this fi gure. After gating the 
live cells, CD16high cells were excluded. MO-MDSC were characterized as CD14+CD11b+HLA-DRlowCD15+
and PMN-MDSC were characterized as CD14-CD11b+HLA-DRlowCD15+. MDSC levels were determined as 
frequency of alive. B. Frequency of both MO-MDSC and PMN-MDSC in PBMC was signifi cantly higher 
in NSCLC patients than in healthy controls. ** p<0.01; ***p < 0.001; Mann-Whitney U test.
ILT3 is expressed by subpopulations of MDSC
ILT3 expression could be detected on both PMN-MDSC and MO-MDSC (Figure 2A). In 
contrast to MO-MDSC, which showed a homogeneous high expression of ILT3 (right panel), 
2
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PMN-MDSC comprised two subsets of high and low ILT3 expression (left panel). Figure 2B 
shows ILT3 expression on PMN-MDSC of four different patients, compared to their CD11b-
CD14- cells (mainly lymphocytes) and CD11b+CD14+ cells (mainly monocytes). Whereas the 
lymphocytes were consistently negative for ILT3 (mean fluorescence intensity (MFI) = 53), 
monocytes showed high and homogeneous ILT3 expression (median MFI = 7399). The 
expression of ILT3 on PMN-MDSC was intermediate and showed two peaks in most patients, 
although the distribution over ILT3high (MFI >103) and ILT3low (MFI <103) fractions varied 
extensively between patients (percentage of ILT3high cells varied between 0.2% and 92.9%). In 
contrast to PMN-MDSC, virtually all MO-MDSC were positive for ILT3 with a homogeneous 
expression of the marker, which was slightly but significantly lower than expression in the 
monocyte population (MFI = 6275, p<0.001).
The ILT3high fraction of PMN-MDSC is increased in lung cancer patients 
and is not correlated with T and B cell frequencies or monocytes
The proportions of ILT3high PMN-MDSC within the total PMN-MDSC population varied 
considerably between patients. As shown in Figure 3A, the fraction of ILT3high of PMN-
MDSC was significantly higher in NSCLC patients (39%, SD 24%) compared to healthy 
controls (12%, SD 10%; p < 0.0001). The proportion of ILT3high PMN-MDSC did not correlate 
with the proportion of PMN-MDSC (Figure 3B). To investigate whether the ILT3high fraction 
of PMN-MDSC had an effect on, or was affected by, other immunological cell populations, 
we analyzed T cells, the CD4+/CD8+ T cell ratio, B cells and monocytes. No statistically 
significant correlations were found for the ILT3high fraction of PMN-MDSC with proportions 
of B cells, T cells, the CD4+/CD8+ ratio and monocytes in NSCLC patients. Furthermore, no 
correlation with MO-MDSC existed (Figure 3B). Analyses with absolute numbers of these 
cell populations gave similar results (data not shown).
Soluble ILT3 is elevated in serum of NSCLC patients and does not 
correlate with immunological cell populations
It has been described that besides membrane-bound ILT3, also soluble ILT3 (sILT3) can have 
immune suppressive effects [21]. In multiple types of cancer, sILT3 is present in the serum of 
patients and is able to strongly abolish T cell responses against tumor antigens [21, 22]. To 
test whether sILT3 is present in the serum of the NSCLC patients, sILT3 levels were quantified 
by ELISA in a pilot of 30 randomly chosen NSCLC patients and 8 healthy controls. Figure 4A 
demonstrates that sILT3 was present in the serum of NSCLC patients and that the levels of 
sILT3 were significantly higher (p = 0.03) compared to the levels of sILT3 in healthy controls. 
We hypothesized that soluble ILT3 might be produced by ILT3 expressing MDSC. However, 
no correlation was found between the serum levels of sILT3 and the proportions of ILT3high 
cells in the PMN-MDSC population (Figure 4B). Furthermore, sILT3 was not correlated 
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with the mean fl uorescence intensity (MFI) values of surface ILT3 on monocytes or MDSC 
populations (data not shown). To check whether sILT3 levels were related to the peripheral 
immune profi le of the patients, we assessed the correlation between sILT3 serum levels and 
peripheral immune cell proportions in the patient cohort. No signifi cant correlations were 
found between the levels of sILT3 and the frequency PMN-MDSC and MO-MDSC, T cells, 
the CD4+/CD8+ ratio, B cells and monocytes (Figure 4C).
Figure 2. ILT3 expression on MDSC. A. Flow cytometric data of a representative patient, displayed 
as density plot based on ILT3 and CD33 expression. Left panel: PMN-MDSC, right panel: MO-MDSC. 
B. Histograms of 4 diff erent patients with ILT3 expression of PMN-MDSCs (shaded) compared to the 
expression within the CD11b-CD14- population (dashed line, mainly lymphocytes) and CD11b+CD14+ 
population (dotted line, mainly monocytes). Proportions of ILT3high fraction are displayed as percent-
age of PMN-MDSC.
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Figure 3. ILT3high proportion of PMN-MDSC in NSCLC patients. A. ILT3high proportions of PMN-MDSC 
were significantly higher in NSCLC patients than in healthy controls. *** p<0.001, Student’s t test. B. 
In NSCLC patients, correlations between the proportion of ILT3high PMN-MDSC and various immune 
subsets were analyzed with the Spearman rho test. None of the tests revealed a significant correlation 
(p>0.05 in all analyses).
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Figure 4. Serum sILT3 in NSCLC patients Figure 5: ILT3high proportion of PMN-MDSC in NSCLC patients. 
A. Soluble ILT3 was measured by ELISA in serum samples of healthy controls (n=8) and stage IV NSCLC 
patients (n=30). Levels were signifi cantly higher in NSCLC patients compared to healthy controls. * 
p<0.05, Student’s t test. B. sILT3 levels of NSCLC patients did not correlate with the fraction of ILT3high
cells of PMN-MDSC (Spearman’s rho test). C. In NSCLC patients, correlations between level of sILT3 
in serum and various immune subsets were analyzed with the Spearman rho test. None of the tests 
revealed a signifi cant correlation (p>0.05 in all analyses).
2
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Increased proportions of circulating MDSC correlate with a poorer 
outcome in NSCLC patients
For various types of cancer, it has been shown that higher levels of MDSC correlate with 
reduced survival of patients [25, 26]. To validate this effect in our patient cohort, patients 
were divided into two groups, based on the proportions of MDSC. Values that were higher 
than the mean + 2 standard deviations of healthy controls were considered to be elevated. 
In this way, we identified patients with elevated PMN-MDSC and patients with elevated MO-
MDSC. In accordance with reported findings [25, 26], patients with elevated proportions 
of PMN-MDSCs had a significantly shorter survival than patients with low proportions of 
PMN-MDSC (p=0.017). Likewise, patients with elevated proportions of MO-MDSC had a 
significantly shorter survival than patients with low MO-MDSC values (p=0.007). The survival 
curves are shown in Figure 5A and B. Of note, proportions of PMN-MDSC and MO-MDSC 
were significantly correlated (p<0.001; not shown).
Figure 5. Survival curves of NSCLC patient groups based on frequency of MDSC. Survival curves 
of NSCLC patients divided into two groups, based on the mean value + 2SD of healthy controls. A. 
Survival curve of patients with elevated versus low PMN-MDSC levels B. Survival curve of patients 
with elevated or low MO-MDSC levels.
The ILT3high fraction of PMN-MDSC correlates with a poorer outcome in 
NSCLC patients
To assess if ILT3 expression on PMN-MDSC influenced clinical outcome, NSCLC patients 
were divided in two groups based on the percentages of ILT3high cells of PMN-MDSC, in 
the same way as with proportions of MDSC. Figure 6A shows a slightly shorter overall 
survival for patients with a higher percentage of ILT3high PMN-MDSC, although this did not 
reach statistical significance (p=0.15). However, it is conceivable that the impact of high 
ILT3 expression on PMN-MDSC is limited in patients with low proportions of these cells. 
Therefore, we performed a sub analysis on the group of patients with the highest levels of 
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PMN-MDSC (above median; Figure 6B). We found a signifi cant negative correlation with 
overall survival (p=0.023, Figure 6C). In contrast, in patients with low proportions of MDSC, 
the percentage of ILT3high cells did not infl uence overall survival (Figure 6D). Analysis on 
progression free survival showed similar results, but only the eff ect of MO-MDSC level 
reached statistical signifi cance (data not shown). Serum levels of sILT3 were not correlated 
with survival (data not shown).
Figure 6. NSCLC patient survival based on ILT3 fractions of MDSC. A. Patients with an elevated per-
centage of ILT3high PMN-MDSC versus patients with low percentage of ILT3high PMN-MDSC. Survival 
curves were not signifi cantly diff erent. B. No correlation was found between the level of total PMN-MD-
SC and the percentage of ILT3high PMN-MDSC (Spearman’s rho; p=0.38). For the curves in Figure C 
and D, patients were divided based on the frequency of PMN-MDSC and the percentage of ILT3high 
PMN-MDSC. Cut off  values were at median value of all patients to create equally sized groups. C. In 
patients with high levels of PMN-MDSC, the fraction of ILT3high cells correlated signifi cantly with overall 
survival. D. In patients with low levels of PMN-MDSC, the percentage of ILT3high PMN-MDSC did not 
signifi cantly contribute to overall survival. The curves were compared with a log-rank test, stratifi ed for 
treatment arm. PBMC = peripheral blood mononuclear cells. MO-MDSC = monocytic myeloid-derived 
suppressor cells. PMN-MDSC = polymorphonuclear myeloid-derived suppressor cells.
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DISCUSSION
This is the first study showing that the immune suppressive molecule ILT3 is expressed by 
MDSC. In recent years, MDSC have received a lot of attention for their immune suppressive 
role in cancer, which they can execute through a diversity of mechanisms, such as arginase-1 
and iNOS expression and oxidative stress [27]. Given that MDSCs are a heterogeneous 
population of immature cells, these mechanisms are likely to be differentially employed by 
the different subsets of MDSC and dependent on the context of the microenvironment. 
With the demonstration of ILT3 expression on the cell membrane of MDSC, we describe 
a, for MDSC previously unknown pathway, that MDSC might use to execute their immune 
suppressive function. The heterogeneity of MDSC is further demonstrated by our finding 
that ILT3 is not expressed on all circulating MDSC of lung cancer patients, but on MO-MDSC 
and a subset of PMN-MDSC only.
Little is known about MDSC under physiological conditions. In healthy individuals, immature 
myeloid cells with the same phenotype as MDSC are continuously generated in the bone 
marrow, where they differentiate into mature myeloid cells before entering the circulation. 
Under pathological conditions they can be released from the bone marrow before 
maturation. However, in mice it has been described that MDSC are also present in the 
liver during physiological conditions and are thought to play a pivotal role in maintaining 
homeostasis [28]. So, the function of MDSC is probably different in healthy controls 
compared to cancer patients. It has been described that MDSC of diseased mice have an 
increased capacity to suppress T cell proliferation compared with MDSC of normal mice 
[28]. This is supported by the finding that MDSC from healthy controls show a decreased 
expression of immune suppressive molecules compared with MDSC from cancer patients 
[29]. Likewise, in a previous study we showed that arginase-1 is expressed in PBMC in much 
larger amounts in lung cancer patients than in healthy controls [23, 30]. Our finding that 
ILT3 is upregulated on MDSC of NSCLC patients is in agreement with functional differences 
with regard to immune suppression by MDSC in NSCLC patients and healthy controls.
ILT3 expression on DC is of critical importance in the induction of tolerance [31, 32]. ILT3 
can be induced on APCs by cytokines such as IL-10, interferon (IFN)-α and IFN-β and by 
interaction with CD8+ T suppressor cells (Ts) [33, 34]. Other inducers of ILT3 on APC are 
vitamin D3 analogs, COX-1/2 inhibitors, and tryptophan depletion in the environment, 
resulting in T cell non-responsiveness and tolerance [18, 33, 35]. Intracellular signaling via the 
ITIMs of ILT3 induces tolerance in DCs via downregulation of the NFκB pathway and plays 
an inhibitory role in antigen presentation [36]. However, these signaling pathways are not 
likely to play an important role in ILT3 expressing MDSC, since MDSC are not classical APC 
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and are defi ned by low HLA-DR expression. Therefore, ILT3 induced immune suppression 
by MDSC is not likely to exert its eff ectiveness via co-stimulation or antigen presentation 
as holds true for DCs. However, extracellular signaling by membrane bound ILT3 as well 
as sILT3 has been shown to induce immune suppressive CD8+ T suppressor cells and CD4+
Tregs [18, 19]. MDSC might therefore use this extracellular signaling pathway to exert their 
immune suppressive function, as indeed this cell population is known to induce Tregs and 
T cell anergy.
In this study we did not fi nd a correlation between ILT3 expression on MDSC and the 
proportion of T cells in PBMC. However, functionality of these T cells was not assessed in 
this study. Given that MDSC might induce anergy in T cells or induce Tregs from naïve T 
cells, functionality rather than number of T cells could be diminished by ILT3+ MDSC and 
should be investigated in further studies. Unfortunately, the amount of blood collected from 
each patient in combination with the low levels and phenotypic instability of the MDSC 
populations did not allow for functional studies to compare the ILT3high and ILT3low PMN-
MDSC subsets or the comparison with suppressive capacity of MO-MDSC.
The clinical relevance of both membrane-bound and soluble ILT3 has been demonstrated 
in studies of diff erent cancer types. In B-CLL, myeloid leukemia, pancreatic and gastric 
cancer, membrane-bound ILT3 is expressed on tumor cells and in B-CLL its expression on 
tumor cells is associated with aggressive growth [13, 37, 38]. Elevated expression on DCs 
was found in colorectal cancer patients when compared to healthy controls [14]. Moreover, 
strong infi ltration of CD68+ ILT3high macrophages has been demonstrated in lymph nodes 
containing metastatic carcinoma cells [22]. Also, sILT3 is elevated in serum of melanoma, 
colorectal and pancreatic carcinoma patients [21, 22]. In contrast, in SLE and autoimmune 
thyroid disease, where in contrast to cancer the immune system is over activated, ILT3 
expression is decreased on DCs of patients [15, 39] and in multiple sclerosis, ILT3 was 
reported to be decreased on circulating monocytes [16]. In line with these results, we found 
elevated sILT3 levels and a higher percentage of ILT3+ PMN-MDSC in NSCLC patients, which 
indicates a role for this molecule in tumor pathogenesis or progression, most likely via 
stimulating tumor immune escape. In this cohort of stage IV NSCLC patients, the detrimental 
eff ect of the presence of elevated proportions of circulating MO-MDSC and PMN-MDSC 
was confi rmed, as elevated proportions of MDSC were correlated with a decreased overall 
survival. We were unable to demonstrate a signifi cant eff ect of the percentage of ILT3high
PMN-MDSC on clinical outcome for the whole patient population, although the mean 
survival time was shorter in patients with elevated ILT3high PMN-MDSC (Figure 6A). However, 
when patients with PMN-MDSC proportions above median were selected, an elevated 
percentage of ILT3high PMN-MDSC was correlated with reduced survival. This fi nding 
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supports our hypothesis that ILT3 expression on MDSC plays a role in immune suppression, 
but only in patients with higher proportions of PMN-MDSC its influence is large enough to 
be detected in survival analyses. In contrast to PMN-MDSC, all MO-MDSC expressed ILT3 
on their membrane. Given that the frequency of MO-MDSC in peripheral blood was very 
low but still rendered a significant correlation with overall survival, MO-MDSC might be a 
stronger immune suppressor than PMN-MDSC in stage IV NSCLC patients. Although we did 
not provide evidence for this, one might speculate that this could be due to the constitutive 
expression of ILT3 on MO-MDSC. Moreover, the proportion of ILT3high PMN-MDSC did not 
correlate with the proportions of other immunological cell types, thereby indicating that 
its clinical value is not a reflection of an altered balance in the rest of the immune system, 
but rather might exert a tumor promoting function, either via altering functionality of the 
immune cells rather than cell numbers, or by acting locally on tumor progression or immune 
escape. The absence of evidence for clinical relevance of the level of sILT3 in serum in this 
study might be due to the small size of serum samples measured, although the lack of any 
correlation with circulating immune cell populations provided no further indication of its 
role in peripheral blood. sILT3 might however function more locally, since it has been shown 
to be produced by tumor associated CD68+ macrophages [21]. Given that sILT3 levels did 
not correlate with the expression level on circulating MDSC or monocytes, it is not likely 
that sILT3 is produced in the periphery in high amounts, but might rather reflect the local 
immune composition and a suppressive microenvironment.
Taken together, our results show that ILT3 is expressed on MDSC and indicate that this 
effects the clinical outcome. The relevance of ILT3 in cancer patients is supported by results 
from literature [14, 37, 38] and therefore further investigation of its mode of action on 
MDSC should be performed. Yet, it is debatable that ILT3 on its own would determine the 
immune suppressive status of MDSC. Rather, the sum of all immune suppressive mechanisms 
and their relative contribution to the activity of MDSC, will determine the extent of its 
unfavorable effects in cancer patients.
MDSC play an important role in mediating immune suppression and therefore represent 
a significant hurdle to successful immunotherapy in NSCLC [2]. Therefore, combining 
immunotherapeutic approaches with MDSC inhibiting drugs like gemcitabine or VEGF 
blockers to elicit more potent anticancer effects, is a promising development.
To our knowledge this is the first study that demonstrates the expression of ILT3 on human 
MDSC. Future studies will underscore the importance of this molecule on MDSC in other 
experimental or clinical settings.
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MATERIAL AND METHODS
Study population
The patients in this study were participating in the NVALT12 study (trial number NCT01171170), 
a randomized phase II multicentre study on the eff ect of a nitroglycerin patch or placebo in 
patients with stage IV NSCLC treated with carboplatin, paclitaxel and bevacizumab. Patients 
in the NVALT12 study were diagnosed with stage IV non-squamous NSCLC and were not 
eligible for treatment with curative intent. Disease stage was determined in accordance with 
the American Joint Committee on Cancer (AJCC). Blood samples were collected before start 
of treatment and analysed by fl ow cytometry. In this study, 118 patients were included for 
analysis of ILT3 expression. Twenty age-matched healthy controls (HC) (mean age 54 years) 
with no history of malignancies and/or autoimmune diseases were enrolled in the study. 
Written consent was obtained from all individuals before blood sampling and the study 
was approved by the ethical committee of the Erasmus Medical Center (MEC-2012-048 (HC) 
and CCMO: NL33442.042.10 (NSCLC patients)).
Isolation of PBMC
PBMC were isolated using a Ficoll-Hypaque (GE Healthcare, Diegem, Belgium) density 
gradient. Blood was supplemented to 50 mL with phosphate buff ered saline (PBS, Gibco, 
Breda, The Netherlands) before layering onto the Ficoll-Hypaque. After centrifugation of 
20 minutes at 1200xg, PBMC were collected from the plasma-Ficoll interphase. Cells were 
washed twice with 50 mL PBS and counted prior to further analysis. In previous research, 
we demonstrated that MDSC levels remain constant in the fi rst six hours, but decrease 
signifi cantly when stored for a longer time [23]. Therefore, fl ow cytometry on PBMC was 
performed immediately and within six hours after blood was collected.
Flow cytometry
PBMC were stained with the following conjugated monoclonal antibodies: anti-CD15 PE, 
anti-CD16 PERCP-Cy5.5, anti-CD33 PE-Cy7, anti-CD11b APC, anti-HLA-DR APC-Cy7 (all from 
BD Biosciences), anti-CD14 PE-Texas-Red (Invitrogen, Breda, The Netherlands), anti-ILT3 
FITC (R&D Systems) and a live/dead marker 4’,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes, Eugene, OR, USA) to analyze MDSC. Staining with anti-CD4 FITC, anti-CD8 APC, 
(all from BD Biosciences), anti-CD3 APC-eFluor 780 (eBioscience, San Diego, CA, USA), and 
DAPI was performed for the analysis of T cells.
Cells were washed with FACS buff er (PBS, 0.25% BSA, 5 mM EDTA, 0.05% NaN3) and stained 
for 30 min at 4°C with the above-mentioned antibodies, appropriately diluted in FACS buff er 
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supplemented with 2% normal human serum. Flow cytometry was performed on a LSRII 
flow cytometer (BD Biosciences) and data were analyzed with FlowJo software (Tree Star).
MDSC were characterized as previously described [23]. In the MDSC staining, the CD16 
marker was used to exclude mature granulocytes based on their CD16++ expression, as has 
been considered important for MDSC purity [5, 24]. PMN-MDSC were characterized as 
CD11b+ CD14- HLA-DR- CD33+ CD15+ and MO-MDSC were characterized as CD11b+ CD14+ 
HLA-DR- CD33+ CD15+. Total monocytes were characterized as being CD11b+ CD14+. In the 
lymphocyte staining, T cells were characterized as CD3+ and divided into a CD4+ CD8- (CD4+ 
T cells) and a CD4- CD8+ (CD8+ T cells) subset. B cells were characterized as CD19+ cells.
Measurement of soluble ILT3 in serum
For quantitative detection of ILT3 in serum, a commercially available enzyme-linked 
immunosorbent assay (ELISA) was used according to manufacturer’s specifications (Cusabio 
biotech.). All samples were assayed in duplicate and quantified using a standard curve. The 
detection range was from 31.2-2000 pg/ml.
Statistical analysis
Differences between healthy controls and lung cancer patients were evaluated by Mann–
Whitney U test. Correlations were assessed by using the Spearman’s rho correlation test. The 
effects of sizes of immunological cell populations and expression levels of ILT3 on survival 
were assessed with a log-rank (Mantel-Cox) test. In these analyses, patients were stratified 
for treatment group. Statistical analysis was performed using the statistical program SPSS 
(version 21.0, SPSS Inc., Chicago, USA). All p-values were two-sided and p-values below the 
conventional level of significance (p<0.05) were considered statistically significant. Figures 
were made in GraphPad Prism (version 5.0, GraphPad Software, San Diego, CA, USA).
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Both surgery and stereotactic ablative body radiotherapy (SABR) are guideline-specified 
treatments for early stage non-small cell lung cancer (NSCLC). However, despite curative 
treatment approaches, patients may develop disease recurrences which are often incurable 
[1]. Immune infiltration of the tumor is correlated to survival, and depending on the immune 
cell types present, either has a positive (immune activating cells) or negative (immune 
suppressive cells) prognostic value [2]. Radiotherapy has both been reported to suppress 
and activate the immune system. This depends most likely on the dose and, as part of the 
effects are caused by dying tumor cells, also by tumor type and stage [3]. NSCLC is known 
to suppress the immune system [4], and tumor removal by itself might therefore also have 
an immune stimulatory effect. We hypothesized that the two treatment options (SABR 
or surgery) would differentially affect the immune response in early stage NSCLC. Here, 
we assessed the effects on the induction of T-cell activation in the early post-treatment 
period. Some of the results of these studies have been previously reported in the form of 
an abstract [5].
Blood samples were collected from 23 histological or cytological proven early stage (cT1-
T2aN0M0) NSCLC patients who underwent surgery (n=13) or SABR in 3 to 8 fractions 
(n=10), as determined by the treating physician (ClinicalTrials.gov identifier NCT02488850). 
All patients signed informed consent before inclusion in the study. Peripheral blood 
mononuclear cells (PBMC) were isolated at baseline, and at four time points during the 
first six weeks after treatment. PBMC were stained with antibodies against T-cell subset and 
activation markers and analyzed by flow cytometry. Flow cytometry procedures, 4h cell 
stimulation with phorbol-12-myristate-13-acetate and ionomycin and cytokine stainings have 
been described previously [6]. Linear mixed effects models using maximum likelihood with 
patient-specific random effects were used to determine changes in immune populations. 
Normality of the residuals was checked and if needed, transformation of the data was 
applied. Statistical analyses were performed in R for windows, version 3.2.3. Figures were 
generated in GraphPad Prism 5.
In both groups the proportions of total CD4 and CD8 T-cells within PBMC did not 
substantially change over the first 6 weeks of treatment. Likewise, proportions of different 
T-cell subsets, including γδ-T-cells, NKT-cells and naïve and memory T-cells remained stable 
over time, where regulatory T-cell proportions increased from 5% to 6% of CD4 on average 
(not shown). To determine the activation status of the T-cells, we assessed expression of 
CD69, CD25, PD-1, CTLA4 and the proliferation marker Ki67, likely reflecting relevant effector 
cells [7]. We did not observe changes over time in CD69, CD25 and CTLA4. However, the 
fractions of proliferating (Ki67+) and PD-1 expressing T-cells increased significantly after 
SABR (p<0.001 for both Ki67+ FoxP3-CD4+ non-regulatory T-cells and Ki67+ CD8 T-cells, 
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p=0.032 and p=0.029 for PD-1+ CD4 and CD8 T-cells, respectively)(Figure 1). In the surgery 
group, smaller but signifi cant changes were seen in Ki67+ proportions. The interaction term 
of time and group, however, showed that there was a signifi cant diff erence in kinetics of 
Ki67+ CD8 T-cells between the two treatments (p<0.001), but did not reach signifi cance for 
Ki67+CD4 T-cells. No signifi cant changes in PD-1+ proportions were observed in the surgery 
group. PD-1 is upregulated on T-cells upon recognition of the cognate antigen, and can be 
indicative of either activation or exhaustion of T-cells [2]. To assess whether the PD-1+ T-cells 
in the peripheral blood of these patients were functionally active or exhausted, we analyzed 
their interferon γ (IFNγ) production. Figure 2A shows that in PD-1+ CD4 and CD8 T-cells, the 
fractions of IFNγ-producing cells were larger than in the PD-1- T-cell populations (p<0.001 
for both CD4 and CD8 T-cells), indicating that the PD-1+ cells are more functionally active 
than the PD-1- T-cells. Moreover, in four of nine SABR-treated patients (one patient had a 
non-evaluable sample at baseline), PD-1+ proportions increased with at least >4%. Figure 
2B shows that in these four patients, the increase in PD1+ T-cells coincided with an increase 
in proportions of IFNγ+ T-cells, again supporting that in early stage NSCLC patients, PD-1
expression is indicative of increased T-cell functionality rather than exhaustion. Of note, 
the only surgery-treated patient that showed an increase in PD1+ T-cells, also showed an 
increase in IFNγ+ T-cells (not shown). 
In this non-randomized observational study, we showed that SABR induced peripheral 
blood T-cell activation in a major subgroup of patients with early stage lung cancer, 
whereas after surgery, only a minor and temporary increase in proliferation was induced. 
The T-cell response to SABR was mainly characterized by an increased PD-1 expression and 
proliferation, while earlier activation markers did not detectably increase in peripheral blood. 
No evidence of superiority of either of the two treatments with respect to clinical outcome 
has been published as of today [8]. In our study, with a median follow up time of 712 days, 
the recurrence rates were similar (surgery: 2 out of 13, SABR: 3 out of 10), whereby the small 
sample size does not allow for statistical evaluation. The observed immune activation after 
SABR, however, can potentially be benefi cial in several combination treatment strategies. 
Firstly, PD-1 is upregulated on T-cells after cognate antigen recognition, and acts as a 
checkpoint for T-cells by negatively modulating the immune response upon binding of its 
ligand. Blockade of this receptor-ligand interaction prolongs the immune response and has 
been shown to improve clinical outcome in NSCLC signifi cantly [9].
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Figure 1. T-cell proliferation and PD-1 expression after surgery or SABR in early stage NSCLC patients. 
Ki67 positive proportions of FoxP3- non-regulatory CD4 T-cells and CD8 T-cells (A) and PD-1 positive 
proportions of CD4 and CD8 T-cells (B) at baseline and during the fi rst six weeks after treatment with 
either surgery (n=13) or SABR (n=10) were determined by fl ow cytometry. Changes over time were 
assessed per group with linear mixed eff ects models with patient-specifi c random eff ects. Diff erences 
in kinetics between the two groups (A) were assessed by the time*group interaction term. *** = p < 
0.001; ** = p < 0.01; * = p < 0.05; n.s. = not signifi cant.
Our fi ndings that SABR induces T-cell activation and concomitant PD-1 expression suggests 
that the combination of SABR with an inhibitor of the PD-1/PD-L1 axis, may be an interesting 
treatment strategy, particularly as it is known that PD-L1 is upregulated on tumor cells and 
myeloid cells in response to IFNγ, which we found to be increased simultaneously. Secondly, 
combinations of surgery and radiotherapy treatment are sometimes administered in the 
context of post-surgical adjuvant radiotherapy [10]. In light of our results, a superior outcome 
might be achieved when radiotherapy is administered prior to surgery as a neo-adjuvant 
immune activating therapy. In fact, a phase II clinical trial is currently recruiting to evaluate 
this hypothesis [11]. In conclusion, SABR induces systemic T-cell activation, characterized 
by PD1 expression in a major fraction of patients, while surgery does not. These fi ndings 
argue for combining SABR with checkpoint inhibitors or other immunotherapies with or 
without surgery. Furthermore, it would be of interest to incorporate immune-monitoring, 
which may be expanded with additional activation markers [7], in upcoming (clinical) studies.
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Figure 2. Intracellular IFNγ expression after in vitro stimulation of peripheral blood T-cells. A. In-
tracellular IFNγ expression in PD-1+ and PD-1- fractions of T-cells of NSCLC patients. *** = p > 0.001 
(Wilcoxon signed rank test). B. Changes in IFNγ-producing T-cells in NSCLC patients 6 weeks after 
SABR. Two groups of patients are depicted, the patients that showed an increase in PD-1 positive 
T-cells 6 weeks after treatment (black solid lines) versus the patients that do not show an increase in 
PD-1 positive T-cells (grey dashed lines).
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STATEMENT OF TRANSLATIONAL RELEVANCE
To rationally combine checkpoint inhibition and conventional treatment modalities in 
advanced NSCLC, a better understanding of the immunomodulatory effect of conventional 
treatments is required. In this study, increased proliferation of peripheral blood CD8 effector 
T cells was observed after treatment of stage IV NSCLC patients with paclitaxel/carboplatin/
bevacizumab. Proliferating CD8 T cells expressed higher levels of PD-1 and CTLA-4. Since 
similar populations have been found to be associated with response to checkpoint inhibition, 
these results suggest that paclitaxel/carboplatin/bevacizumab treatment induces an immune 
profile reflecting sensitivity for checkpoint inhibition.
ABSTRACT
Introduction: Chemotherapy has long been the standard treatment for advanced stage 
non-small cell lung cancer (NSCLC), but checkpoint inhibitors are now approved for use 
in several patient groups and combinations. To design optimal combination strategies, a 
better understanding of the immune modulatory capacities of conventional treatments 
is needed. Therefore, we investigated the immune-modulatory effects of paclitaxel/
carboplatin/bevacizumab (PCB), focusing on immune populations associated with response 
to checkpoint inhibitors in peripheral blood.
Methods: 223 stage IV NSCLC patients, enrolled in the NVALT12 study, received PCB, with 
or without nitroglycerin patch. Peripheral blood was collected at baseline and after the first 
and second treatment cycle. Proportions of T cells, B cells, and monocytes were determined 
by flow cytometry. Furthermore, several subsets of T cells and the expression of Ki67 and 
co-inhibitory receptors on these subsets were determined.
Results: Whereas proliferation of CD4 T cells remained stable following treatment, proliferation 
of peripheral blood CD8 T cells was significantly increased, particularly in the effector memory 
and CD45RA+ effector subsets. The proliferating CD8 T cells more highly expressed PD-1 and 
CTLA-4 compared to non-proliferating CD8 T cells. Immunological responders (>2-fold increased 
proliferation after treatment) did not show an improved progression free or overall survival.
Conclusions: Paclitaxel/ carboplatin/ bevacizumab induces proliferation of CD8 T cells, 
consisting of effector cells expressing co-inhibitory checkpoint molecules. Induction of 
proliferation was not correlated to clinical outcome in the current clinical setting. Our 
findings provide a rationale for combining PCB with checkpoint inhibition in lung cancer.
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INTRODUCTION
Despite the great progress that has been made in the fi eld of lung cancer treatment over 
the last decades, non-small cell lung cancer (NSCLC) remains to be responsible for the 
highest cancer mortality worldwide [1]. Current treatments for metastasized NSCLC consist 
of platinum-based chemotherapy, specifi c therapies targeting genetic abnormalities, and 
checkpoint inhibition. Checkpoint inhibitors targeting programmed death receptor (PD)-1 
or PD-ligand 1 (PD-L1) are now a cornerstone in the treatment of NSCLC: PD-1 inhibitors 
nivolumab and pembrolizumab, and PD-L1 inhibitors durvalumab and atezolizumab are 
all FDA approved treatments under certain conditions for patients with NSCLC in diff erent 
stages of the disease [2-6]. For fi rst-line treatment in NSCLC, pembrolizumab is FDA 
approved as single treatment for patients with >50% PD-L1-positive tumor cells and in 
combination with pemetrexed/carboplatin for non-squamous NSCLC regardless of PD-L1 
status [7, 8]. Recently, the IM150 study was the fi rst phase III study showing improved 
survival with fi rst line treatment of a PD-L1 inhibitor in an unselected group of patients. 
Here, combined treatment of atezolizumab with paclitaxel/carboplatin/bevacizumab (PCB) 
performed better than PCB alone and was FDA approved recently [9]. As a result, the 
question now arising is whether the addition of chemotherapy treatment increases the 
response to checkpoint inhibitors. It is therefore important to understand the immune 
modulatory eff ects of chemotherapy.
In previous reports on the immune modulatory eff ects of chemotherapy, contradictory 
results were obtained. For example, Ramakrishnan and colleagues found an increased CD8+
T cell infi ltration after treatment with carboplatin/paclitaxel in various mouse models [10]. On 
the other hand, Pfi rschke and colleagues did not observe any induced CD8 T cell responses 
after treatment with paclitaxel in mouse models, in contrast to treatment with oxaliplatin/ 
cyclophosphamide. Indeed, variable eff ects on several immune cell populations have been 
described for diff erent chemotherapeutic treatments, as reviewed by Galuzzi et al. [11].
Monitoring chemotherapy-induced changes requires sequential patient samples. While the 
availability of tumor biopsies of metastasized NSCLC is limited, peripheral blood is relatively 
easy and non-invasive to obtain. Furthermore, peripheral blood immune populations have 
been shown to have predictive or prognostic value in several studies [12]. Recently, Ki67 
expression of CD8 T cells has been suggested as biomarker for response to checkpoint 
inhibition in both melanoma and NSCLC [13, 14]. In the current study, we investigated the 
peripheral blood immune profi le of patients with metastasized NSCLC during treatment 
with the PCB chemotherapy combination, with a focus on immune populations that have 
been reported to be associated with response to checkpoint inhibition. We used multiplex 
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flow cytometry as a method to assess (surface) protein expression on a single cell level, 
allowing assessment of specific immune populations and their activation status. We aimed 
to identify populations that are affected by the chemotherapy/bevacizumab combination 
and might act as a catalyst for response to immunotherapy treatment.
MATERIALS AND METHODS
Study population
The patients in this study were all enrolled in the NVALT12 study (trial number NCT01171170), 
a randomized phase II multicenter study on the effect of a nitroglycerin patch or placebo in 
patients with stage IV NSCLC treated with PCB. Details of the study are described elsewhere 
[15]. In short, 223 non-squamous NSCLC patients were included who were all diagnosed 
with stage IV disease and were not eligible for treatment with curative intent. Patients 
were treatment-naïve and received PCB every three weeks for three cycles. Nine patients 
did not start treatment; these patients were excluded from the analysis. The same dose 
of paclitaxel (175 mg/m2) and carboplatin (AUC=6) was administered to each patient and 
no major dose adjustments were made after the first cycle. Bevacizumab was continued 
every three weeks until progression. This study had two treatment arms: a control arm 
with patients only receiving the PCB combination, and an experimental arm in which a 
nitroglycerin patch was applied for five consecutive days around the day of chemotherapy 
administration. Written consent was obtained from all individuals before blood sampling 
and the study was approved by the Dutch Central Committee on Research Involving Human 
Subjects (CCMO: NL33442.042.10). The study was conducted in accordance with the ethical 
standards of the institutional and national research committee and with the 1964 Helsinki 
Declaration and its later amendments.
Peripheral blood processing
For the exploratory objectives of this study, peripheral blood was collected from patients on 
the day of the first, second and third cycle of treatment, prior to treatment administration. 
These samples correspond to week 0, week 3 and week 6 from start of therapy. Twenty 
mL of blood was drawn in EDTA tubes and processed within six hours of blood collection. 
Peripheral blood mononuclear cells (PBMC) were isolated via standard density-gradient 
centrifugation using Ficoll-Hypaque (GE Healthcare, Diegem, Belgium). One million cells 
were used for flow cytometry staining of myeloid-derived suppressor cells (MDSC). The 
remaining cells were cryopreserved in 10% dimethyl sulfoxide (Sigma-Aldrich, St Louis, Mo), 
40% fetal calf serum (Gibco) and RPMI (Invitrogen, Molecular Probes, Waltham, Mass) until 
further use.
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Flow cytometry
Three diff erent fl ow cytometry stainings were performed on the PBMC samples: one myeloid 
staining (performed on fresh material), a T cell staining and an intracellular cytokine staining 
(both performed on cryopreserved samples). Prior to the intracellular cytokine staining, 
cells were stimulated for 4 hours at 37°C with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin (both from Sigma-Aldrich, USA), supplemented with GolgiStop (BD Biosciences, 
USA) [16]. The antibodies used for the three stainings are listed in Supplementary Table 
S1. First, extracellular markers were stained for 30 minutes at 4°C. Subsequently, cells were 
fi xed and permeabilized with FoxP3 transcription factor fi x/perm mix (eBioscience) (T cell 
staining) or fi xed with 2% PFA and permeabilized with 0.5% saponin (intracellular cytokine 
staining). Next, intracellular markers were stained for 60 minutes at 4°C. FoxP3, Ki67, CTLA-
4, Granzyme B and IFNγ were stained intracellular. All other markers were included in the 
extracellular staining. To identify dead cells, 4’,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes) (myeloid staining) or LIVE/DEAD™ fi xable aqua dead cell stain kit (Invitrogen) (T 
cell and intracellular cytokine staining) were used. Data were acquired using an LSR II fl ow 
cytometer equipped with three lasers and analyzed using FlowJo (Tree Star, Inc., USA). FMO 
controls were used for gating where appropriate.
Statistical analysis
Statistical analyses were performed in R version 3.4.2 for windows (The R Foundation 
for Statistical Computing) and by Prism 5 (GraphPad). P<0.05 was considered statistically 
signifi cant. Changes of immune populations over time were tested against baseline, using 
the Wilcoxon signed rank test, taking into account paired samples. Multiple comparison 
correction was applied by adjusting the α: p<0.025 was considered as signifi cant in case 
of two comparisons (i.e. week 3 vs week 0 and week 6 vs week 0). The bar graphs show 
median values with error bars representing the interquartile range. Survival of diff erent 
patient subpopulations was displayed using Kaplan Meier curves and tested using a log-
rank test. Tumor lesion measurements for RECIST1.1 responses were used as a measure of 
total tumor burden. Total tumor diameter was determined as the sum of the diameters of 
target lesions measured on computed tomography (CT) scans.
RESULTS
Patient characteristics
In this study, we analyzed peripheral blood samples of patients that were enrolled in the 
NVALT12 study, the details of which are previously published [15]. For immune monitoring 
analysis, we used data of all patients whose blood was collected and processed for both 
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week 0 and at least one of the later time points (week 3 and week 6), which resulted in 
a total of 131 patients with paired samples. No significant differences in baseline immune 
populations or clinical outcome were observed between these 131 patients and the patients 
from whom only a baseline sample was available, ruling out a ‘lost to follow-up’ bias 
(Supplementary Table S2). 68 patients received standard PCB combination therapy in the 
control arm of the study, and 63 patients received an additional nitroglycerin patch with 
the aim to dilate blood vessels to increase chemotherapy efficacy in the experimental arm 
(Supplementary Table S3). However, the experimental arm did not improve progression 
free survival (PFS) or overall survival (OS) (see ref [15]). We first checked whether there were 
any differences in the dynamics of major immune populations between the two treatment 
arms. After the second treatment cycle (week 6 after start of treatment) no significant 
differences were seen between the proportions of T cells, the CD4/CD8 T cell ratio, the 
proportions of myeloid cells, and the proportions of B cells (Supplementary Table S3). 
Because no differences in clinical outcome (PFS and OS) between the two treatment arms 
were reported and because our data did not indicate any effects on immune dynamics, we 
decided to pool the two treatment arms for the remaining analyses.
Chemotherapy in NSCLC patients results in increased proportions of T 
cells
We assessed whether any major PBMC populations were changed within the first six weeks 
after the start of treatment. Absolute number of total PBMC did not change over time 
(Supplementary Figure S1). At week 6, the proportions of T cells were significantly increased 
compared to baseline values (median 46.3% vs. 42% of PBMC, p=0.001, Wilcoxon signed 
rank test; Figure 1). As T cells play an important role in anti-tumor immunity, we further 
explored the chemotherapy-induced changes in peripheral blood T cells by assessing the 
relative fractions of CD8 T cells (cytotoxic T lymphocytes; CTLs), non-regulatory CD4 T 
cells (T helper cells) and regulatory T cells (Tregs). The proportions of these subsets within 
the total T cell population remained stable over time (Supplementary Figure S2). As the 
staining protocol for myeloid cells was expanded to include the marker CD16 after inclusion 
of the first 40 patients, this allowed us to additionally characterize three monocyte subsets 
in 95 patients. These analyses revealed a relative increase in non-classical monocytes and 
intermediate monocytes and a decrease in classical monocytes (Supplementary Figure S3).
Proportions of Ki67+ cells within the CD8, but not within the CD4 T cell 
population increase after chemotherapy treatment
Because we observed an increase in the proportions of total T cells, we assessed the 
proportions of proliferating (Ki67+) cells within the T cell subsets. An increase in the 
proportions of proliferating cells was observed specifically in the CD8+ T cells (p=0.004 at 
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week 3 and p<0.001 at week 6, compared to baseline; Figure 2B). A transient decrease was 
seen in the proportions of Ki67+ Tregs at week 3 (p=0.003, compared to baseline), returning 
to baseline levels at week 6. No changes in the proliferation of non-regulatory CD4 T cells 
were observed.
Figure 1. Proportions of major leukocyte populations in NSCLC patients treated with chemotherapy. 
Proportions of CD3+ T cells (A), CD19+ B cells (B) and monocytes (C) in PBMC of NSCLC patients treated 
with PCB before start (week 0), after the fi rst (week 3) and second (week 6) cycle of chemotherapy, 
as determined by fl ow cytometric analysis. Bars represent median values with interquartile range. * 
p<0.025 ** p<0.005 ***p<0.0005 (α level adjusted for multiple comparisons; Wilcoxon signed rank test)
Figure 2. Changes in the proliferation of T cell subsets in peripheral blood of NSCLC patients treat-
ed with chemotherapy. Ki67 expression was assessed as marker of proliferation on CD8 T cells (A), 
FoxP3- non-regulatory CD4 T cells (B) and FoxP3+ regulatory CD4 T cells (C) by fl ow cytometry of 
PBMC samples before treatment (week 0) and 3 and 6 weeks after start of treatment. Ki67+ T cells 
are depicted as percentage of the parent population. ** p<0.005, *** p<0.0005, ns = not signifi cant 
(Wilcoxon-signed rank test)
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Increased proliferation occurs mainly in eﬀ ector CD8 T cells
Next, we asked whether the increase in proliferation of CD8 T cells could be attributed to 
a specifi c maturation subset. To this end, we identifi ed fractions of CD45RA+CCR7+ naïve T 
cells (TN), CD45RA-CCR7+ central memory T cells (TCM), CD45RA-CCR7- eff ector memory T cells 
(TEM) and CD45RA+CCR7- eff ector T cells (TEMRA), as shown in Figure 3A. Proportions of Ki67+
CD8 T cells were increased in all four subsets at week 6 compared to baseline. The largest 
proportions of Ki67+ T cells were present within the CD8 TEM subset. Both TEM and TEMRA CD8 
showed a clear increase of the Ki67+ fraction starting at week 3 (TEM p=0.007; TEMRA p<0.001). 
These results indicate that mainly the eff ector CD8 T cells respond to chemotherapy with 
an increased capacity for proliferation.
Figure 3. Changes in Ki67+ proportions within maturation stages of CD8 T cells. A) The diff erent 
maturation stages for CD8 T cells were determined by fl ow cytometry using the markers CD45RA and 
CCR7, defi ning the following subsets: naive (TN: CD45RA
+CCR7+), central memory (TCM: CD45RA-CCR7+), 
eff ector memory (TEM: CD45RA
-CCR7-) and CD45RA+ eff ector (TEMRA: CD45RA+CCR7-). B) Ki67+ propor-
tions of T cell maturation subsets as defi ned in panel A. Ki67+ T cells are depicted as percentage of the 
parent population. * p<0.025, ** p<0.005, *** p<0.0005, ns = not signifi cant (Wilcoxon-signed rank test)
Proliferating CD8 T cells have higher expression of co-inhibitory receptors
To further investigate the phenotype of the proliferating eff ector CD8 T cells, we determined 
the expression of PD-1 and cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4). 
These two well-known co-inhibitory receptors can be targeted by checkpoint inhibitors 
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currently approved for treatment of several cancer types. Figure 4 shows the expression 
of these surface markers in CD8 TEM cells. Similar results for CD8 TEMRA cells were obtained 
(Supplementary Figure S4). Proliferating CD8 TEM showed higher proportions of PD-1
+ cells 
than non-proliferating CD8 TEM. At week 3, a small decrease was seen in the proportions of 
PD1+ T cells (Figure 4A). Furthermore, within the PD-1-positive fraction, mean fl uorescence 
intensity (MFI) values indicated a higher per cell expression level of PD-1 in proliferating 
versus non-proliferating cells (Figure 4B). Expression of CTLA-4 was generally low in 
peripheral blood T cells. However, expression of CTLA-4 was higher in Ki67+PD-1+ CD8 T 
cells than in CD8 T cells that were single positive for either Ki67 or PD-1 (Figure 4C).
In summary, these fi ndings show that proliferation of CD8+ T cells is associated with higher 
expression of the co-inhibitory receptors PD-1 and CTLA-4 over the 6 weeks period 
evaluated.
Figure 4. Co-inhibitory receptor expression on proliferating CD8 TEM cells in peripheral blood of 
chemotherapy-treated NSCLC patients. A) Proportions of PD1+ cells within Ki67- and Ki67+ CD8 TEM
populations over time. B) PD-1 expression on Ki67- and Ki67+ PD-1+ CD8 TEM cells over time, as depicted 
by mean fl uorescent intensity (MFI). The MFI value is presented as biexponentially transformed value. C) 
Expression of CTLA-4 CD8 TEM subsets as defi ned by PD1 and Ki67 expression over time. Biexponentially 
transformed MFI value is depicted. In all graphs, the bars show median values with the interquartile 
range depicted by the error bars. * p<0.025, ** p<0.005, *** p<0.0005 (Wilcoxon-signed rank test)
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Increased proliferation of CD8 T cells in peripheral blood of NSCLC patients 
after chemotherapy treatment does not correlate with clinical response
To investigate whether the observed increase in proliferation of effector CD8 T cells 
correlated with the clinical outcome of these patients, we defined immunological responders 
(iR) as the patients in whom an increase in the proportions of Ki67+ CD8 T cells at week 3 or 
week 6 of at least a two-fold was observed (n=35). Immunological non-responders (iNR) 
were defined as patients who showed no increase at either week 3 or week 6 (fold change 
<1; n=31). These cut-off values were chosen based on the distribution of the data as seen 
from figure 5A, and closely resemble the 25% and 75% percentiles to provide groups that 
show distinct Ki67 dynamics with at least 30 patients per group. No significant differences in 
both PFS and OS were observed between the iR and iNR patient groups (Figure 5B). Notably, 
also baseline proportions of Ki67+ CD8 T cells did not correlate with survival (β = 1.01, 95%CI 
0.98-1.04; Cox regression). The proportions of PD1+ cells were equal in proliferating TEM from 
in iR and iNR patients (Figure 5C), but the per-cell expression levels of both PD1 and CTLA-4 
decreased over time in iR, but not in iNR patients (Figure 5D and 5E).
Huang et al. [13] have shown that in melanoma patients treated with a PD-1 inhibitor, 
increased proportions of Ki67+ CD8 T cells were correlated with clinical outcome, but only 
when combined with total tumor burden into a Ki67+CD8/tumor burden ratio. Therefore, 
we calculated the ratio of Ki67+ of CD8 T cells over the tumor burden, estimated by the total 
tumor diameter defined during RECIST1.1 response evaluation. In this cohort of PCB-treated 
NSCLC patients, we did not detect a difference in OS between patients with a high or low 
Ki67+CD8/tumor burden ratio (Supplementary Figure S5).
Proliferation of CD8 T cells is correlated with proportions of MDSCs
Besides immune activating cell populations, we analyzed two main immune suppressive cell 
populations, Tregs and myeloid-derived suppressor cells (MDSC), in the peripheral blood. 
Neither the proportions of FoxP3+ Tregs (as shown in Figure 1B), nor the expression of PD-1 
and CTLA-4 on Tregs (Supplementary Figure S6) changed over time. In contrast, granulocytic 
MDSC, characterized by expression of CD33, CD11b, CD15 and a lack of expression of CD14 
and HLA-DR, were elevated 3 weeks after start of treatment, but returned to baseline 
levels by week 6, in both iR and iNR patients (Figure 6A). Proportions of monocytic MDSC 
(CD33+CD11b+HLA-DR-CD14+CD15-) did not change over time (data not shown). The fraction 
of proliferating CD8 T cells was significantly correlated to the proportion of granulocytic 
MDSC, but not monocytic MDSC in the peripheral blood (spearman ρ = 0.27, p<0.001, 
Figure 6B), suggesting a balance between the immune suppressive and immune activating 
components within patients. No differential PFS was observed between patients with a high 
and patients with a low Ki67+CD8 T cells/ MDSC ratio (Figure 6C).
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Figure 5. Comparison between immunological responders and immunological non-responders A) 
Immunological responders (iR; indicated in the red rectangle) were defi ned as patients with an increase 
in Ki67+ CD8 T cells of at least two-fold compared to baseline at week 3 or week 6. Immunological 
non-responders (iNR; indicated in the blue rectangle) were patients who had a fold-change from 
baseline <1 at both week 3 and week 6. 35 patients were defi ned as iR and 31 patients were defi ned 
as iNR. B) Kaplan Meier plots of progression-free (left) and overall (right) survival of iR and iNR pa-
tients. Curves were compared with a log-rank test, which resulted in a p value >0.05 (not signifi cant). 
HR = Hazard ratio. C) Proportions of PD1+ cells within Ki67- and Ki67+ CD8 TEM populations over time 
in iR patients (red) and iNR patients (blue) as defi ned in fi gure 5A. D) PD-1 expression on Ki67- and 
Ki67+ PD-1+ CD8 TEM cells over time in iR patients (red) and iNR patients (blue), as depicted by mean 
fl uorescent intensity (MFI). The MFI value is presented as biexponentially transformed value. E) CTLA-4 
expression on Ki67+PD1+ CD8 TEM cells at week 0, 3 and 6 in iR patients (red) and iNR patients (blue). 
Biexponentially transformed MFI value is depicted. In panel C-E, bars depict median values with the 
interquartile range. * p<0.025, ** p<0.005, *** p<0.0005 (Wilcoxon signed rank test)
Taken together, although proliferation of CD8 T cells was correlated with proportions of 
MDSCs, we did not observe a correlation of the Ki67+CD8 T cells/MDSC ratio with PFS.
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Figure 6. Myeloid-derived suppressor cells in chemotherapy-treated NSCLC patients are correlated 
with proliferation of CD8 T cells. A) Proportion of granulocytic MDSC (CD33+CD11b+CD14-CD15+H-
LA-DR-) of PBMC as measured by fl ow cytometry at three diff erent time points before and during treat-
ment with chemotherapy. iR patients are shown in red, iNR patients in blue (as defi ned in Figure 5A). B) 
Spearman correlation between the proportion of proliferating (Ki67+) CD8 T cells and the proportion 
of MDSC. C). Kaplan Meier curves for progression-free survival of patients with a Ki67+CD8/MDSC 
ratio higher or lower than the median value. ** p<0.005, *** p<0.0005 (Wilcoxon signed rank test)
DISCUSSION
In this study, we found that the PCB chemotherapy combination increased proliferation of 
peripheral blood CD8+ T cells in stage IV NSCLC patients. The proliferating CD8 T cells were 
mainly of the eff ector phenotype and expressed higher levels of the co-inhibitory receptors 
PD-1 and CTLA-4 than did their non-proliferating counterparts. The increased proliferation, 
however, had no signifi cant impact on the prognosis of patients.
Two recently published studies showed an increased proliferation of CD8 eff ector T cells 
during treatment with PD-1/PD-L1 inhibitors in melanoma [13] and in NSCLC [14], which was 
suggested to be associated with an improved response to the PD-1 checkpoint inhibition 
therapy. The relatively high expression of PD-1 and CTLA-4 and the eff ector phenotype of 
proliferating CD8 T cells in our study, are similar to those published studies, indicating the 
involvement of the same eff ector T cell population. Consequently, our fi ndings implicate 
that the increased proliferation that was previously reported after PD-1/PD-L1 inhibition, is 
not specifi c for response to immunotherapy, but can be induced by PCB as well.
Although in melanoma, a higher Ki67+ CD8 T cells to tumor burden ratio was associated 
with improved response to checkpoint inhibitors [13], in our current study no correlation was 
observed between the increased proliferation in CD8 T cells (either alone or in combination 
with tumor burden) and response to chemotherapy. In this study, no time points beyond 
6 weeks were available for analysis, so any delayed eff ects of immune modulation which 
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could have aff ected clinical outcomes were not assessed. In this context, it is of note that it 
was reported that in response to checkpoint inhibition, Ki67+ CD8 T cells peaked after three 
or six weeks in most patients (13). Even though no correlation with clinical outcome was 
found in patients treated with PCB, it is conceivable that the increase in Ki67+ CD8 T cells in 
combination with a decrease in tumor burden in a subgroup of patients, leads to an immune 
signature (a high Ki67+CD8/tumor burden ratio) that signifi es susceptibility to checkpoint 
inhibition. Nevertheless, without additional treatment these T cells are not eff ective in 
prolonging survival. This may partly be ascribed to PD-L1 expression by tumor cells or other 
cells in the tumor micro-environment, which can effi  ciently inhibit the proliferating PD-1+
eff ector T cells, thereby precluding eff ective tumor cell killing. Furthermore, T cells might be 
hampered to enter the tumor, either by physical constraints – e.g. dense tumor stroma – or 
by intra-tumoral immune suppressive factors [17-19], While peripheral blood off ers the ideal 
compartment for sequential immune monitoring, to ensure that our fi ndings of an increased 
immune activation in PBMCs actively contributes to an improved immune response within 
the tumor, our fi ndings require additional validation in paired tumor biopsies.
The importance of a systemic immune response for tumor eradication has been shown 
by Spitzer et al. [20], which indicates that peripheral blood immune subsets are clinically 
relevant for cancer treatment. Moreover, it was shown that a particular subset of proliferating 
CD4 eff ector memory T cells was important to prevent recurrences. Since we did not detect 
induction of proliferation in CD4 T cell subsets after chemotherapy, it might be that the 
proliferating CD8 T cells lack T cell help needed to be fully equipped to attack the tumor. 
In the studies monitoring patients on checkpoint inhibition, CD4 T cell proliferation was 
increased, although to a lesser extent than the CD8 T cells.
One factor that was not addressed in this study, is the specifi city of the proliferating CD8 T 
cells. It has been reported in literature that the PD-1+ T cell fraction is enriched for tumor-
specifi c T cells [21], which suggests that the increased proliferation mainly occurring in the 
PD1+ fraction, might be enriched for tumor specifi c T cells. However, currently we cannot 
draw any conclusions about the specifi city of the proliferating CD8 T cells induced after 
PCB in comparison with checkpoint inhibition.
We have previously reported that higher numbers of MDSC were correlated with a poorer 
OS in the same cohort of NSCLC patients [22]. Here, we show that the proportions of Ki67+
CD8 T cells were correlated with the proportions of MDSCs in peripheral blood of advanced 
stage NSCLC patients, suggesting a negative feedback loop of immune suppression in case 
of increased proliferation of CD8 T cells. This correlation might also contribute to the lack of 
improved clinical outcome in patients that exhibit an induction of CD8 T cells proliferation. 
4
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Furthermore, no correlations with clinical outcomes were found for any other myeloid cell 
populations, including monocyte subsets, or Treg (not shown).
Our findings of an induced CD8 effector cell proliferation are of particular interest given 
the recently reported positive phase III study comparing the same chemotherapy/ 
bevacizumab combination and atezolizumab versus PCB alone [9]. Since a positive result 
was reported for the first time in an unselected (for PD-L1 expression) patient population 
using this combination strategy, this might indicate a beneficial effect of the combination of 
checkpoint inhibition with chemotherapy/ bevacizumab, compared to checkpoint inhibition 
alone. Based on our data we cannot determine the differential role of the different agents. 
Certainly for anti-VEGF agents, like bevacizumab, data are available for its potential immune 
modulatory effect [23, 24].
Our finding that PCB increases proportions of proliferating CD8 T cells, which have been 
reported to correlate to response to checkpoint inhibition in relation to tumor burden 
[13], supports the hypothesis that chemotherapy, in this case combined with an anti-
vascular endothelial growth factor (VEGF) antibody, may increase responsiveness to PD-
(L)1 checkpoint inhibition. Furthermore, the relatively frequent expression of PD-1 on these 
proliferating CD8 T cells after therapy that we reported, highlights the potential of combined 
treatment of PCB with anti-PD-1 or anti-PD-L1 therapy. Due to their expression of PD-1, 
inhibition of the PD-1/ PD-L1 axis could reinvigorate these CD8 T cells to an effective immune 
response, especially since they are mainly of the effector phenotype. Although limited, the 
decreased per-cell expression of PD-1 after chemotherapy in immunological responders 
might point to a further increased susceptibility to treatment during later time points. This 
would be supported by the reported finding that T cells with intermediate PD1 expression 
are most sensitive to anti-PD-1 treatment [25].
Future studies will have to confirm whether the combination of chemotherapy and 
checkpoint blockade represents an effective combination, compared to checkpoint inhibition 
alone. To date, no clinical trials in NSCLC patients have directly compared these two arms. 
This study warrants further investigation into this combination strategy, in which Ki67+ CD8 
T cells need to be re-evaluated as potential predictive biomarkers.
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SUPPLEMENTARY DATA
Supplementary Table S1. Antibodies used for fl ow cytometry staining.
Antibody Intracellular/ extracellular Manufacturer
Myeloid staining
anti-CD15 PE Extracellular BD Biosciences
anti-CD16 PerCP-Cy5.5 Extracellular BD Biosciences
anti-CD33 PE-Cy7 Extracellular BD Biosciences
anti-CD11b APC Extracellular BD Biosciences
anti-HLA-DR APC-Cy7 Extracellular BD Biosciences
anti-CD14 PE-Texas-Red Extracellular Invitrogen
anti-ILT3 FITC Extracellular R&D Systems
T cell staining (direct)
anti-CCR7 FITC Extracellular R&D systems
anti-CD25 PE Cy7 Extracellular eBioscience
anti-CD3 APC-eFluor780 Extracellular eBioscience
anti-CD8 AF700 Extracellular eBioscience
anti-CD45RA PE Texas Red Extracellular Invitrogen
anti-CD19 PerCPCy5.5 Extracellular BD Biosciences
anti-CD14 PerCPCy5.5 Extracellular BD Biosciences
anti-CD16 PerCPCy5.5 Extracellular BD Biosciences
anti-CD4 BV786 Extracellular BD Biosciences
anti-CD28 BV605 Extracellular BD Biosciences
anti-PD1 BV711 Extracellular BD Biosciences
anti-FoxP3 PE Intracellular eBioscience
anti-Ki67 APC Intracellular eBioscience
anti-CTLA4 BV421 Intracellular BD Biosciences
Intracellular cytokine staining
anti-CD3 APC-eFluor780 Extracellular eBioscience
anti-CD8 AF700 Extracellular eBioscience
anti-CD45RA PE Texas Red Extracellular Invitrogen
anti-CD69 FITC Extracellular BD Biosciences
anti-CD4 BV786 Extracellular BD Biosciences
anti-PD1 BV711 Extracellular BD Biosciences
anti-Granzyme B PE Intracellular Invitrogen
anti-IFNγ APC Intracellular BD Biosciences
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Supplementary Table S2. Clinical and immunological Characteristics of lost-to-follow up patients 
versus patients
Study Pt (N=131) Lost FU (N=92) p-value
Clinical response
CR/PR/SD/PD (n)
2/56/55/12 1/30/31/8 0.97
T cells (% of PBMC) 35.7 (25.2-44.5) 44.5 (35.7-29.9) 0.16
CD4/ CD8 ratio 1.4 (0.8-2.1) 2.1 (1.4-0.7) 0.63
Myeloid cells (% of PBMC) 19 (11.1-33.2) 33.2 (19-10.4) 0.27
B cells (% of PBMC) 6.9 (4-10.7) 10.7 (6.9-3.6) 0.09
Naïve (% of T cells) 26.2 (14.5-39.2) 39.2 (26.2-13.2) 0.19
Central memory (% of T cells) 22 (15.6-27.6) 27.6 (22-10.3) 0.56
Effector memory (% of T cells) 24.7 (17.3-33) 33 (24.7-18.3) 0.96
CD45RA+ Effector memory
(% of T cells)
17 (8.5-30.5) 30.5 (17-11.3) 0.08
Values of immune populations represent medians and interquartile range between brackets; 
p-value for clinical response is tested with chi-square test; p-value for immune populations is 
from Mann-Whitney U test; CR = complete response; PR = partial response, SD = stable disease, 
PD = progressive disease
Supplementary Table S3. Patient data of patients whose blood was received for at least two time 
points. Patient characteristics, clinical response and immune populations after treatment.
Arm A (PCB)
(n=68)
Arm B (PCB + N) 
(n=63)
Total
(n=131)
Clinical response*
Complete response
Partial response
Stable disease
Progressive disease
Not evaluable
1 (1.5%)
35 (51.5%)
25 (36.8%)
3 (4.4%)
4 (5.9%)
1 (1.6%)
21 (33.3%)
30 (47.6%)
9 (14.3%)
2 (3.2%)
2 (1.5%)
56 (42.7%)
55 (42.0%)
12 (9.2%)
6 (4.6%)
Immune populations after 
treatment (week 6) Median (IQ range) Mann-Whitney
% T cells
CD4/CD8 ratio
% myeloid cells
% B cells
47.7 (34.3-56.7)
2.6 (1.4-3.5)
17.0 (7.4-24.9)
5.9 (3.6-8.9)
43.7 (33.5-52.7)
1.8 (1.2-2.9)
17.4 (8.4-29.5)
7.5 (4.4-10.2)
N.S.
N.S.
N.S.
N.S.
Immune populations after 
treatment (week 3) Median (IQ range) Mann-Whitney
% T cells
CD4/CD8 ratio
% myeloid cells
% B cells
42.5 (28.1-52.1)
2.2 (1.2-3.6)
18.0 (7.6-27.7)
5.4 (3.5-10.6)
43.2 (29.9-51.0)
1.7 (1.3-2.7)
20.4 (9.4-28.4)
6.2 (4.1-10.6)
N.S.
N.S.
N.S.
N.S.
* as defined by RECIST1.1; PCB=paclitaxel/carboplatin/bevacizumab, N = nitroglycerin patch, IQ 
range = inter quartile range
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Supplementary Figure S1. Absolute numbers of immune cells per liter peripheral blood of NSCLC 
patients treated with chemotherapy. Absolute leukocytes, neutrophils, PBMC (leukocytes–neutrophils), 
T cells, B cells and monocytes were determined at baseline (week 0) and after the fi rst (week 3) and 
second (week 6) cycle of chemotherapy. Data are shown from a subgroup of patients of whose abso-
lute white blood cell counts were determined on the same day as the PBMC fl ow cytometry analysis 
(n=74). *** p<0.001; ns = not signifi cant (Wilcoxon signed rank test)
Supplementary Figure S2. Proportions of major T cell subsets in NSCLC patients treated with 
chemotherapy. Proportions of CD8+ T cells (A), non-regulatory CD4+ T cells (B) and regulatory CD4+
T cells (C) in PBMC T cells of NSCLC patients treated with PCB before start (week 0), after the fi rst 
(week 3) and second (week 6) cycle of chemotherapy, as determined by fl ow cytometric analysis. Bars 
represent median values with interquartile range. * p<0.025 ** p<0.005 ***p<0.0005 (α level adjusted 
for multiple comparisons; Wilcoxon signed rank test)
4
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Supplementary Figure S3. Monocyte subsets in peripheral blood of NSCLC patients treated with 
chemotherapy. Proportions of classical (CD14++CD16-), intermediate (CD14++CD16+) and non-clas-
sical (CD14intCD16+) monocytes before (week 0), and after the first (week 3) and second (week 6) 
chemotherapy cycle, as defined in a subset of patients (n=97). Box plot whiskers depict the 10-90% 
range. * p<0.05, *** p<0.001, ns = not significant (Wilcoxon signed rank test)
Supplementary Figure S4. Co-inhibitory receptor expression on proliferating CD8 TEMRA cells in pe-
ripheral blood of chemotherapy-treated NSCLC patients. A) Proportions of PD1+ cells within Ki67- and 
Ki67+ CD8 TEMRA populations over time. B) PD-1 expression on Ki67- and Ki67+ PD-1+ CD8 TEMRA cells over 
time, as depicted by mean fluorescent intensity (MFI). The MFI value is presented as biexponentially 
transformed value. C) Expression of CTLA-4 CD8 TEMRA subsets as defined by PD1 and Ki67 expression 
over time. Biexponentially transformed MFI value is depicted. In all graphs, the bars show median 
values with the interquartile range depicted by the error bars. * p<0.05, ** p<0.01, *** p<0.001 (Wil-
coxon-signed rank test)
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Supplementary Figure S5. Ki67+ CD8/ tumor burden ratio in NSCLC patients in relation to clinical 
outcome. The Ki67+ CD8/tumor burden ratio was calculated by dividing the percentage of Ki67+ cells 
of CD8 T cells, by the total tumor diameter before treatment. Total tumor diameter was determined 
as the sum of the diameters of target lesions measured on computed tomography (CT) scans. A) The 
Ki67+CD8/tumor burden ratio in non-responders, stable disease patients and responders (both partial 
and complete), as defi ned by RECIST criteria. B) Overall survival of patients with a Ki67+CD8/tumor 
burden ratio >50 (n=79) and <50 (n=87). Kaplan Meier curves were compared with a log-rank test, 
which showed no signifi cant diff erence.
Supplementary Figure S6. PD1 and CTLA4 expression on Tregs. Fraction of PD1+ Tregs (left) and 
CTLA4 MFI of Tregs (right) as determined by fl ow cytometry in patients at week 0, 3 and 6.
4
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ABSTRACT
Over the last decades, the role of the immune system in the development and treatment of 
cancer has been more and more recognized and understood. Various individual immune 
populations have been shown to be associated with treatment response or survival outcome, 
but the clinical value differs for the different cancer types, stages and treatments. We 
hypothesized that a combination of immune populations can be used to predict survival 
of non-small cell lung cancer (NSCLC) patients. To analyze multiple immune populations 
derived from complex flow cytometry data, we used a semi-automatic analysis pipeline 
FloReMi, which has recently been developed. In this study, we assessed the feasibility 
of this method for our research question by applying the pipeline on a study with 180 
stage IV NSCLC patients receiving chemotherapy treatment. Peripheral blood samples 
were collected and immune populations were examined using three flow cytometry panels 
with 12-16 markers each. Population frequencies and expression levels were extracted from 
these data and a random survival forest model was trained and evaluated using five-
fold cross validation. The feature extraction from the FloReMi pipeline was compared to 
manually obtained features and showed a good correlation (average ρ = 0.81). A total of 
63,423 features were extracted from the flow cytometry data in the FloReMi pipeline. The 
feature selection step selected 37-41 features to be used in the prediction model. The 
RSF model had an error rate of 0.421, which was lower than the error rate of the random 
survival forest model trained with manually obtained features (0.472). The model did give a 
significant prediction of overall survival (p= 9.6∙10-4). The top feature found with the FloReMi 
analysis was the frequency of HLA-DR-CD33+ population. In conclusion, semi-automatic 
gating with FloReMi is a feasible way to extract an exhaustive number of features from 
flow cytometry data. Although prediction of survival based on the selected features was 
statistically significant, in contrast to a model based on manually obtained features, the 
accuracy of prediction is too low to be of clinical significance. Therefore, this method is more 
suitable for explorative research than to develop clinically applicable prediction rules. The 
selected features derived from this pipeline require further investigation and validation to 
assess their clinical value.
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INTRODUCTION
The immune system plays an important role in the development of cancer and in the 
response to cancer therapy [1]. There has been an increasing number of immunotherapies 
that harness the immune system to fi ght cancer, which have been FDA approved for 
treatment against various kinds of cancers [2], but also conventional therapies have been 
reported to rely heavily on the patients’ immune system for their eff ect [1, 3]. One of the 
cancer types in which immunotherapy has been successfully implemented over the last 
decade, is non-small cell lung cancer (NSCLC). However, only a minority of patients benefi ts 
from long-term responses, so a better tailoring of treatments to the right patient is needed. 
Several immune populations have been described to correlate with survival in various 
types of cancer, either in the tumor microenvironment or in the peripheral blood. While 
some markers are either favorable or unfavorable in several cancer types, many immune 
populations rendered contradictory results in literature, which might be either dependent 
on tumor type, or other (sometimes unknown) factors [4]. In NSCLC, various immune 
populations present in the local tumor microenvironment, have been reported to have 
prognostic value, as reviewed elsewhere [5, 6]. In peripheral blood, elevated proportions 
of myeloid-derived suppressor cells have been reported to be associated with a reduced 
survival [7, 8]. Naïve regulatory T cells in peripheral blood are also associated with a worse 
survival, while terminally diff erentiated regulatory T cells are associated with an improved 
survival [9].
To predict survival of cancer patients or their response to therapy with the goal to facilitate 
personalized medicine, it is likely that a combination of known biomarkers will give the 
most accurate prediction. For example, as has been shown in melanoma, the increase in 
Ki67 expressing PD1-positive CD8 T cells, solely did not predict response to PD-1 inhibition. 
However, combined with tumor burden, the Ki67+CD8/tumor burden ratio was signifi cantly 
associated with survival [10]. We hypothesized that the immune profi le of non-small cell 
lung cancer patients, comprising a combination of immune markers, can predict survival 
and may be used to personalize cancer treatment.
The most frequently used sample type to study the immune profi le of patients is the 
peripheral blood, which is easily accessible and can be obtained sequentially to monitor 
dynamics of immune populations. Flow cytometry is the most common technique to defi ne 
various immune cells, using various markers at the same time at the single cell level. Due to 
technical developments, the number of fl uorochromes that can be measured at the same 
time is increasing, which leads to the generation of increasingly complex data. Moreover, 
with the introduction of CyTOF that makes use of mass spectrometry to distinguish diff erent 
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isotopes instead of fluorescence, even more markers (currently up to 50) can be measured 
per cell. Manual analysis of these data becomes very labor intensive, and in addition is 
prone to researcher bias. (Semi)-automatic data analysis will become indispensable in 
future research using flow cytometry. Currently, various (semi)-automatic pipelines are 
being developed [11], but are not yet commonly used in the (tumor) immunology field. In 
this study, we used and evaluated a recently developed pipeline (FloReMi) [12] to predict 
survival in a cohort of NSCLC patients, based on their immune profile as determined by flow 
cytometry on peripheral blood samples. We evaluated whether the use of this pipeline can 
reliably define various immune populations, and whether this provides a useful prediction 
model for personalized medicine when used with a clinical trial cohort of about two hundred 
patients.
MATERIAL AND METHODS
Patient samples
The patients in this study were participating in the NVALT12 study (trial number NCT01171170), 
a randomized Phase II multicenter study on the effect of a nitroglycerin patch or placebo in 
patients with stage IV NSCLC treated with carboplatin, paclitaxel, and bevacizumab. Patients 
in the NVALT12 study were diagnosed with stage IV non-squamous NSCLC and were not 
eligible for treatment with curative intent. Disease stage was determined in accordance with 
the American Joint Committee on Cancer (AJCC). Further details of the study are described 
elsewhere [13]. Blood samples were collected before the start of treatment and peripheral 
blood mononuclear cells (PBMC) were isolated using standard density gradient procedure. 
Written consent was obtained from all individuals before blood sampling and the study 
was approved by CCMO: NL33442.042.10). Patient characteristics that were collected and 
used in the current study were age, sex, smoking status (current smoker, ex-smoker and 
non-smoker) and WHO performance score.
Flow cytometry data acquisition
Three different stainings were performed on the PBMC samples, which are described in 
Chapter 4 [14]. Flow cytometry data was acquired on an LSR II (BD Biosciences) with 
three lasers. Application settings were used to calibrate the fluorescence signals on each 
measurement day. Manual gating was performed in FlowJo version X (FlowJo, LCC).
FloReMi analysis pipeline
We used the FloReMi pipeline as described in van Gassen et al. [12] with some adjustments 
for the current dataset. All analyses were performed in R version 3.3.2 for windows. Below, 
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the four steps of the FloReMi pipeline are described: preprocessing, feature extraction, 
feature selection and survival prediction.
Preprocessing
During preprocessing, only good quality events were selected from the fcs fi les, by selecting 
only those events that were recorded during stable fl ow. To this end, th resholds were set 
for each sample as the average fl ow ± X events/s with X=100 as default, adjusted manually 
for individual samples when necessary based on visual analysis. Moreover, margin events 
on the FSC and SSC channels were removed. The values of the fl uorescence channels were 
compensated using the compensation matrix derived from the BD FACSDiva software, 
as calculated based on compensation controls, and subsequently transformed with 
biexponential transformation. With manual gates generated in FlowJo, a population of 
single live cells (MDSC staining) or single live T cells (T cell stainings) was selected as starting 
population for feature extraction.
Feature extraction
For a selection of markers (see Table 1, column 2) gates were created automatically based 
on one-dimensional histograms using the deGate function of the fl owDensity package. 
For each of these markers, an optimal threshold was determined, which divided cells into a 
positive and a negative population. All automatically determined thresholds were visualized 
and manually checked. Where needed, manual adjustments to the thresholds were 
implemented. Features were created using the fl owType function of the fl owType package: 
for each staining, populations were defi ned by combining all possible combinations of 
marker values (positive, negative or neutral), extracting both frequency of the populations, 
as well as the MFI value of all markers (table 1 column 2 and 3) as features. Whether 
thresholds were set for certain markers or not, was determined based on their expression 
profi le: if a clear positive and negative population could be distinguished, or if an FMO 
control could be used to defi ne the threshold, the marker was used with a split to create 
a positive and negative populations. For markers with a more gradual expression profi le, 
the expression was only included as MFI value. For the markers Ki67 and PD1 in staining A, 
thresholds were set based on the 99.5 percentile of isotype controls. Furthermore, based on 
variance between samples (determined by visual inspection of the histograms), a threshold 
was set for each sample individually, or for a whole batch of samples measured on the same 
day using aggregated data.
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Table 1. Markers used for feature extraction in FloReMi pipeline.
Staining Markers for splits and MFI Markers for MFI only
A CCR7, FoxP3, CD45RA, PD1, CD4, Ki67, CD8 CD25, CTLA4, CD28, CD3
B CD69, Granzyme B, CD45RA, CD4, IFNγ and CD8 PD1, CD3
C FSC-A, SSC-A, CD14, CD33, CD11b, HLA-DR, CD15
Feature selection
For the feature selection step, a Cox proportional hazards model was applied for all 
individual features, determining the strength of their association with overall survival. Then, 
all features were sorted based on either the p-value or the concordance index from these 
individual Cox proportional-hazards models (both sorting methods were evaluated during 
optimization of the model). Features were selected starting from the feature with the lowest 
p-value or the highest concordance index, only selecting features that had a correlation 
coefficient (Pearson r) <0.2 for correlation with already selected features. The first 5000 
features of the sorted feature list were evaluated for feature selection.
Survival prediction
For survival prediction, a random survival forest (RSF) model was trained used using the 
rfsrc function of the randomForestSRC R package. The number of trees was set to 500 and 
missing data (caused by missing MFI values for ‘empty’ population, or by samples on which 
not all three stainings were performed due to insufficient cell numbers) were imputed using 
the on-the-fly random imputation strategy implemented in the rfsrc library [15].
Cross validation
To evaluate the performance of the model, we performed a five-fold cross-validation. In 
contrast to the original pipeline [12], the feature selection step was included in the cross-
validation. This means that feature selection was performed only on the train data within the 
five folds, preventing selection of features based on their predictive value on the complete 
data, including the validation set, which would lead to a bias. The trained RSF model was 
evaluated on the five validation sets, which resulted in a predicted survival score for each 
patient in the validation set. We evaluated the predictive value of the individual folds using 
their error rate. This error rate was calculated in the rfsrc function and is calculated as 1 – C, 
with C being Harrell’s concordance index [16]. To evaluate overall performance of the cross-
validation, a Cox regression was performed on the complete dataset, using the predicted 
survival score as single variable to predict actual survival. Concordance index and p-value 
were used as performance measure of this Cox regression model.
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RESULTS
FloReMi-derived features are strongly correlated with manually defi ned 
populations
Flow cytometry data were obtained from peripheral blood samples of 190 stage IV non-
squamous NSCLC patients. The raw fcs fi les were analyzed with two diff erent methods: 
the (semi-)automatic analysis pipeline FloReMi (as described in van Gassen et al [12]), and 
manual gating in FlowJo as the golden standard. Our fi rst aim was to compare the features 
that were extracted with the FloReMi pipeline, with the manually defi ned features. For this 
aim we focused on stainings A and B, because for these stainings, a substantial number of 
populations was manually gated (in contrast, staining C was used to defi ne MDSC only). The 
manual gating strategy for these panels are shown in fi gure 1, which led to the identifi cation 
of 44 and 49 populations in staining A and B, respectively. In the FloReMi analysis pipeline, 
the preprocessing step included quality control of the samples and selection of the start 
population. On average 3.4% (± 3.1%) of events were removed from the sample in the 
quality control step, based on an unstable fl ow or values outside of the outer margins. A 
start population for further analysis was used, based on the manual gates for T cells in both 
stainings. All events that passed quality control and that were within the start population 
gate, were used for the subsequent step of the pipeline: feature extraction. During this step, 
26,244 and 6,561 features were extracted from panel A and B, respectively. These features 
consisted of the proportions of all defi ned populations within the start population, and 
additionally the MFI values of all markers on each of these populations, as defi ned by the 
markers in table 1. To assess the reliability of the automatically extracted features in the 
FloReMi pipeline, we calculated the correlation between the manually gated populations 
and the corresponding features from the FloReMi analysis and found a mean Spearman 
ρ value of 0.81 (± 0.19). Figure 2 shows the correlation between some of the automatically 
defi ned and manually gated populations, as an example. In general, larger populations 
correlated more strongly than the (very) small populations. From these results, we concluded 
that using the FloReMi pipeline, reliable features can be extracted from raw fl ow cytometry 
data.
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Figure 1. Manual gating of immune populations in T cell stainings A and B. A) Staining A was per-
formed on cells immediately after thawing. After pregating on live cells and single cells (based on FSC-A 
and FSC-H), T cells were gated as CD3+Lin- cells. Next, CD4+ and CD8+ T cells were gated. CD4 T cells 
were subdivided based on their CD45RA and FoxP3 expression according to Miyara et al. (Immunity 
2013), with activated Tregs gated as FoxP3highCD45RA-, resting Tregs as FoxP3intCD45RA+. All other CD4+ 
T cells together were identifi ed as non-regulatory CD4 T cells. Non-regulatory CD4 T cells and CD8 
T cells were further gated based on their CD45RA and CCR7 expression into naïve (CD45RA+CCR7+), 
central memory (TCM; CD45RA-CCR7+), eff ector memory (TEM; CD45RA-CCR7-) and CD45RA+ eff ector 
(TEMRA; CD45RA+CCR7-) cells using Boolean gates. On all populations, the proportions of CD25+, PD1+
and Ki67+ cells were assessed. B). Before staining, cells were stimulated for 4 hours with PMA/iono-
mycin. After pregating on live cells and single cells (based on FSC-A and FSC-H), T cells were gated as 
CD3+ cells. Next, CD4+ and CD8+ T cells were gated. Using boolean gates, the proportions of Granzyme 
B and IFNγ-positive and negative populations were determined on both CD4 and CD8 T cell subsets. 
Of each of the combined populations, proportions of CD45RA+, CD69+ and PD1+ cells were assessed.
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Figure 2. Correlations between manual gating and automatic gating in the FloReMi pipeline. A se-
lection of manually gated populations, and their corresponding FloReMi populations. For proportions 
of marker-positive cells within specifi c population, the two corresponding FloReMi populations were 
divided by each other (for example PD1+CD4-CD8- cells divided by all CD4-CD8- cell to calculate per-
centage PD1+ cells within the CD4-CD8- population). The top two rows are populations from staining 
A, the bottom row are populations from staining B. The numbers on the axes represent percentages. 
The Spearman ρ correlation of both populations was calculated for all baseline patient samples (n=190).
Prediction model for survival in NSCLC patients using ﬂ ow cytometry 
features
For the prediction model, we used the extracted features from the three stainings (A, B 
and C). Staining B was performed on a stimulated and an unstimulated sample for each 
patient, and features derived from both samples, as well as the diff erence between the 
two samples, were included. Additionally, some of the features based on clinical/ patient 
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characteristics collected in the clinical trial were included: age, sex, smoking status (current 
smoker, ex-smoker and non-smoker), WHO performance score and treatment arm. The 
total number of features before feature selection was 26,244 (A) + 3 ∙ 6561 (B) + 17,496 (C) 
+ 5 (clinical) = 63,428.
An RSF model was trained and evaluated using five-fold cross-validation: data of four 
folds (80%) were used for feature selection and to train the model, which was evaluated 
using the data of the fifth fold. This was repeated five times, using each of the folds once 
for evaluation. In the same way, cross-validation was performed for an RSF model using 
the features from manual gating instead (frequencies and MFIs as shown in figure 1). The 
predicted score for both models was plotted against the actual overall survival time in 
figure 3. The correlation between the predicted and actual survival time was evaluated 
with a cox model using the predicted score as variable for actual OS. Strikingly, while the 
predicted score was not significantly associated with the actual overall survival in the model 
using features from manual gating (p=0.97), the predicted score of the FloReMi model was 
significantly associated with the actual overall survival (p=9.6∙10-4). The model evaluation of 
the cross-validation of both models is summarized in table 3. An error rate for each fold of 
CV was calculated, and the average and range are displayed. An error rate of 0 represents 
a perfect prediction, whereas a random prediction would result in an error rate of 0.5. The 
number of selected features differed per fold. Both the concordance index and the p-value 
were derived from the Cox regression using the predicted scores. From these results, we 
concluded that the FloReMi pipeline can achieve a significant predictive value in lung cancer 
patients, but that this prediction is only marginally better than random.
Figure 3. Correlation between RSF prediction from cross-validation and actual survival data. Actual 
OS time is displayed as number of days. An RSF model was trained using the automatically extracted 
features from the FloReMi pipeline (left) and using the features derived from manual gating in FlowJo 
(right).
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Table 2. Results of the fi nal model and prediction on the holdout data.
FloReMi RSF model RSF model with manual features
Error rate 0.421 (0.38-0.48) 0.472 (0.35-0.55)
Number of features 43.2 (37-51) 16.6 (15-18)
Cox regression p-value 9.6E-4 0.971
Cox concordance index 0.58 0.49
Table 3. Selected features.
# feature subset staining
1 % of cells CD33+HLA-DR- C
2 CD45RA MFI CD69-GzmB-CD8- B diff erence
3 CD14 MFI CD14+CD33-CD11b+ C
4 median FSC-A CD14-CD11b-HLA-DR+CD15+ C
5 CD14 MFI CD33+CD11b-HLA-DR-CD15- C
6 % of cells FoxP3+CD45RA-PD1-CD4-CD8+ A
7 CD25 MFI CCR7-CD45RA-CD4-Ki67+CD8- A
8 CD8 MFI CCR7-FoxP3-CD45RA+PD1+CD4-CD8- A
9 HLA-DR MFI FSC-A+SSC-A-CD14-CD33+CD11b+HLA-DR+CD15- C
10 median FSC-A SSC-A+CD33-CD11b+HLA-DR+CD15- C
11 PD1 MFI CD69-CD4+CD8- B diff erence
12 CD25 MFI CCR7+FoxP3+CD4-Ki67+CD8+ A
13 FoxP3 MFI CCR7+CD45RA-PD1-Ki67+CD8+ A
14 CD45RA MFI CCR7-FoxP3+CD45RA-PD1-CD4+CD8+ A
15 HLA-DR MFI FSC-A+SSC-A-CD14-CD33+CD11b- C
16 CTLA4 MFI FoxP3-CD45RA-PD1-CD4+Ki67+CD8+ A
17 CD33 MFI SSC-A-CD15+ C
18 GzmB MFI CD69-IFNg+CD8+ B diff erence
19 CD3 MFI CD69+GzmB-CD45RA-CD4-CD8- B unstimulated
20 HLA-DR MFI FSC-A+SSC-A+CD14-CD33-CD11b-HLA-DR+ C
21 median SSC-A FSC-A+SSC-A+CD14-CD33-CD11b-CD15+ C
22 CTLA4 MFI CCR7-FoxP3+CD4-Ki67+CD8+ A
23 median SSC-A FSC-A-SSC-A-CD33-CD11b-CD15- C
24 median FSC-A FSC-A-SSC-A-CD33-CD11b+HLA-DR-CD15+ C
25 CD33 MFI CD14+CD33-HLA-DR- C
26 CD11b MFI FSC-A-CD33-CD11b-HLA-DR- C
27 median FSC-A FSC-A-CD14-CD11b+HLA-DR-CD15- C
28 HLA-DR MFI FSC-A+CD14-CD11b+CD15- C
29 CD69 MFI CD69+CD4+IFNg-CD8+ B stimulated
30 PD1 MFI GzmB+IFNg+ B diff erence
31 CCR7 MFI CCR7+FoxP3-CD45RA+PD1+Ki67+ A
32 HLA-DR MFI FSC-A-HLA-DR- C
33 CD3 MFI CD45RA-IFNg+CD8- B diff erence
34 CD11b MFI FSC-A+SSC-A- C
35 FoxP3 MFI CCR7-FoxP3+CD4+Ki67-CD8+ A
36 PD1 MFI CCR7-CD45RA-Ki67+ A
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37 FoxP3 MFI CCR7+FoxP3+PD1+Ki67-CD8+ A
38 CD4 MFI CD69+GzmB+CD45RA-IFNg-CD8- B stimulated
39 CD8 MFI CD69-CD4- B difference
40 CD4 MFI CCR7-FoxP3+CD45RA+CD8+ A
41 PD1 MFI CCR7+FoxP3-CD45RA+PD1+CD4+Ki67+ A
42 PD1 MFI GzmB-CD45RA-CD4-CD8- B difference
43 CD11b MFI FSC-A-SSC-A-CD11b-HLA-DR+CD15+ C
44 CD45RA MFI CD69-GzmB+CD4+IFNg- B difference
45 CD45RA MFI CD45RA+PD1+CD4+Ki67+ A
46 CD15 MFI SSC-A+CD14+CD33+HLA-DR-CD15+ C
47 CD25 MFI CCR7-CD45RA+PD1-CD4+CD8+ A
48 CD45RA MFI CD69-GzmB+CD45RA-CD4- B difference
49 HLA-DR MFI FSC-A-SSC-A+CD14+CD33+HLA-DR-CD15- C
50 CD14 MFI FSC-A-CD14+CD33-CD11b-HLA-DR+ C
51 CD8 MFI FoxP3+CD45RA+PD1-CD4+Ki67+CD8- A
Figure 4. Survival of patients based on individual FloReMi selected features. A-E show the top 6 
selected features (see table 3). Patient groups were split on the median value of the feature, and the 
curves were compared with a log-rank test.
Survival analysis of individual selected features
From a biological viewpoint, it is valuable to know which features contribute to a significant 
prediction of overall survival. Since the five folds of cross-validation each led to a different 
set of features, we performed a feature selection step on all samples for a final selection 
of features, which are listed in table 3. To assess the clinical value of the resulting FloReMi 
features with a conventional statistical analysis method, we compared survival of patients 
based on the top six selected features, in which two patient groups with above or below 
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median value for the feature were compared. Five of the top six selected features showed 
a signifi cant diff erence between the patient groups (Figure 4).
DISCUSSION
Flow cytometry panels are becoming increasingly complex as the technique advances, 
leading to generation of large amounts of high-dimensional data. With manual analysis of 
these data, only two markers can be analyzed at the same time, which can be labor-intense, 
subjective and ineffi  cient when working with large marker panels. Various computational 
models are being developed to overcome these problems, with the objective of visualization 
and/ or computation of fl ow cytometric data, as reviewed in [11]. The FloReMi pipeline is 
one example of these newly developed tools and is aimed specifi cally to predict survival 
of patients using features extracted from fl ow cytometry data, which fi tted our research 
question and patient cohort. Here, we used this pipeline for the fi rst time on a dataset 
other than the dataset used for development of the pipeline, to assess the value of this 
analysis method for predicting survival of cancer patients based on their immune profi le. 
We showed that feature extraction using semi-automatic gating produces reliable features 
in an unbiased manner. Subsequent survival prediction using these features provided a 
signifi cant prediction, although only marginally better than random.
The FloReMi pipeline consists of four steps: pre-processing, feature extraction, feature 
selection and survival prediction, which can be used independently. After pre-processing 
to ensure quality of the data, feature extraction generated an exhaustive number of 
immune populations based on cutoff s to defi ne positive and negative populations for 
each marker. Although by using cutoff s, information on the continuous variable is lost, this 
does correspond to ‘gating’ in manual analysis, which makes the generated populations 
comparable to manually obtained populations and interpretable. Indeed, a high correlation 
was found with the manually defi ned populations. Moreover, expression level values are 
included in additional features derived from MFI values of each marker for every population. 
The feature extraction step could therefore be useful in future studies to automate analysis 
of extensive marker panels in studies with large numbers of samples.
In the feature selection and survival prediction steps, features are fi rst sorted based 
on their association with outcome in the train data. The most informative features are 
selected without including features that are correlated to other selected feature, to reduce 
redundancy. This led to a manageable list of selected features (around 40), that were used 
to train a survival model. From a biological view point, it is interesting to review this list of 
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selected features. We have shown previously that myeloid-derived suppressor cells (MDSC) 
are associated with survival in this cohort of patients [7]. Therefore, we hypothesized that 
amongst others, MDSC-related features would be selected and provide predictive value 
in the survival model.
The first selected feature that had the strongest correlation to survival in the training data, 
was the percentage of CD33+HLA-DR- cells of total PBMC in staining C. This feature partly 
overlaps with our definition of MDSC (which are CD33+HLA-DR-, but additionally also CD11b+, 
and CD14+ or CD15+ depending on the MDSC subset) [7], but has also been reported as a 
broader definition of MDSC in combination with the absence of lineage marker expression 
[17, 18]. The second selected feature was the difference in CD45RA expression between the 
stimulated and unstimulated condition CD69-GzmB-CD8- cells. This feature is more difficult 
to interpret, as overall CD45RA expression does not differ between the stimulated and 
unstimulated condition, but rather the size of the CD69- T cell population, likely affecting 
the CD45RA MFI (data not shown). In general, features consisting of an MFI on a certain 
population do not always have a clear biological meaning, especially when it concerns an 
MFI feature of a population negative for that marker (for example feature #8 in table 3). 
Due to the exclusion of features based on their correlation with other selected features, 
better known or interpretable features might be excluded if they are lower on the sorted 
list. Further investigation into the (biological or technical) relation between the correlated 
features would be worthwhile to discover the most biologically relevant features. For 
example, instead of excluding the majority of features, feature clustering could be used in 
which an average cluster value could be used in the survival model.
The overall performance of the survival model was only marginally better than random. 
However, using only the manually obtained features, no predictive value was generated at 
all. This does suggest that the FloReMi pipeline is able to improve survival prediction by 
using the flow cytometric data to its maximal extent, including features that would otherwise 
not been manually gated for.
There are several possible explanations for the low performance of the survival prediction 
in this study. Firstly, there might be limited predictive value in the peripheral blood immune 
profile of NSCLC patients. However, the potential of the immune profile as prognostic 
marker has been shown by the immunoscore as developed in colorectal cancer [19]. Here, 
a combined score of immune populations in the local tumor environment had strong 
prognostic value and was used to classify patients in different risk groups. The prognostic 
value of immune populations in peripheral blood is less definite, but several immune 
populations have been shown to be associated with survival in NSCLC [20, 21]. Whereas 
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log-rank tests evaluate the association of certain markers with survival in a group of patients, 
this is arguably not suffi  cient to indeed predict survival of an individual patient. The top 
feature discovered with the FloReMi pipeline, HLA-DR-CD33+ cells, has a similarly strong 
association with survival as the previously published MDSC [7], which suggests that this 
method is not inferior to manual survival analysis.
Secondly, even though the analysis pipeline is an unbiased approach to data analysis, the 
choice of markers in the fl ow cytometry panel is still a manual procedure which will introduce 
some bias. In our study design, we tried to create panels containing the most relevant 
markers focused on T cells or myeloid-derived suppressor cells based on literature. Still, 
the number of markers to be included in a single staining is limited, and therefore these 
stainings might not have captured all relevant immune parameters for survival prediction in 
NSCLC. In contrast, gene expression analysis would represent a more unbiased approach, 
which has been employed by some other groups in NSCLC [22, 23] and other cancer types 
[24-26]. The drawback of RNA sequencing, however, is the lack of information on protein 
levels.
Thirdly, feature selection using features sorted on their p-value derived from individual 
association with survival, will render some false positive fi ndings. The most strongly 
associated features are selected, but no threshold is used as how strong this association (p 
value or eff ect size) should be before inclusion in the selected feature list. In contrast to the 
fi rst reported use of the pipeline, we here have included feature selection within the cross-
validation. In the original report, a leave-one-out cross-validation provided a concordance 
index of 0.99, but in this analysis the features were preselected on outcome for the whole 
dataset. Final evaluation of the holdout set provided a concordance index of 0.67 equaling 
an error rate of 0.33, which has been reached here in the best performing folds as well. The 
disadvantage of selecting features within the cross-validation is the prolonged calculation 
time, as feature selection calculation is relatively time-consuming compared to fi tting the 
RSF model. Therefore, further improvements to the feature selection step should take into 
account calculation time as a relevant factor next to interpretability of results.
Lastly, survival models for patients based solely on their peripheral blood immune profi le 
would be unlikely to reach a predictive value close to 1, as there are a myriad of factors 
infl uencing survival of cancer patients. Therefore, the FloReMi method would be more 
valuable as an explorative tool to discover populations that are associated with patient 
survival, by investigating the selected feature list.
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In summary, the semi-automatic analysis pipeline of flow cytometry data can be used to 
analyze high-dimensional flow cytometry data derived from peripheral blood of NSCLC 
patients to extract large amounts of features, which can be used for any kind of further 
analysis. Survival prediction using these features can potentially generate biological and 
clinical value, although this should be further investigated in another clinical dataset with 
known clinical value. The selected features in this study, could be interesting targets for 
further investigation on their clinical value in NSCLC patients.
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SUPPLEMENTARY DATA
Supplementary table 1. Antibodies used for fl ow cytometry
Marker Fluorochrome Company Catalog #
Staining A: T cells (immediately stained)
CCR7 FITC R&D systems FAB197F
CD14 PerCPCy5.5 BD Biosciences 550787
CD16 PerCPCy5.5 BD Biosciences 560717
CD19 PerCPCy5.5 BD Biosciences 561295
CD25 PE Cy7 eBioscience 25-0259-42
CD28 BV605 BD Biosciences 562976
CD3 APC-eF780 eBioscience 47-0038(-42)
CD4 BV786 BD Biosciences 563877
CD45RA PE Texas Red Invitrogen MHCD45RA17
CD8 AF700 eBioscience 56-0088-42
CTLA4 BV421 BD Biosciences 562743
FoxP3 PE eBioscience 12-4777(-42)
Ki67 APC eBioscience 17-5699(-42)
PD1 BV711 BD Biosciences 564017
LIVE/DEAD™ fi xable aqua dead cell stain BV510 Invitrogen L34966
Staining B: T cells (stimulated)
CD3 APC-eF780 eBioscience 47-0038(-42)
CD4 BV786 BD Biosciences 563877
CD45RA PE Texas Red Invitrogen MHCD45RA17
CD69 FITC BD Biosciences 555530
CD8 AF700 eBioscience 56-0088-42
GzmB PE Invitrogen MHGB04
IFNγ APC BD Biosciences 554702
PD1 BV711 BD Biosciences 564017
LIVE/DEAD™ fi xable aqua dead cell stain BV510 Invitrogen L34966
Staining C: Myeloid cells
CD11b APC BD Biosciences 340937
CD14 PE-Texas Red Invitrogen MHCD1417
CD15 PE BD Biosciences 555402
CD16 PerCP-Cy5.5 BD Biosciences 560717
CD33 PE-Cy7 BD Biosciences 333946
HLA-DR APC-Cy7 BD Biosciences 335796
ILT3 FITC R&D systems AF2425
DAPI Measured in 
BV421
Invitrogen D1306
Supplementary Table 2. Number of features extracted from each staining and per patient
T cell staining A T cell staining B MDSC staining
Number of markers to split 7 6 7
Number of markers for MFI 11 8 7
Features per sample 26,244 6,561 17,496
Features per patient 26,244 19,683 17,496
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CELL LYSATE IN MESOTHELIOMA: FROM 
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STATEMENT OF TRANSLATIONAL RELEVANCE
Malignant pleural mesothelioma is a highly lethal neoplasm for which new treatment 
options, like immunotherapy, are urgently needed. Early results from studies investigating 
checkpoint inhibitors show either no efficacy (anti CTLA-4) or a temporary beneficial effect 
in a minority of patients (anti PD-l). This is ascribed to the absence of a tumor-directed 
T-cell response. Previously, we demonstrated that autologous tumor lysate-pulsed dendritic 
cell immunotherapy increased T cell response towards malignant mesothelioma. However, 
the use of autologous tumor material hampers implementation in large clinical trials, 
which might be overcome by using allogeneic tumor cell lines as tumor antigen source. 
Here, we present a translational study that provides the basis for allogeneic lysate loaded 
DC immunotherapy. First, we show efficacy of this strategy in a murine mesothelioma 
model. Subsequently, we established clinical grade human mesothelioma cell lines to pulse 
autologous DC from 9 patients in a first-in-human trial. We show that this treatment is safe 
and feasible in mesothelioma patients. Our findings pave the way for clinical application 
of dendritic cell immunotherapy in mesothelioma to be evaluated in phase III clinical trials.
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ABSTRACT
Purpose: Mesothelioma has been regarded as a non-immunogenic tumor, which is also 
shown by the low response rates to treatments targeting the PD-1/PD-L1 axis. Previously, 
we demonstrated that autologous tumor lysate-pulsed dendritic cell (DC) immunotherapy 
increased T-cell response towards malignant mesothelioma. However, the use of autologous 
tumor material hampers implementation in large clinical trials, which might be overcome 
by using allogeneic tumor cell lines as tumor antigen source. The purpose of this study 
was to investigate if allogeneic lysate pulsed DC immunotherapy is eff ective in mice and 
safe in humans.
Experimental Design: Firstly, in two murine mesothelioma models, mice were treated with 
autologous DCs pulsed with either autologous or allogeneic tumor lysate, or injected with 
PBS (negative control). Survival and tumor-directed T cell responses of these mice were 
monitored. Results were taken forward in a fi rst-in-human clinical trial, in which 9 patients 
were treated with 10, 25 or 50 million DC per vaccination. DC vaccination consisted of 
autologous monocyte-derived DC pulsed with tumor lysate from 5 mesothelioma cell lines.
Results: In mice, allogeneic lysate-pulsed DC immunotherapy induced tumor-specifi c T cells 
and led to an increased survival, to a similar extent as DC immunotherapy with autologous 
tumor lysate. In the fi rst-in-human clinical trial, no dose limiting toxicities were established 
and radiographic responses were observed. Median PFS was 8.8 months (95% CI 4.1-20.3) 
and median OS not reached (median follow up 22.8 months).
Conclusions: DC immunotherapy with allogeneic tumor lysate is eff ective in mice and safe 
and feasible in humans.
97
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm for which new treatment 
options are urgently needed [1]. Recently reported randomized studies investigating 
immunotherapy (cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor 
tremelimumab) and molecular targeting (FAK inhibition, defactinib) were found to be 
negative for the primary endpoint of an increase in overall survival [2, 3]. The phase III MAPS 
trial targeting angiogenesis (anti-VEGF, bevacizumab) in combination with chemotherapy 
showed a modest increase in survival [4].
A number of new agents are being tested in early phase studies in MPM, mostly focusing 
on immunotherapy with checkpoint inhibitors. Initial results have become available on the 
blockade of programmed death receptor (PD)-1/ programmed death ligand 1 (PD-L1) in 
MPM showing single agent response rates ranging between 9-25% [5]. Response rates to 
PD1/PDL1 inhibitors in these ranges have also been found in other solid malignancies, such 
as non-small cell lung cancer (NSCLC) [6]. As the effect of checkpoint inhibitors is based 
on reinvigoration of anti-tumor T cell responses, response to therapy is correlated to the 
presence of tumor infiltrating T cells pretreatment [7]. Also in mesothelioma, an immune 
infiltrate including T cells is correlated to improved survival [8]. An immunotherapeutic 
approach aiming to increase the number of tumor-directed T cells, is vaccination. In a recent 
systematic review on the efficacy of tumor vaccines and cellular immunotherapies it was 
established that cell-based vaccination has the highest efficacy in complex tumors like NSCLC 
[9]. Dendritic cell (DC)-based immunotherapy is a potent cell-based immunotherapeutic 
approach [10, 11], which aims to boost the immune system of cancer patients by enhancing 
tumor antigen presentation and subsequent activation of tumor-specific (cytotoxic) T cells. 
DCs are reduced in number in the peripheral blood of mesothelioma patients, and are less 
functional in terms of activation and antigen presentation compared to healthy controls [12]. 
Therefore, ex vivo DC activation and maturation might improve their immune function and 
direct them to present tumor associated antigens (TAA). To pulse DCs ex vivo, a variety of 
sources of tumor antigens can be used, such as proteins or peptides, DNA or mRNA in the 
case of known antigens, or whole tumor cells or tumor lysate, in which undefined antigens 
are present as well [13].
In previous studies in both murine models and patients with mesothelioma, we have 
demonstrated that dendritic cell vaccination induces tumor-specific CD8 T cell responses 
accompanied by promising survival rates [14-16]. In these studies, we have used an 
autologous tumor lysate as a source to pulse DCs, as vaccination with a broad range of 
antigens can induce a broad repertoire of anti-tumor T cells and therefore might be more 
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eff ective [17]. Two recent publications showed the potential of a polyvalent vaccination to 
induce a broad range of T cell responses in a setting of long synthetic peptide vaccination 
in melanoma [18, 19]. For our DC vaccination strategy in mesothelioma, we generated 
autologous tumor lysate from patients’ own tumor material obtained via pleural drainage, 
tumor resection or biopsies, which was used to pulse DCs. This approach was found to be 
safe and well tolerated by mesothelioma patients [15, 16]. However, using an autologous 
whole tumor cell lysate limited the number of patients that could be included due to logistic 
limitations, such as the amount and quality of the tumor material. This impeded scaling up 
the treatment for multicenter clinical trials [20].
An alternative source to pulse the DCs with a broad spectrum of antigens, is the use 
of an allogeneic tumor lysate generated from cell line cultures, which contain TAA [17]. 
We hypothesized that DC immunotherapy with an allogeneic lysate prepared from tumor 
cell lines would be able to induce antitumor responses similar to the autologous tumor 
cell lysate. In this study, we fi rst examined the effi  cacy of allogeneic tumor lysate DC 
immunotherapy in vivo in two diff erent murine mesothelioma models (CBA/j and BALB/c 
mice), in which we demonstrated that allogeneic tumor lysate loaded DC immunotherapy 
was similarly eff ective in improving survival of mesothelioma-bearing mice as autologous 
tumor lysate DC immunotherapy. To translate these fi ndings to human, we developed a 
human allogeneic tumor cell lysate, generated from 5 clinical grade mesothelioma cell lines. 
In a fi rst-in-human phase I study, patients with mesothelioma were treated with increasing 
numbers of autologous DCs pulsed with allogeneic lysate. We found that the treatment is 
safe, induces an anti-tumor immune response, and is associated with radiographic responses 
and promising overall survival.
METHODS
PRECLINICAL:
Tumor cell lines culture
The AB1 and AC29 mouse mesothelioma cell lines were kindly provided by Prof. Bruce 
W.S. Robinson, Queen Elizabeth II Medical Centre, Australia. The AB1 and AC29 cell lines 
have been derived from malignant mesothelioma after intraperitoneal (i.p.) inoculation of 
crocidolite asbestos into BALB/c (H-2d) and CBA/j (H-2k) mice, respectively. Both cell lines 
were obtained in the years 2003–2005, aliquoted and stored at -190°C.
These cell lines were maintained in RPMI 1640 GlutaMax™ supplemented with 50μg/ml 
gentamycin (all obtained from Invitrogen, Breda, the Netherlands) and 5% fetal bovine 
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serum (FBS) (HyClone, Thermo Scientific). Tumor cells were cultured from early passages 
(max. 5 passages following cell line acquisition).
Tumor lysate production
AB1 and AC29 tumor cells were harvested from 80% confluent culture flasks and resuspended 
at a concentration of 50x106 cells/ml for AB1 and 100x106 cells/ml for AC29 in phosphate 
buffered saline (PBS). Cells were disrupted by five freeze-thaw cycles and subsequent 
sonication to produce a homogeneous lysate.
Isolation and loading of DCs
As in a murine model, it is not possible to obtain sufficient amount of monocyte-derived 
DCs from peripheral blood, DCs were obtained from bone marrow culture using a modified 
version of a previously described procedure [21]. Instead of flushing the femurs and tibias 
of naïve BALB/c or CBA/j mice for the bone marrow, major leg bones were crushed using 
a mortar and pestle with addition of approximately 3 mL of RPMI medium. Cells were 
passed through a 100 µm cell strainer, depleted of red blood cells and cultured in DC 
culture medium, composed of RPMI supplemented with 5% FBS, 50 μg/ml gentamycin, 
50 μM beta-mercaptoethanol (Sigma- Aldrich, Missouri, USA) and 20 ng/ml recombinant 
murine granulocyte macrophage-colony-stimulating factor (GM-CSF) (gift from prof. Bart 
Lambrecht). Cells were placed in 90 mm culture dishes (Nunc™) with a total number of 2x106 
cells/10 ml at seeding and incubated at 37o C (Innova Co-170, New Brunswick Scientific) in 
a humidified atmosphere at 5% CO2 (day 0). On day 3, the 10 ml of DC culture medium was 
added. On day 6, 10 ml of the media was replaced by 10 ml fresh DC medium. After 8 days in 
culture, DCs were pulsed with AB1 (3 tumor cell equivalents per DC) or AC29 (6 AC29 tumor 
cell equivalents per DC) tumor lysate. After 8 hours, LPS was added to allow full maturation. 
The next day, DCs were harvested by gentle pipetting and purified by Lympholyte-Mammal 
(Cedarlane, Hornby, ON, Canada) density gradient centrifugation, washed three times with 
PBS and resuspended at a concentration of 1-3x106 viable cells in 500 µl PBS.
Verification maturation status of DCs
To verify the purity and maturation of DCs, the cultured cells were assessed with flow 
cytometry on a FACS LSR II (BD Biosciences). DCs were characterized as CD11c+MHC-II+. 
CD40, CD80 and CD86 were used to verify maturation of DCs. The following antibodies 
with matched isotype controls were used: anti-CD11c-PE Texas Red, anti-MHC class II-Alexa 
Fluor 700, anti-CD40APC (eBioscience), anti-CD80PerCP-Cy5.5 and anti-CD86PE-Cy7 (BD 
Biosciences). DAPI, 4’,6-diamidino-2-phenylindole (Invitrogen) was used as a viability dye.
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In vivo survival experiments
Female BALB/c mice and CBA/j mice (Harlan, Zeist, The Netherlands) were housed at the 
animal care facility of the Erasmus MC, Rotterdam. The experiment was approved by the 
local Ethical Committee for Animal Welfare. Experiments were started at 6-8 weeks of age. 
At day 0, mice were injected intraperitoneally (i.p.) with a 0.5x106 AB1 tumor cells (BALB/c 
mice) or 15x106 AC29 tumor cells (CBA/j mice). The number of tumor cells for these mouse 
models were titrated to achieve a tumor incidence in untreated mice of at least 80%, with 
mice generally surviving until at least two weeks after tumor inoculation [14, 22]. At day 
7, mice received an i.p. injection with PBS or DCs immunotherapy pulsed with either AB1 
tumor lysate or AC29 tumor lysate. 6 mice were used per group.
Each vaccine contained 1-3 x 106 DCs, depending on the yield, and equal for all mice within 
the experiment. Tumor growth, physical well-being, body weight, and the survival were 
monitored every other day for 70 days after tumor injection.
In vitro degranulation assay and ﬂ ow cytometric analysis
Splenocytes from PBS treated, DC treated or naive mice were restimulated with tumor 
cells. 50.000 AC29 or AB1 tumor cells were seeded in a fl at bottom 24 wells plate (Costar™, 
Corning Inc), to which 1 x 106 splenocytes were added the next day, together with 10μg/ml 
CD107a -FITC (BD Bioscience). After one hour, the protein transport inhibitor Golgi stop™ 
was added (BD Bioscience). As a positive control, splenocytes were stimulated with 50 ng/
ml phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml Ionomycin (Sigma). Unstimulated 
splenocytes were used as negative control. After 4 hours of incubation at 37°C, splenocytes 
were harvested and stained for fl ow cytometry with anti-CD3-APCCy7, anti-CD8-PE-Cy7, 
anti-CD44-PerCP-Cy5.5 and anti-CD62L-APC (eBioscience). Fixable Viability Dye eFluor® 
506 (eBioscience) was used to exclude dead cells. For staining of intracellular IFNγ, cells 
were fi xed with 2% paraformaldehyde and permeabilized with 0,5% saponin, before IFNγ 
was stained intracellularly with anti-IFNγ-Pacifi c Blue (eBioscience).
Caspase 3/7 assay
CD8+ T cells were isolated from splenocytes from DC treated mice using the CD8+ Isolation 
kit (Miltenyi Bioscience). Purifi ed CD8+ T cells were then co-cultured with AB1 tumor cells 
or AC29 tumor cells in a 20:1 or 50:1 ratio in a black coated and transparent fl at bottom 96 
microplate (Greiner). Cell PlayerTM Caspase 3/7 reagent (Essen Bioscience) was added at 5 
μM fi nal concentration per well to detect apoptosis during the co-culture. Cells were cultured 
in the IncucyteTM FLR (Essen Bioscience) for 4 days at 37o C in a humidifi ed atmosphere at 
5% CO2 and images were captured every 2.5 hours for caspase 3/7 upregulation.
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CLINICAL:
Study design
In this first-in-human open label non-randomized dose escalation phase I study we enrolled 
adult patients with mesothelioma. In total, nine MPM patients divided over 3 cohorts (3 
patients per cohort) received autologous monocyte-derived DCs (Mo-DC) pulsed with 
allogeneic tumor cell line lysate. The first cohort received 10 million Mo-DC per vaccination, 
the second cohort received 25 million Mo-DC per vaccination and the third cohort received 
50 million Mo-DC per vaccination. The autologous Mo-DC and the allogeneic tumor cell line 
lysate used to load the autologous Mo-DC were produced under GMP-certified conditions. 
The study was approved by the Central Committee on Research involving Human Subjects 
(NL4433000014) as defined by the Medical Research Involving Human Subjects Act. 
Procedures followed were in accordance with the ethical standards of these committees 
on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. 
The trial is registered within clinicaltrials.gov, number NCT02395679.
Patient selection
Patients with histologically or cytologically confirmed MPM were eligible to participate in the 
study. Moreover, patients had to be non-progressive after at least 4 cycles of pemetrexed 
and platinum containing chemotherapy (as determined by CT). Patients that refused 
chemotherapy treatment as first line treatment were also eligible. Other inclusion criteria 
were: measurable disease on CT dimensions according to modified Response Evaluation 
Criteria In Solid Tumors (RECIST) [23] , at least 18 years of age, able to give written informed 
consent, ambulatory (WHO-ECOG performance status 0 or 1, with an expected survival of 
at least 3 months), normal organ function and adequate bone marrow reserve (absolute 
neutrophil count > 1.0 x 109/l, platelet count > 100 x 109/l, and Hb > 6.0 mmol/l), a positive 
DTH skin test (induration > 2mm after 48 hours) against at least one positive control antigen 
tetanus toxoid, ability to return to the Erasmus MC for adequate follow-up as required by 
this protocol, written informed consent according to ICH-GCP, and planned start date of 
vaccination at least 5 weeks after the last dosage of chemotherapy.
A potential subject who met any of the following criteria was excluded from participation in 
this study: medical or psychological impediment to probable compliance with the protocol; 
current use or discontinuation of less than 6 weeks of steroids (or other immunosuppressive 
agents), with the exception of prophylactic usage of dexamethasone during chemotherapy; 
prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial 
or in-situ cancer of the bladder or other cancer for which the patient has been disease-
free for five years; serious concomitant disease or active infections; history of autoimmune 
disease or organ allografts, or with active acute or chronic infection, including HIV and viral 
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hepatitis; serious intercurrent chronic or acute illness such as pulmonary (asthma or COPD) 
or cardiac (NYHA class III or IV) or hepatic disease or other illness considered by the study 
coordinator to constitute an unwarranted high risk for investigational DC treatment; known 
allergy to shell fi sh (may contain KLH); pregnant or lactating women; inadequate peripheral 
vein access to perform leukapheresis and concomitant participation in another clinical trial.
Procedures
Patients received MesoPher (see below: Production of DC vaccination) via intradermal 
(i.d.) and intravenous (i.v.) injections with two thirds of the dose i.v. and one third i.d. in 3 
biweekly vaccinations, followed by a booster after 3 and 6 months. The combined i.d. and i.v. 
administration was chosen to induce a systemic immune response, as proposed by Adema 
et al. [24] and was used in previous phase I trials by our group as well [15, 16]. Cohorts of 3 
patients received a dose level to evaluate safety. Within each cohort a patient was required 
to complete 7 days after the vaccination without toxicities before a new patient was treated. 
If none of these 3 patients in one cohort had a DLT within 8 weeks of starting the fi rst dose, 
the next dose level was started.
Outcomes
The primary objective was to determine the safety of the diff erent dose schedules, to 
establish the recommended dose for further studies. Secondary objectives were antitumor 
activity according to radiological examinations, immunological profi ling and overall survival.
Safety evaluation
Physical examination and hematological and biochemistry assessments were performed 
weekly. A 12 lead ECG and laboratory testing was performed before the patient could be 
included in the trial, and before every vaccination. Toxicity was scored according to the 
NCI-CTCAE version 4.0.
The following toxicities occurring during 8 weeks after the fi rst vaccination, were defi ned 
as dose-limiting (DLTs), when considered possibly, probably or defi nitively related to study 
medication. Hematological toxicity: thrombocytopenia grade 3 during longer than 7 days or 
grade 4 or a neutropenia grade 3 during longer than 7 days or grade 4. Non-hematological 
toxicity: any grade 3/4 toxicity except for diarrhea, nausea, vomiting, hypertension if not 
adequately treatable, skin toxicity. Immune related toxicity: any grade 4 except for rash 
and (drug related) fever.
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Tumor evaluations
Tumor evaluations were performed every 6 weeks by chest CT preferably using contrast 
and response was determined according to the modified RECIST. Objective responses had 
to be confirmed 6 weeks after the initial assessment. Duration of response was from first 
documented response until disease progression.
Immunological evaluations
Serum samples were collected before start of treatment, on the day of each vaccination, 
and two weeks after each vaccination. A DTH skin test was performed two weeks after 
the third vaccination with the lysate, MesoPher, tumor lysate-pulsed DCs without KLH 
and injection fluid as negative control. DTH reaction was measured 48h after intradermal 
injection. If a positive reaction was observed, a 3 or 6 mm punch biopsy was taken from the 
skin induration, and was used immediately for isolation of skin-test infiltrating lymphocytes 
(SKIL).
Rapid expansion of skin-test infiltrating lymphocytes
Skin biopsies were placed in a 6-wells plate with 3 ml medium consisting of RPMI, 7% normal 
human serum and low concentrations IL-2 (100 IU/ml) for 7 days. Subsequently T cells were 
rapidly expanded with a feeder system as described elsewhere [25].
Dextramer staining and analysis
Online prediction algorithms (netCTL: http://www.cbs.dtu.dk/services/NetCTL/ and 
netMHCpan: http://www.cbs.dtu.dk/services/NetMHCpan/) were used to select HLA-A2 
binding mesothelin peptides with high affinity and predicted MHC presentation. Dextramers 
were ordered from Immudex (Copenhagen, Denmark). Dextramer A: PE-conjugated HLA-A2 
dextramer with peptide SLLFLLFSL (mesothelin20-28), Dextramer B: APC-conjugated HLA-A2 
dextramer with peptide VLPLTVAEV (mesothelin531-539). Dextramer staining was performed 
according to manufacturer’s protocol. Anti-CD3-BV711 and anti-CD8-FITC (clone SK1) (BD 
Biosciences) were used for extracellular staining. DAPI was used as viability dye. Samples 
were measured on an LSR-II flow cytometer (BD). FMO controls were used to determine 
dextramer-positive populations.
Statistical analysis
All statistical tests on the murine experiments were performed in GraphPad Prism 5. The size 
of the first-in-human dose escalation study was based on the standard 3+3 dose escalation 
design, and therefore we did not perform a further samples size estimation.
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Production of DC vaccination (MesoPher)
Eligible patients underwent autologous DC pulsed with allogeneic tumor lysate-based 
immunotherapy (MesoPher). Allogeneic tumor lysate was produced under GMP-compliant 
conditions and consists of fi ve unique, clinical grade human MM cell lines, which are 
patented under patent ID P6038325NL. For the production of MesoPher, Mo-DC were 
generated from CD14+ monocytes according to a 10-day culture protocol. CD14+ monocytes 
were enriched from patient derived apheresis products by CliniMACS procedure (CD14+
procedure, Miltenyi). Purity of the CD14+ monocytes after CliniMACS procedure was >97% 
and viability was >95% for all MesoPher preparations. Hereafter CD14+ monocytes were 
cultured in T225 fl asks (100 million cells per fl ask) in X-VIVO 15 (Lonza) supplemented with 
2% NHS (Sanquin) and adhered overnight on 37°C, 5% CO2. The following day half of the 
medium was refreshed with fresh medium supplemented with 2% NHS, and 1000 IU/ml 
rhGM-CSF (Miltenyi) and 1600 IU/ml rhIL-4 (Miltenyi) were added. Cells were cultured for 
3 additional days at 37°C, 5% CO2. On the fi fth day of culture, immature unpulsed Mo-DC 
were harvested and reseeded in 6-wells plates (1 million cells/well) in presence of tumor 
lysate (tumor cell equivalent to DC ratio 1:3), and supplemented with 800 IU/ml rhGM-CSF, 
500 IU/ml rhIL-4 and 10 µg/ml VACMUNE KLH (BioSyn). On day 8 of the culture immature 
pulsed Mo-DC were matured with 5 ng/ml IL-1B, 15 ng/ml IL-6, 20 ng/ml TNF-alpha (all 
Miltenyi) and 10 µg/ml PGE-2 (Pfi zer). On day 10 of the culture, cells were harvested and 
had to comply with the following quality demands in order to release the batch: sterile, 
>80% viability, >90% MHC class II+ CD11c+ cells and >80% CD80+ cells of the MHC class II 
CD11c+ cells.
RESULTS
Allogeneic and autologous tumor lysate-loaded DCs mediate comparable 
survival in mesothelioma bearing mice
To investigate whether allogeneic tumor lysate-loaded DCs were as eff ective as autologous 
tumor lysate-loaded DCs in improving survival in mesothelioma bearing mice, we set up 
an in vivo experiment using two diff erent mouse models for mesothelioma, as depicted 
in fi gure 1A. Mesothelioma was induced in these mice as described previously [26]. These 
mouse models are diff erent in both mouse strain and aggressiveness of tumor growth 
and are chosen to assure robustness of the treatment across diff erent models. In short, 
BALB/c mice were injected with the syngeneic AB1 cell line and CBA/j mice were injected 
the syngeneic AC29 mesothelioma cell line. Seven days following tumor inoculation, BALB/c 
mice and CBA/j mice received either PBS (vehicle), autologous tumor lysate pulsed-DC (AB1 
for BALB/c and AC29 for CBA/j), or allogeneic tumor lysate pulsed-DC (AC29 for BALB/c and 
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AB1 for CBA/j). The survival of these mice is depicted in figure 1B. The results show that DC 
immunotherapy significantly improved survival in tumor bearing mice of both BALB/c and 
CBA/j mouse strains compared to PBS treated control mice (p<0.05), with no significant 
differences in efficacy between autologous lysate-loaded and allogeneic lysate-loaded DC 
immunotherapy.
Allogeneic tumor lysate-loaded DCs induce an anti-tumor T cell response 
in mesothelioma bearing mice
To demonstrate the induction of a tumor specific T cell response, splenocytes from surviving 
CBA/j mice were stimulated with tumor cells. Interferon (IFN) γ production was assessed by 
intracellular cytokine staining and degranulation was assessed by cell surface expression of 
CD107. IFNγ+ and CD107+ splenic CD8 T cells were increased upon stimulation with tumor 
cells in DC treated mice, but not untreated mice. No difference was observed between the 
autologous lysate and allogeneic lysate treatment (figure 2A and 2B). CD8 T cells from all 
groups were equally capable of IFNγ production and degranulation upon PMA/ionomycin 
stimulation (not shown). This increased CD8 T cell functionality after DC treatment coincided 
with increased proportions of effector memory (CD44+CD62L-) CD8 T cells in treated versus 
untreated mice, at the expense of naïve T cells (figure 2C). To confirm that the induced T 
cells in these mice were capable of killing tumor cells, we co-cultured splenic CD8 T cells 
from DC immunotherapy treated and untreated BALB/c mice with AB1 tumor cells. Tumor 
cell growth was diminished when co-cultured with CD8 T cells from DC immunotherapy-
treated mice compared to untreated mice, which was due to increased apoptosis as shown 
by increased caspase expression (Supplementary figure S1).
Altogether, these results demonstrate that treatment with DCs pulsed with either autologous 
or allogeneic tumor lysate induce an effective anti-tumor immune response and improve 
survival in mesothelioma bearing mice.
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Figure 1. Effi  cacy of allogeneic tumor lysate-pulsed dendritic cell immunotherapy in mesothelio-
ma bearing mice. A) Schematic image of the two mesothelioma mouse models and autologous or 
allogeneic pulsed dendritic cell immunotherapy. Two diff erent mouse strains were used, CBA/j and 
BALB/c, inoculated i.p. with their syngeneic mesothelioma cell line (AC29 for CBA/j and AB1 for BALB/c). 
Syngeneic DCs were cultured from the bone marrow of littermates and pulsed with tumor lysate of 
either of two tumor cell lines. In the autologous lysate condition, mice were treated with DCs pulsed 
with the tumor lysate matching their tumor, while in the allogeneic condition, mice were treated 
with DCs pulsed with the tumor lysate of the allogeneic tumor cell line. B) Survival of mesothelioma 
bearing mice treated with DC vaccination. 7 days after tumor inoculation, mice were injected i.p. with 
either PBS (group A, blue), autologous DCs pulsed with autologous tumor cell lysate (group B, red) 
or autologous DCs pulsed with allogeneic lysate (group C, green). Kaplan Meier curves are shown for 
the CBA/j mice (top) and BALB/c mice (bottom). Statistical survival diff erence between the groups was 
determined using the log-rank test
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Figure 2. DC immunotherapy-induced immunological changes in a murine mesothelioma model. A) 
Representative flow cytometry plots of IFNγ production (left) and CD107 expression (right) in splenic 
CD8 T cells after co-culture with tumor cells. Splenocytes of surviving CBA/j mice (autologous: n=4, 
allogeneic: n=3), were isolated when the mice were sacrificed and cultured in the presence of AC29 
tumor cells. As controls, both tumor bearing and naïve mice were included (naïve: n=2, tumor-bearing: 
n=1). B) Quantification of IFNγ production (left) and CD107 expression (right) in splenic CD8 T cells, 
either stimulated with tumor cells or unstimulated. * = p<0.05 (paired Student’s t test for stimulated 
vs unstimulated, unpaired Student’s t test for comparison autologous vs allogeneic treatment) C) 
Proportions of effector phenotype (CD44+CD62L-) CD8 T cells (Teff, left) and naïve phenotype (CD44-
CD62L+; right) CD8 T cells in splenocytes isolated from treated mice, and tumor bearing and naïve 
mice as negative controls. * = p<0.05 (one-way ANOVA).
No dose limiting toxicity was induced by allogeneic tumor lysate pulsed DC immunotherapy 
in a first-in-human trial targeting mesothelioma
The comparable outcome between autologous lysate-pulsed DC immunotherapy and 
allogeneic lysate-pulsed DC immunotherapy in our mesothelioma mouse models, led us to 
initiate a first-in-human phase I clinical trial with allogeneic-lysate pulsed DC immunotherapy 
(MesoPher). To this end, long-term human mesothelioma cell lines were established from 
pleural effusion cells isolated from patients with pathologically proven mesothelioma. Lysate 
of five cell lines was combined to pulse DCs with.
In total, 9 patients were treated according to the predefined treatment schedule between 
January 2015 and October 2015. Data cut off was in April 2017. Patient characteristics are 
summarized in table 1. Five patients were treated as maintenance after chemotherapy whilst 
4 were treatment naïve. Patients received a vaccination regimen of 3 biweekly vaccinations 
and a booster vaccination after 3 and 6 months. In 2 out of 9 patients in the highest dose 
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regimen (patient 7 and 9) no booster vaccination after 6 months could be given due to 
shortage of DCs to generate 5 vaccinations.
Table 1. Patient characteristics
Patients (N = 9)
Age median (range) 69 (45-79)
Sex
male 8 (89%)
female 1 (11%)
Histological subtype
Epithelioid 9 (100%)
Sarcomatoid 0 (0%)
Biphasic 0 (0%)
Stage
1 0 (0%)
2 1 (11%)
3 5 (56%)
4 3 (33%)
ECOG performance score
0 7 (78%)
1 2 (22%)
Prior treatment
Chemotherapy (platinum-based+pemetrexed) 5 (56%)*
Radiotherapy 0 (0%)
Surgery 1 (11%)†
Other 0 (0%)
Response to chemotherapy (if applicable)
SD 3 (60%)
PR 2 (40%)
* Chemotherapy consisted of cisplatin or carboplatin, combined with pemetrexed, with a total of 
4 (n=4) or 6 (n=1) cycles; † Surgery in this patient consisted of abdominal debulking surgery (this 
patient had both pleural and abdominal mesothelioma).
Neither predefi ned dose limiting toxicities nor grade 3 or 4 toxicities were established. A 
summary of all grade toxicity is presented in table 2, with further specifi cations of adverse 
events in table S1. Treatment related adverse events were mild (grade 1 or 2), although 
present in all patients. These treatment-related adverse events included an induration of 
the skin related to the intradermal injections in all patients at vaccination 2 and 3 and a 
grade 1 or 2 fever in all patients after vaccination. This was a transient fever occurring 4-8 
hours after vaccination and lasting for maximally 24 hours.
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Table 2: Toxicities/ adverse events of patients in first-in-human clinical trial
N=9 Any grade, N (%) Grade 3-4, N (%)
Any AE 9 (100) 0 (0)
Injection site reaction 9 (100) 0 (0)
Fever 9 (100) 0 (0)
Respiratory 6 (67) 0 (0)
Lab abnormalities 8 (89) 0 (0)
Gastrointestinal 1 (11) 0 (0)
Appetite 1 (11) 0 (0)
An immune response was induced in patients after three doses of allogeneic tumor lysate 
pulsed DC immunotherapy, in which mesothelin-specific T cells could be detected
As readout for a recall response against the vaccine, a DTH skin test was performed 2 weeks 
after the third vaccination, using a negative control, the lysate only, lysate-pulsed DCs 
with KLH (MesoPher) lysate-pulsed DCs without KLH. No skin reactions were seen in the 
negative control or after injection of the lysate only. All 9 patients responded with redness 
and thickening of the skin 48 hours after injection of MesoPher with KLH. Injection with 
lysate-pulsed DCs without the adjuvant KLH resulted in a response in 5 out of 9 patients, 
which all received a dose of at least 25 million DC.
To assess whether in the positive skin reaction, tumor specific T cells could be detected, we 
isolated T cells from a biopsy of the DTH test skin induration. Mesothelin was chosen as a 
relevant model-antigen, as all 9 patients in our study had histologically proven mesothelin 
expression in diagnostic tumor biopsies. Using dextramers against two different mesothelin-
epitopes, we assessed reactivity against these epitopes in all HLA-A2 positive patients of 
which viable T cells were obtained from the skin biopsy. In four out of six evaluable patients, 
mesothelin-specific T cells could be detected (figure 3). In three of these four patients, T cells 
against both epitopes were observed, while in one patient (patient 2), T cells against one 
epitope were detected. These data show that the immune reaction induced by MesoPher 
contained T cells specific for a relevant tumor-associated antigen, which could be detected 
in the majority of evaluable patients.
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Figure 3. Mesothelin-specifi c CD8 T cells in skin-test infi ltrating lymphocytes after injection with 
allogeneic lysate-pulsed DCs. T cells were isolated from a biopsy of the positive post-treatment DTH 
test with the vaccine, and expanded in vitro. CD8 T cells specifi c for two mesothelin-peptides were 
detected using FCM with peptide-MHC multimers. Results were obtained of all HLA-A2+ patients of 
which suffi  cient T cells could be expanded from the biopsy. A) Gating strategy of dextramer binding 
CD8 and non-CD8 T cells. B) Quantifi cation of dextramer-binding CD8 T cells. The bars in these graphs 
represent peptide-MHC binding T cells, as percentage of either CD8 or non-CD8 T cells, whereby the 
non-CD8 T cells were used as a negative control.
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Figure 4. Overall survival and RECIST responses after first vaccination. A) Swimmer plot of patients in 
phase I clinical trial with MesoPher treatment. Overall survival of patients since date of first vaccination 
is represented by the filled bars. Start and end of RECIST responses are depicted by the red triangles 
and black squares, respectively. First evaluation of response was after 6 weeks for all patients. Except 
patient 5 that experienced a partial response, all other patients had stable disease at first evaluation. 
Patients treated with chemotherapy prior to inclusion in the study are depicted with a grey diamond. 
The other patients were treatment naïve. B) Pre- and post-vaccination computed tomography (CT) 
scans of patient 5. CT scans with contrast of the ongoing response of one treatment naïve patient 
receiving allogeneic lysate-pulsed autologous DC vaccination. Tumor mass is indicated with pink 
arrows. All lesions were solid. This patient was treatment naïve and received 5 doses of 25 million DCs. 
Pretreatment tumor burden decreased with 70% after the third vaccination (six weeks after start of 
treatment) and continued to decrease.
Radiographic responses and promising overall survival after DC 
immunotherapy
Response and survival data of all patients are summarized in figure 4A and supplementary 
figure S2, with now eight of nine patients experiencing progression. In two patients treated 
both in the 25 million DC cohort, a confirmed partial response was established after the 
treatment. One patient was pretreated with chemotherapy and one patient treatment naïve. 
The pretreated patient had a response with a duration of 15 months, while the treatment 
naïve patient has an ongoing response with a current duration of 21 months. This patient 
showed a remarkable decrease of total tumor burden of 70% after the third vaccination 
(Figure 4B and supplementary figure S3). In the other 7 patients, a stable disease was 
established leading to a disease control rate of 100%. Median overall survival has not been 
reached, since 7 patients are currently alive after a median follow up of 22.8 months (range, 
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18.5-27.4 months). Median progression free survival (PFS, defi ned as time from registration 
until progression or death, whichever came fi rst) was 8.8 months (95% confi dence interval 
(CI) 4.1-20.3). PFS at 12 months was 33% (95% CI 8%-62%). Treatment beyond progression 
was started in all but one patient after progression and is described in supplementary 
table S2. The one patient that did not start treatment beyond progression has a slow 
progression of the tumor (and not a 30% enlargement from nadir) and is not experiencing 
clinical deterioration.
DISCUSSION
We here show that autologous dendritic cell therapy with an allogeneic tumor cell lysate is 
eff ective in a murine model of mesothelioma and that a comparable treatment is safe and 
feasible in patients, with promising clinical activity.
The goal of DC-based immunotherapy is to augment the patient’s immune system by 
means of improving tumor cell recognition by T cells. When using autologous tumor lysate 
to pulse DCs, a personalized set of antigens is presented to the patients’ T cells. Practical 
limitations in obtaining autologous lysate from patients, led to use of an allogeneic lysate 
derived from tumor cell lines, which relies on the existence of common tumor antigens that 
are shared between patients.
In two diff erent murine mesothelioma models, a comparable survival was found between 
mice receiving allogeneic tumor lysate-pulsed DCs and mice receiving autologous tumor 
lysate-pulsed DCs. Moreover, our in vitro experiments show that in this model a similar 
functional tumor-specifi c CD8 T cell response was established, demonstrated by the 
production of IFNγ and degranulation of the CTLs. This indicates that allogeneic tumor 
lysate is as immunogenic as autologous tumor lysate when used in a DC immunotherapy 
setting. We cannot rule out the possibility, however, that allogeneic tumor lysate is slightly 
less eff ective, since the groups were too small to defi nitely compare effi  cacy between the 
DC treatments with either allogeneic or autologous lysate. Also, unpulsed DC, which are 
known to have some, but a notably inferior, eff ect on survival [14], were not included as a 
separate arm in these experiments. But, most importantly, our fi ndings clearly show effi  cacy 
of DC immunotherapy using allogeneic tumor lysate.
The results of our murine experiments led us to initiate a fi rst-in-human clinical trial, which 
showed that treatment was safe and feasible. The trial was designed as a 3+3 design and 
no dose limiting or major toxicities were established, even in the highest dose. Two partial 
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responses were observed in the 25 million cells dose cohort, which indicates that this 
dose is high enough to induce radiographic responses. Since the yield of monocytes from 
leukapheresis limited the number of vaccinations that could be given at the 50 million 
dose cohort, we decided that the dose of 25 million cells was the optimal dose level to be 
taken forward in further clinical trials. As it was decided to initiate further studies with the 
25 million cell dose level, we found it unethical and unnecessary to include further patients 
in the trial as no additional safety data are to be expected for this dose. In contrast to 
e.g. targeted therapies where a higher dose is expected to be more effective, since DC 
immunotherapy relies on the induction of an anti-tumor immune response and expansion of 
effector cells within the patient, a larger number of DC’s is not necessarily needed to induce 
a stronger immune response [27]. To increase effectivity of DC immunotherapy, it is probably 
more beneficial to change the microenvironment to facilitate optimal conditions for the 
expansion and migration of T cells to the tumor. In future studies, it might be of interest to 
determine effectivity not only by radiographic response, but also by immunological readout, 
e.g. by monitoring increases in (tumor-specific) CTLs.
Evidence of an immune response induced by vaccination was seen in all patients in the 
form of a positive response to the DTH skin test after the third vaccination. A DTH response 
has been shown to correlate with overall survival in a DC vaccination setting in melanoma, 
although the clinical applicability of this correlation is still largely unclear [28]. At the time 
of the second or subsequent vaccinations, a similar reaction was observed at the site 
of intradermal injection. This response did not occur after the first vaccination and thus 
indicates an induction of a tumor lysate-directed response. Interestingly, in the lowest dose 
cohort and one of the patients of the second cohort, the DTH response was not present if 
pulsed DCs without KLH were administered. This finding underlines the importance of an 
adjuvant to enhance immune activation, especially in lower doses of DC vaccination. On 
the other hand, the positive skin reaction towards pulsed DCs without the adjuvant KLH 
in the higher doses proves that this DC vaccination induced a response against the lysate, 
and not against KLH only. This was also confirmed by the presence of mesothelin-specific 
T cells in the skin induration. Frequencies of mesothelin-specific T cells in the skin biopsy 
were very low, which was expected, since the full tumor lysate consists of a broad array of 
tumor antigens, of which mesothelin was chosen as a relevant candidate. Future studies 
will have to prove whether assessment of particular tumor antigen-specific T cell responses 
can be used as a biomarker for clinical responses.
One of the limitations of the study is that in human number of total tumor-specific T cells 
before and after therapy could not be determined in assays similar to the assays performed 
in mice, as no viable tumor material was available of the patients. Another limitation of 
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the study is that this was a selected patient population with only patients who were not 
progressing after chemotherapy and 4 treatment naïve patients, refusing chemotherapy 
at that moment.
Although conventional radiographic response criteria may be suboptimal in immunotherapy, 
as they may not refl ect tumor growth optimally [20], we determined objective response 
rate and progression free survival by modifi ed RECIST criteria [23]. The radiographic 
partial response in 2 of the 9 patients shows the potency of DC immunotherapy to 
induce tumor reduction. While in the medical literature, safety of allogeneic lysate 
pulsed DC immunotherapy has been reported for colorectal cancer [29, 30], melanoma 
[31, 32], urological cancers [33] and thyroid cancer [34] using doses up to 10 million DC 
per vaccination, clinical responses in this study are promising compared with previously 
reported studies. Although none of these studies had effi  cacy as primary outcome, the 
reported radiographic responses were stable disease at best in most studies [29, 31, 33-37], 
with an exception of one complete response in melanoma [32] and one partial response 
(out of 20) in a MAGE antigen expressing colorectal cancer patient [30].
For melanoma, immunotherapy has been successful over the last decades, which has led 
to FDA approval of three diff erent checkpoint inhibitors (CTLA4 inhibitor ipilimumab and 
PD1 inhibitors nivolumab and pembrolizumab) and an oncolytic virus therapy (T-VEC). 
With the high mutational load of melanoma [38], a broad repertoire of tumor specifi c T 
cells can potentially arise [39]. MPM, however, is a poorly immunogenic tumor with a lower 
mutational burden and lower response rates to e.g. checkpoint inhibitors [5]. The clinical 
responses, including a 70% tumor reduction at fi rst radiographic assessment in one patient, 
indicates that that DC immunotherapy is capable to evoke an eff ective tumor-killing immune 
response, even in a non-immunogenic tumor type.
In two recent studies in melanoma, vaccination with long synthetic peptides in most cases 
led to delayed outgrowth of metastases, while the combination with checkpoint inhibitors 
was very potent to induce partial or complete responses [18, 19]. For mesothelioma, with 
the potential induction of de novo tumor directed immune responses or enhancement of 
pre-existing responses by DC vaccination, combination therapy of DC vaccination with a 
checkpoint inhibitor that can reinvigorate this immune response, is anticipated to provide 
a synergistic eff ect as well. Indeed, clinical responses towards checkpoint inhibitors were 
observed in the patients that had received MesoPher previously but ultimately developed 
disease progression. Out of three patients that received the PD-1 checkpoint inhibitor 
nivolumab, two showed a partial response and one showed stable disease. Moreover, the 
use of immunological readouts such as systemic T cell activation, the presence of tumor 
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antigen-specific T cells or various immune suppressive cells will also aid in determining the 
best combination approach.
Other immunotherapy approaches are being explored as well for mesothelioma, most of 
which exploit the tumor-associated antigen mesothelin. These approaches include adoptive 
T cell transfer with mesothelin-CAR T cells, which might also be given regionally and 
therefore may overcome a potential T cell homing problem [40]. Other approaches include 
a chimeric anti-mesothelin antibody involving antibody-dependent cellular cytotoxicity 
(ADCC) [41] and an immunotoxin-coupled anti-mesothelin antibody approach [42].
The overall survival of patients in this study is promising. However, the number of patients 
in this trial is too limited to draw firm conclusions. Randomized trials with allogeneic-lysate 
pulsed dendritic cell immunotherapy in malignant pleural mesothelioma are now warranted 
to establish efficacy of the current approach. In fact, such a trial is planned to open in 2017.
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SUPPLEMENTARY DATA
Supplementary Materials and Methods: Preparation of allogeneic tumor lysate
Mesothelioma tumor cell line establishment
For the production of allogeneic tumor lysate, tumor cell lines were established from pleural 
eff usion cells isolated from diff erent patients with pathologically proven mesothelioma. After 
signing informed consent, patient pleural eff usion was collected under sterile conditions and 
transported to the cleanroom facility immediately. Pleural fl uid was centrifuged (400xg, 15 
min, RT) and cells were isolated and cultured in RPMI 1640 + Glutamax (Lonza CAT BE12-
702F) supplemented with 10% (v/v) centrifuged pleural eff usion supernatant. During the 
fi rst days of the culture, cells were washed every day to remove non-adherent cells. When 
culture fl asks reached >80% confl uency cells were harvested with TrypLe Select (Gibco 
CAT 12563) and part of the cells were reseeded in new T175 culture fl asks. In this way, 
after several passages, six long-term mesothelioma tumor cell lines were established and 
patented (Patent ID: P6038325NL).
Production of allogeneic tumor cell lysate
For the production of allogeneic tumor lysate, fi ve of these tumor cell lines were selected 
based on the diversity in patient (age, sex), clinical (survival, response to therapy) and cellular 
characteristics of the cell lines (morphology, growth rate). Furthermore, the cell lines met 
the following criteria: 1) negative results for sterility, mycoplasma and adventitious viruses 
(Hepatitis B virus [HBV], Hepatitis C virus [HCV], human immunodefi ciency virus [HIV type I 
& II], human T cell lymphotropic virus [HTLV type I&II], and Treponema pallidum [syphilis]), 
2) diversity of the cell lines in patient-, clinical- and cellular-characteristics (age and sex of 
the donor, medical history, treatment response, progression-free survival, overall survival, 
and histological subtype) and 3) guarantee for long term culture. For the production of 
the lysate, tumor cell lines were cultured in RPMI 1640 + Glutamax (Lonza CAT BE12-702F) 
supplemented with 2% Normal Human Serum (NHS, Sanquin), upscaled and batches of 
tumor cells (serial subcultures) were frozen at <-70°C during every harvest procedure (50 
million cells/ml). After compliance with the QC assays performed on these serial subcultures 
(namely Sterility assays [Negative], STR profi ling analysis [no diff erence in short tandem 
repeats throughout the culture] and volume determination [less than 10% deviation from 
the theoretical value]), these were pooled per cell line to form fi ve intermediate products. 
After compliance with the QC assay (Sterility [Negative]), these were pooled to form one 
large master batch. The large master batch was freeze thawed for 5 cycles and gamma 
irradiated with 100 Gy to establish the tumor cell lysate. To ensure complete cell lysis QC 
assays were performed: 1) Colony formation during cell culture (1 ml of tumor cell lysate was 
placed into culture for 14 days, no colony formation was detected) and 2) Flow cytometric 
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cell analysis using DCFDA for alive cells and DAPI for dead cells (no alive cells were detected). 
After compliance of these QC assays, the tumor lysate was aliquoted into cryovials each 
containing 1,05 ml (52,5 million tumor cell equivalents [TCE]/1,05 ml).
Supplementary figures and tables
Supplementary Figure S1. CD8 T cells from DC immunotherapy treated mice show tumor cell killing 
capacity. A) AC29 tumor cell growth co-cultured with magnetic activated cell sorted (MACS) splenic 
CD8 T cells of DC immunotherapy treated and untreated mice. Cells were grown and confluency was 
measured by an IncuCyte® cell count proliferation assay B) Caspase staining (green) at start and at 
end (60 hours) of co-culture visualized with fluorescence microscopy in an IncuCyte® apoptosis assay.
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Supplementary Figure S2. Progression free survival of patients in the fi rst-in-human clinical study. 
Progression free survival (PFS, defi ned as time from registration until progression or death, whichever 
came fi rst) of all nine patients included in the fi rst-in-human trial.
Supplementary Figure S3: Pre- and post-vaccination computed tomography (CT) scans of patient 5 
at two diff erent heights. CT scans with contrast illustrating ongoing response of patient 5, as in fi gure 
3, at two diff erent heights (upper panels and lower panels). Tumor mass is indicated with pink arrows. 
This patient was treatment naïve and received 5 doses of 25 million DCs. Pretreatment tumor burden 
decreased with 70% after the third vaccination (six weeks after start of treatment) and continued to 
decrease.
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Supplementary table S1: specification of all observed grade 1 and 2 respiratory, gastrointestinal 
and lab abnormalities
N=9 Grade 1 (N) Grade 2 (N)
Respiratory (n=6) Cough (4)
Dyspnea (3)
Lab abnormalities 
(n=8)
Anemia (5)
Aspartate aminotransferase increase (3)
CPK increase (2)
Blood bilirubin increase (2)
Alanine aminotransferase increase (1)
Alkaline phosphatase increase (1)
ANA titer increase (1)
LDH increase (1)
Creatinine increase (1)
Hypernatremia (1)
Eosinophil increase (1)
Alanine aminotransferase increase (1)
White blood cell count decrease (1)
Gastrointestinal 
(n=1)
Diarrhea (1)
Supplementary table S2: additional treatment after progression
Patient Follow up treatment Best Response
MCV001 none
MCV002 cisplatin - pemetrexed SD
MCV003 dendritic cell booster PD
MCV004 pembrolizumab not yet evaluated
MCV005 none
MCV006 nivolumab SD
MCV007 cisplatin - pemetrexed PR
MCV008 nivolumab PR
MCV009 nivolumab PR
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ABSTRACT
Introduction: Malignant pleural mesothelioma (MPM) is a malignancy with a very poor 
prognosis for which new treatment options are urgently needed. We have previously shown 
that dendritic cell (DC) immunotherapy provides a clinically feasible treatment option. 
In the current study, we set out to assess the immunological changes induced by DC 
immunotherapy in peripheral blood of MPM patients.
Methods: Peripheral blood was collected from nine patients enrolled in a phase I dose 
escalation study, before and after treatment with DCs that were pulsed with an allogeneic 
tumor lysate preparation consisting of a mixture of five cultured mesothelioma cell lines. We 
used immune profiling by multiplex flow cytometry to characterize different populations of 
immune cells. In particular, we determined frequencies of T cell subsets that showed single 
and combinatorial expression of multiple markers that signify T cell activation, maturation 
and inhibition. Therapy-induced T cell reactivity was assessed in peptide/MHC multimer 
stainings using mesothelin as a prototypic target antigen with confirmed expression in the 
clinical tumor lysate preparation. T cell receptor (TCR) diversity was evaluated by TCRB 
gene PCR assays.
Results: We observed an increase in the numbers of B cells, CD4 and CD8 T cells, but 
not NK cells at 6 weeks post treatment. The increases in B and T lymphocytes were not 
accompanied by major changes in T cell reactivity towards mesothelin nor in TCRB diversity. 
Notably, we did observe enhanced proportions of CD4 T cells expressing HLA-DR, PD-1 (at 2 
weeks after onset of treatment) and ICOS (6 weeks) and a CD8 T cell population expressing 
LAG3 (2 weeks).
Discussion: DC immunotherapy using allogeneic tumor lysate resulted in enhanced 
frequencies of B cells and T cells in blood. We did not detect a skewed antigen-reactivity of 
peripheral CD8 T cells. Interestingly, frequencies of CD4 T cells expressing activation markers 
and PD-1 were increased. These findings indicate a systemic activation of the adaptive 
immune response and may guide future immune monitoring studies of DC therapies.
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INTRODUCTION
Malign ant pleural mesothelioma (MPM) is a solid tumor of the pleural lining that is strongly 
related to the exposure to asbestos [1]. Overall survival is poor with a median survival of less 
than a year, and conventional therapies like chemotherapy and radiotherapy being able to 
improve survival only by a few months [2]. Immunotherapy has evolved as an important 
new treatment modality in various kinds of cancer, with checkpoint inhibitors currently 
being FDA approved as fi rst line therapy for several cancer types. Initial results of clinical 
studies for MPM with checkpoint inhibitors as second line treatment showed response 
rates of 9-25% [3].
MPM is characterized by a strong immunosuppressive component, with relatively low 
numbers of T cells infi ltrating the tumor [1, 4]. These low numbers of tumor-infi ltrating T 
cells have prognostic value in MPM [5] and might explain the relatively low response rates 
to checkpoint inhibitors [1].
Furthermore, in MPM patients dendritic cells (DCs) have been shown to be reduced in 
numbers and in antigen-processing function compared to healthy controls, which negatively 
aff ected survival outcomes [6]. The reduced functionality of DCs is thought to relate to low 
intra-tumoral T cell numbers. Along these lines, DC vaccination represents a promising 
therapeutic strategy.
Previously, we have developed a cellular therapy for MPM, consisting of autologous DCs 
pulsed with autologous tumor lysate with the intention to cover a broad range of tumor 
antigens [7]. This vaccination strategy was shown to be safe with promising clinical outcomes 
[7, 8]. However, the availability and quality of tumor material that could be obtained, limited 
the feasibility of the treatment with DCs loaded with autologous tumor lysate. To overcome 
this limitation, DC vaccination using allogeneic tumor lysate was developed and tested for 
safety and feasibility in a phase I clinical trial [9]. Allogeneic tumor lysate derived from fi ve 
in vitro cultured clinical-grade human mesothelioma cell lines was used to pulse autologous 
DCs and the resulting DC vaccine was administered to patients i.d. and i.v. once every two 
weeks for three cycles, with a booster vaccination at three and six months after the start 
of treatment. The study was set up as a dose escalation study with three cohorts of three 
patients, and each cohort received 10 million, 25 million or 50 million DCs per vaccination, 
respectively. By circumventing the immunosuppressive tumor immune environment and 
providing enhanced tumor antigen presentation with DC vaccination, impressive objective 
responses could be obtained, as exemplifi ed by a tumor reduction of ~70% at 6 weeks 
post-treatment in one of the patients in this phase-I trial [9].
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In the current study we aimed to characterize the immunological changes induced by 
DC immunotherapy in these nine MPM patients. For a better understanding of the 
immunological changes induced by DC immunotherapy we monitored peripheral blood, 
which is the preferred compartment for sequential sampling. We used extensive multiplex 
flow cytometry with a focus on T cell activation and inhibitory markers and characterized 
T cell specificity using peptide-MHC multimers to obtain a detailed immune profile and 
immune dynamics following DC immunotherapy.
METHODS
Patients
The nine patients in this study participated in a first-in-human clinical trial as described by 
Aerts et al [9]. In short, all patients had pathologically-proven MPM and were included in 
the study at least 6 weeks after their last chemotherapy treatment, or were treatment-naive 
if they had refused chemotherapy treatment. After inclusion in the study, patients received 
leukapheresis, which was used as a source of autologous DCs.
The DCs were prepared as described [9] and pulsed with a lysate, consisting of a mixture 
of five in vitro cultured mesothelioma cell lines. Patients received a total of 3 vaccinations 
every two weeks and blood samples were obtained at baseline and at week 2, 4, 6 and 
8 following initial vaccination. Booster vaccinations were administered at 3 and 6 months 
[9]. One third of the dose was administered intradermally (i.d.), and two thirds of the dose 
intravenously (i.v.). As this was a dose escalation study, patients 1-3 received 10 million 
DCs per vaccination, patients 4-6 received 25 million DCs per vaccination and patients 
7-9 received 50 million DCs per vaccination. Patients 7 and 9 did not receive their second 
booster vaccination due to shortage of patient material. All other patients completed the full 
treatment scheme (Table S1 in Supplementary Material). For flow cytometry (FCM) analysis, 
cohort 1 was not included since the collected peripheral blood samples of patients in cohort 
1 were immediately processed and stored. For cohort 2 and 3 the protocol was amended 
to enable absolute immune cell quantification.
Collection and processing of peripheral blood samples
Ethylene diamine tetra acetic acid (EDTA) anticoagulated peripheral blood was drawn 
from patients at baseline prior to the first vaccination (week 0), at 2 weeks after the first 
vaccination, i.e., prior to the second vaccination (week 2) and 2 weeks after the third 
vaccination at week 6 and analyzed within 6 hours by multiplex FCM. One ml of whole blood 
was used for multiplex FCM and from the remaining blood, peripheral blood mononuclear 
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cells (PBMCs) were isolated by standard Ficoll density gradient centrifugation and were 
stored at -80 °C for further analyses.
Multiplex ﬂ ow cytometric assessment of numbers and phenotype of 
immune cells
To enumerate immune cell populations, whole blood (100μl) was stained with the ‘absolute 
numbers’ panel (Table S2 in Supplementary Material) and incubated for 15 min at room 
temperature. Subsequently, 2 ml of lysis buff er (NH4Cl: 8,26 mg/ml, KHCO3: 1 mg/ml and 
EDTA: 37μg/ml) was added to the blood and incubated for 15 min at room temperature. 
Subsequently 100μl of Flow-Count Fluorospheres (Beckman Coulter Inc) was added and 
samples were measured on a BD LSRFortessa™ fl ow cytometer. A minimum of 10,000 
CD45+ cells were measured to enable clear distinction of defi ned immune cell populations. 
Subsequently, data was analyzed with FlowJo version X (FlowJo, LCC) using the gating 
strategy as exemplifi ed in Figure S1 in Supplementary Material. Values were expressed as 
cells per microliter. To determine the phenotype of T cells, the T cell maturation, activation, 
co-inhibitory and co-stimulatory receptors were analyzed on whole blood with diff erent 
FCM panels (Table S2 in Supplementary Material). 100μl of whole blood was stained with 
each of the panels and incubated for 15 minutes at room temperature. Subsequently, 2 
ml of lysis buff er was added to the blood and after an incubation of 15 minutes at room 
temperature, the cell suspensions were centrifuged at 450g for 5 minutes, washed and 
resuspended in buff ered 0.1% paraformaldehyde (PFA). A minimum of 30.000 CD3+ cells 
were measured on the LSRFortessa™ fl ow cytometer to obtain clearly detectable immune 
populations. The FCM data were analyzed with FlowJo version X.
Determination of  mesothelin-spe cifi c T cells
PBMCs were thawed and subsequently T cells were rapidly expanded with a feeder system 
as described elsewhere [10]. After this rapid expansion protocol, T cells were co-cultured with 
artifi cial antigen presenting cells (aAPC) [11] loaded with mesothelin peptide A: SLLFLLFSL 
(mesothelin20-28), or mesothelin peptide B: VLPLTVAEV (mesothelin531-539) (Immudex, 
Copenhagen, Denmark). The aAPC cell line is based on K562 cells, retrovirally transduced 
with CD80, CD83, and HLA-A2 for optimal antigen presentation and co-stimulation, and 
enables enrichment of antigen-reactive T cells with protocols optimized in our laboratory 
[12]. 2.5 x 106 aAPC cells/ml were incubated at room temperature for fi ve hours with 10μg/
ml peptide and subsequently irradiated (120 Gy). Subsequently, these peptide-loaded 
aAPC cells were co-cultured with T cells (ratio 1:20) in T cell medium (RPMI Hepes [Lonza] 
supplemented with 10% human serum [Sanquin, Amsterdam, The Netherlands], 1% 
L-glutamine and 1% penicillin/streptomycin), 180 IU IL-2 per ml (Chiron, Amsterdam, The 
Netherlands), and 5 ng IL-15 per ml (Le-Perray-en-Yvelines, France). Mesothelin-driven T cell 
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expansion was continued for 4 cycles, after which T cells were examined for their binding 
ability to corresponding mesothelin peptide-HLA-A2 complex multimers. In this study, we 
performed a maximum of 4 peptide-specific expansion cycles.
Dextramer A: PE-conjugated HLA-A2 dextramer with peptide SLLFLLFSL (mesothelin20-28) and 
dextramer B: APC-conjugated HLA-A2 dextramer with peptide VLPLTVAEV (mesothelin531-539) 
were both ordered from Immudex (Copenhagen, Denmark). Dextramer staining was 
performed according to manufacturer’s protocol. Anti-CD3-BV711 (clone UCHT1) and anti-
CD8-FITC (clone SK1) mAbs (both from BD Biosciences) were used together with dextramers 
for extracellular staining. 4’,6-diamidino-2-phenylindole (DAPI) was used as viability dye. 
Samples were measured on an LSR-II flow cytometer (BD). Fluorescence-minus-one (FMO) 
controls were used to enable gating and determine dextramer-positive populations.
GeneScan T cell clonality analysis
Cell pellets from PBMC samples were frozen and stored until further use. Genomic DNA 
was isolated using the AllPrep DNA / RNA Mini kit (QIAGEN, Hilden, Germany) according 
to manufacturer’s instructions. T-cell receptor (TCR) b gene repertoire was measured using 
commercially available multiplex TCR Vβ-Jβ PCR assays (Invivoscribe, San Diego, CA, USA) 
as developed and approved by the BIOMED-2 / EuroClonality consortium [13]. GeneScan 
fragment analysis was done on an ABI 3130 xl instrument (ThermoFisher Scientific) and data 
were analyzed using PeakScanner software. Data interpretation was based on GeneScan 
patterns of duplicate PCR results, largely following the EuroClonality guideline [14].
DC – PBMC co-cultures
Mature lysate-pulsed DC (as were used for the DC immunotherapy) were co-cultured with 
PBMC samples of the same patient. For each patient PBMC samples from week 0, week 2 and 
week 7 were co-cultured with DCs in a 96-wells plate in a 1:10 ratio, in RPMI supplemented 
with 10% normal human serum (duplicate cultures). After 24 hours, the supernatant was 
collected for enzyme-linked immunosorbent assay (ELISA) to determine IFNγ (Invitrogen) 
and the cells were harvested for flow cytometry. For flow cytometric analysis, the cells were 
stained with the following antibodies: anti-CD3-APC-eF780 and anti-CD8-AlexaFLuor700 
(eBiosciences), anti-CD4-BV785, anti-CD56-PE-Cy7 and anti-CD69-FITC (BD Biosciences) 
and anti-CD137-PE (Biolegend).
Statistical analyses
Statistical analyses and graphs were made with GraphPad Prism v5.0. For comparison of 
changes from baseline measurements, Wilcoxon signed-ranks test was used to test for 
significance between baseline measurements and other time points. The heatmap was made 
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in R for windows version 3.4.1 using the package in “gplots” (https://cran.r-project.org/web/
packages/gplots/). Clustering was performed with a complete agglomeration method, and 
distance matrix of all variables was computed with Euclidean distance.
RESULTS
Numbers of B, CD 4 and CD8 T lymphocytes in peripheral blood increase 
upon vaccination with DCs
We fi rst assessed the absolute numbers of specifi c lymphocyte subsets (CD3+CD4+, 
CD3+CD8+, CD3-CD19+ and CD3-CD56+) from the six patients treated in the second and third 
cohort (dosage 25 million and 50 million DC per vaccination), using the gating strategy as 
shown in Figure S1 in Supplementary Material. Patients showed a signifi cant increase at week 
6 (after 3 vaccinations) compared to baseline in (median) numbers of CD4+ T cells (increase 
from 522 to 634 cells/μl), CD8+ T cells (from 256 to 304 cells/μl) and B cells (from 162 to 199 
cells/μl), but not Natural Killer (NK) cells (Figure 1). Together, these results are indicative for 
a potentiation of adaptive immunity in peripheral blood after DC immunotherapy.
Figure 1. Absolute number of lymphocyte subsets in peripheral blood of patients before and after 
DC immunotherapy. Quantifi cation of absolute numbers of CD4 T cells (CD45+/CD3+/CD4+), CD8 T 
cells (CD45+/CD3+/CD8+), B cells (CD45+/CD3-/CD19+), and NK cells (CD45+/CD3-/CD56+) in peripheral 
blood of patients in cohort 2 and 3 on baseline prior to the fi rst vaccination (week 0), 2 weeks after the 
fi rst vaccination, i.e., prior to the second vaccination (week 2) and 2 weeks after the third vaccination 
(week 6). Diff erences between week 0 and week 6 with respect to paired continuous parameters were 
determined using the exact Wilcoxon signed rank test. * p < 0.05; ns: not signifi cant.
Lysate-specifi c and mesothel in-specifi c T cells are detectable in 
peripheral blood of mesothelioma patients
Next, we investigated whether the increased numbers of T cells due to DC vaccination 
harbored vaccine-specifi c CD8 T cells. For three patients, lysate-pulsed DCs were available 
after completion of the treatment schedule. Co-cultures of PBMC before and after treatment 
with these lysate-pulsed DC showed an increase in CD69-positive CD4+ and CD8+ T cells, 
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CD137-positive CD4+ and CD8+ T cells, and IFNγ secretion after therapy, supporting the 
induction of a vaccine-specific response (Figure S2 in the Supplementary Material).
To further identify vaccine-specific CD8 T cells in all patients we selected mesothelin as 
a prototypic antigen based on the following lines of evidence. Firstly, RNA sequencing 
and western blot data obtained from the mesothelioma cell lines used to generate the 
lysate preparation validated mesothelin mRNA and protein expression. Secondly, immune 
histochemistry confirmed the expression of mesothelin in eight out of eight available patient 
biopsies. Lastly, mesothelin peptide/HLA-A2 complexes with reported immune reactivity [15, 
16], (peptide A: SLLFLLFSL and peptide B: VLPLTVAEV) were bound by CD8 T cells derived 
from patient skin biopsies after challenge with DC vaccine [9], as summarized in Table S2 
in Supplementary Material. To determine whether DC therapy would induce changes in the 
frequency of mesothelin-specific CD8 T cells, we measured the binding of two mesothelin-
peptide/HLA-A2 multimers by CD8 T cells in pre- versus post-vaccination peripheral blood 
samples. To this end, T cell fractions were first propagated using four T cell culture cycles in 
the presence of mesothelin peptides (A and B). Figures 2A and 2B show flow cytometry plots 
for one of the two mesothelin epitopes (peptide B) in propagated CD8 T cell fractions from 
HLA-A2-positive patients (8 out of 9 patients). These analyses show that the frequency of 
mesothelin-specific CD8 T cells is variable among patients, and already pre-exists in 5 out of 
8 HLA-A2 positive patients and does not change significantly upon treatment. Similar data 
were obtained for a second mesothelin epitope (peptide A; Figure S3 in Supplementary 
Material) and no correlation was observed between the frequencies of CD8 T cells specific 
for the two epitopes analyzed (data not shown).
In addition, we studied TCRB diversity of total T cells as a global measure of T cell reactivity 
via GeneScan TCRB PCR (Figure 2C). While some patients showed dominant peaks (e.g. 
patient 9), the GeneScan patterns were generally similar in pre-treatment and post-
treatment PBMC fractions from the MPM patients, indicating that DC therapy did not induce 
clonal T cell expansion or selection. Collectively, these findings show that DC vaccination-
specific T cells are detectable, but that this is not accompanied by an overall enhancement 
of frequencies in peripheral blood, nor obvious shifts in T cell TCRB repertoire.
Increased frequencies of PD-1, HLA-DR and ICOS positive CD4+ T cells 
after DC vaccination.
We then evaluated changes in frequencies of CD4 or CD8 T cells expressing surface 
activation, maturation or co-signaling markers and compiled a heatmap of all variables 
measured by FCM at pre- and post-therapy time points (Figure 3). Hierarchical clustering 
of samples showed clustering of the different time points per patient for the measured 
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variables. This demonstrates that intra-individual diff erences over time are relatively small, 
compared to inter-individual diff erences in the immunological variables that were measured.
To further explore immunological parameters that were modulated by DC immunotherapy, 
we assessed the expression of the various surface markers at multiple time points. Figure 
4A-D display the expression of T cell activation, co-inhibitory and co-stimulatory markers 
that were signifi cantly altered either early after the start of treatment (two weeks after 
the fi rst vaccination) or later during treatment (two weeks after the third vaccination). In 
particular, CD4+ T cells in peripheral blood showed a signifi cant gain of HLA-DR+ and PD-1+
T cells (Figure 4A, B) after the fi rst vaccination. After 3 vaccinations, we detected a signifi cant 
increase of CD278 (inducible T-cell co-stimulator; ICOS) positive CD4+ T cells compared to 
baseline (Figure 4D). CD8 T cells did not show any signifi cant increase of these markers, 
although CD8+ T cells demonstrated a signifi cant enrichment of CD223+ (Lymphocyte 
activation gene-3; LAG-3) T cells (Figure 4C). No signifi cant changes were observed in the 
following markers on both CD4+ and CD8+ T cells: CD25, CD69, CD272 (BTLA), CD137 (4-1BB), 
CD154 (CD40L), CD134 (OX40); (Figure S4 in Supplementary Material).
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Figure 2. Mesothelin-specific CD8 T cells in HLA-A2 positive patients are measurable in pre- and 
post-vaccination samples. A) Peripheral blood samples were collected at baseline (week 0) and 2 
weeks after the third vaccination (week 6). CD8 T cells were propagated in four culture cycles with 
mesothelin-peptide-B loaded aAPC, after which mesothelin-peptide B/HLA-A2 dextramers were used 
to detect mesothelin-specific CD8 T cells. Gating was based on the negative controls, FMO staining 
and the non-CD8 T cell population. All HLA-A2 positive patients are shown; patient 5 was excluded 
(haplotype HLA-A3/HLA-A68). B) Values of gated dextramer-binding CD8 T cells - as shown in panel 
A - presented as proportions of total CD8 T cells. C) Relative frequencies of complementarity determin-
ing region-3 (CDR3) lengths in pre- and post-therapy total T cells from PBMC samples of all patients. 
The Y-axis represents relative frequency as assessed by fluorescence intensity, with the various CDR3 
lengths on the X-axis. A polyclonal repertoire would follow a normal distribution.
In summary, these findings show that following autologous DC therapy in mesothelioma 
patients the frequencies of circulating CD4 T cells expressing HLA-DR, PD-1 or ICOS, as 
well as CD8 T cells expressing the co-inhibitory receptor LAG3 are significantly increased.
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Figure 3. Heatmap of percentages of several diff erent lymphocyte subsets and T cell surface markers 
in peripheral blood from patients in cohort 2 and 3 (MCV004 – MCV009). Columns represent diff erent 
patient samples at week 0, week 2 and week 6 after start of treatment. Rows represent the proportions 
of CD4 T cell, CD8 T cell and CD45 lymphocyte populations that express defi ned markers. Two of the 
co-inhibitory molecules in our panel, CTLA-4 and TIM 3 were expressed at too low frequencies to yield 
reliable values. Therefore, we removed these markers from further analysis. Percentages were normal-
ized according to mean values of all measurements and were clustered by non-hierarchical clustering.
7
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Figure 4. T cell activation and co-stimulatory molecule expression changes induced by DC immuno-
therapy. Representative histograms of flow cytometry data (left) and quantification for patients 4 to 9 
at week 0, week 2 and week 6 after start of treatment (right). A) Proportions of HLA-DR-positive CD4 
and CD8 T cells. B) Proportions of PD-1-positive CD4 and CD8 T cells. C) Proportions of LAG3-positive 
CD4 and CD8 T cells and D) Proportions of ICOS-positive CD4 and CD8 T cells. * p<0.05 - Wilcoxon 
paired signed-rank test, n.s. = not significant.
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DISCUSSION
Here we document on the eff ects of treatment of MPM patients with DC immunotherapy – 
autologous dendritic cells loaded with an allogeneic tumor lysate prepared from fi ve human 
MPM cell lines – on blood immune composition. The clinical outcomes of this fi rst-in-human 
clinical trial have been published previously, and showed feasibility of the therapy, as well 
as promising clinical responses [9].
We used fl ow cytometry to analyze peripheral blood and observed an increase in absolute 
numbers of B cells, and CD4+ and CD8+ T cells, suggesting induction of both a cellular and 
humoral immune response. Additionally, we found a signifi cant increase of HLA-DR, PD-1, 
and ICOS-positive CD4+ T cells, and an increase of LAG3-positive CD8+ T cells after treatment 
with DC vaccination therapy.
As previously shown, a vaccine-induced delayed-type hyperreactivity skin response was 
observed in all patients after treatment [9]. Here, we confi rmed that vaccine-reactive T cells 
were induced in the peripheral blood in three patients (two of whom receiving the lowest 
dose of ten million DCs). The DC immunotherapy was designed to induce a broad immune 
response towards multiple tumor antigens present in the tumor cell lysates. Nevertheless, 
for monitoring purposes that are independent of the availability of tumor material or 
pulsed DCs we analyzed mesothelin-specifi c T cells in peripheral blood during treatment. 
Since mesothelin was determined to be present in the tumor lysate, and expressed on 
the tumor cells of the patients, it was regarded to be a relevant antigen in this setting. 
Interestingly, after mesothelin-derived peptide-driven in vitro T cell propagation, CD8+ T 
cells that bind mesothelin peptide/HLA-A2 complexes could already be detected in baseline 
blood samples of the majority of patients, suggesting that a mesothelin-specifi c immune 
response was already present in these patients prior to therapy. However, DC vaccination 
did not induce changes in frequencies of the mesothelin-specifi c T cells in peripheral blood. 
Additionally, as a measure of T cell clonality, we analyzed the TCRB CDR3 length in pre- and 
post-treatment blood samples, which indicated that no major repertoire shifts occurred.
Both the skin responses against the vaccine in all patients after therapy, and the confi rmation 
of these result by in vitro experiments in three patients, show that a vaccine-specifi c T 
cell response is induced. Furthermore, the increase in CD4+ and CD8+ T cells at week 6, in 
absence of a change of detectable dominant T cell clones (by TCRB CDR3 length analyses) 
in peripheral blood suggest that these T cell responses are of a polyclonal nature. Indeed, 
it has been reported that DC immunotherapy broadens, rather than skews the diversity of 
the T cell repertoire. In melanoma patients, not only the number of neoantigen-specifi c 
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T cells increased, but also the number of clonotypes per antigen increased, indicating a 
further diversification of the repertoire [17].
In contrast, in studies employing vaccination with DCs pulsed with specific peptides, 
dominant T cell clone expansions were observed in peripheral blood [18, 19]. Increases in 
the frequency of tumor-specific T cells were determined by IFN-γ ELISPOT [18] or HLA-A2 
MHC multimers [19]. The use of specific peptides to pulse DCs in these studies likely resulted 
in a more easily detectable clonal expansion of T cells, as compared to our strategy using 
complete tumor cell lysate. In one study monitoring T cells specific for a single antigen after 
DC vaccination using allogeneic tumor lysate increased frequencies of MART-1-specific CD8+ 
T cells were found after treatment in 3 out of 21 patients. In line with our findings, detectable 
numbers of these T cells were already present at baseline in 2 out of these 3 patients [20]. 
Furthermore, as the T cells activation and the co-culture experiment showed the highest 
response two weeks at the start of treatment, we might have missed detectable changes in 
peripheral blood that took place before week six. In conclusion, monitoring TCR-specificity 
against a single tumor-antigen (mesothelin) may support the presence of tumor-specific 
responses, but does not provide information on the repertoire of the tumor-specific T cell 
response.
Whereas a vaccine-specific response was reported to be induced in all nine patients in 
our clinical study [9], it remains unknown whether this response was also reactive against 
the autologous tumor. In previous studies with DC vaccination in mesothelioma using 
autologous tumor material, we found significantly increased cytotoxicity against the tumor 
after treatment, showing induction of a tumor-specific response by DC immunotherapy [7]. 
In the current study, no tumor material was collected for ethical reasons, but we anticipate a 
comparable induction of a tumor-specific immune response based on the clinical outcomes 
in our patient cohort. Two partial responses were reported after DC immunotherapy, of 
which one remarkable response of 70% tumor reduction in a treatment-naïve patient within 
six weeks which lasted for two years [9].
As shown here and by others, monitoring of specific T cells in peripheral blood upon 
immunotherapy with a broad antigen repertoire, is challenging due to the unknown 
antigen composition and low frequency of individual T cell clones, and requires either 
very immunogenic antigens like NY-ESO-1 or MART-1 [21, 22] or in vitro enrichment steps, 
which makes it less attractive for future use in clinical practice. The current study did not 
address whether changes occurred in T cell reactivity in the local compartment. However, 
removal of tumor can be harmful in MPM due to a substantial risk of local tumor outgrowth 
at the intervention site [23], precluding the analysis of local tumor material for monitoring 
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purposes. Next to T cell specifi city, we investigated T cell phenotype, using extended 
multiplex fl ow cytometry. We demonstrated that treatment-related diff erences were most 
notable for CD4+ T cells, with an increase in surface expression of ICOS, PD-1 and HLA-DR 
after treatment. This signifi es T cell activation, because T cells upregulate HLA-DR [24], ICOS 
[25] and PD-1 [26] after (TCR) stimulation.
Interestingly, both HLA-DR+ CD4 T cells and ICOS+ CD4 T cells have been described to 
increase after treatment with ipilimumab (anti-CTLA-4 monoclonal antibody) [27]. Moreover, 
an increase of ICOS+ CD4 T cells is suggested as a possible pharmacodynamic biomarker for 
response to this checkpoint inhibitor [28-30]. Notably, the best responding patient (#5) in 
our study showed the highest numbers of HLA-DR+ CD4+ and ICOS+ CD4+ T cells. Our fl ow 
cytometry panels did not allow analysis of co-expression of ICOS and HLA-DR. Others have 
demonstrated that ICOS+ T cells also expressed CD45RO [25], indicating that T cells bearing 
high levels of ICOS may be in an advanced maturation phase. This would be in concordance 
with the low proportions of CCR7 and CD27-positive T cells in our patient (#5), which are 
markers of less maturated T cells. In the current study patient numbers are too low to 
correlate the immune monitoring data with clinical outcome. Yet, our fi ndings suggest that 
the ICOS+ CD4+ T cell subset may have value in the immune monitoring of future trials with 
DC immunotherapy. Furthermore, Fan and colleagues have described a functional role for 
ICOS in the anti-tumor immune response [31], providing a rationale for the combination of 
DC immunotherapy and engagement of ICOS-signaling in future treatments.
In conclusion, vaccination with a broad spectrum of antigens (as is the case with the 
allogeneic lysate used in the current study) in MPM patients, induced an increase in T cell 
and B cell numbers in peripheral blood. No evidence was found for a mono- or oligo-clonal 
T cell expansion, thus suggesting broad activation of the T lymphocytes after therapy. 
Additionally, changes in the frequencies of defi ned immune cell markers, in particular the 
increase of T cell activation markers in CD4+ T cells, demonstrated treatment-associated 
changes that we would propose as parameters to be included in the monitoring of DC 
vaccination treatments. Future studies with larger patient groups should evaluate their 
relation with treatment effi  cacy.
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Table S2: List of antibodies used for multiplex fl ow cytometry
MARKER LABEL SUPPLIER CAT.NO CLONE PANEL*
CD3 FITC BD Biosciences 345764 SK7 1
CD3 Pacifi c Blue BD Biosciences 558117 UCHT1 2,3,4,5
CD4 PE-Cy7 BD Biosciences 348809 SK3 1
CD4 BV510 BD Biosciences 560769 RPA-T4 2,3,4,5
CD8 APC-Cy7 BD Biosciences 348813 SK1 1
CD8 PerCP BD Biosciences 345774 SK1 2,3,4,5
CD19 APC eBioscience 17-0199-42 HIB19 1
CD25 APC BD Biosciences 340907 2A3 3
CD27 APC-Cy7 BD Biosciences 560222 M-T271 2
CD28 APC BD Biosciences 559770 CD28.2 2
CD45 PerCP BD Biosciences 345809 2D1 1
CD45RA PE-Cy7 BD Biosciences 337186 L48 2
CD56 PE Dako R7251 C5,9 1
CD57 FITC BD Biosciences 333169 HNK-1 2
CD69 PE-Cy7 BD Biosciences 335792 L78 3
CD127 PE BD Biosciences 557938 hIL-7R-M21 3
CD134 (OX40) FITC eBioscience 11-1347-42 ACT35 (ACT-35) 5
CD137 (4-1BB) PE eBioscience 12-1379-42 4B4 (4B4-1) 5
CD152 (CTLA-4) APC BD Biosciences 555855 BNI3 4
CD154 (CD40L) APC-Cy7 Biolegend 310822 24-31 5
CD223 (LAG3) PE-Cy7 eBioscience 25-2239-42 3DS223H 4
CD272 (BTLA) PE Biolegend 344506 MIH26 4
CD278 (ICOS) PE-Cy7 eBioscience 25-9948-42 ISA-3 5
CD279 (PD-1) APC-Cy7 Biolegend 329922 EH12.2H7 4
CD366 (TIM-3) FITC eBioscience 11-3109-42 F38-2E2 4
CCR7 PE R&D FAB197P 150503 2
HLA-DR APC-Cy7 BD Biosciences 335831 L243 3
TCRγδ FITC BD Biosciences 347903 11F2 1
*Panel 1: Absolute numbers, Panel 2: Maturation, Panel 3: Activation/Tregs, Panel 4: Co-inhibitory 
markers, Panel 5: Co-stimulatory markers
Supplementary fi gure S1: Example of gating strategy preceding the enumeration of immune cell 
populations. Lymphocytes were defi ned as CD45+, SSC-Alow (plot1); from CD45+, SSC-Alow lymphocytes, 
T cells (CD3+CD19-) and B cells (CD19+CD3-) were defi ned (plot 2). T cells were further subdivided in 
CD8+ T cells, and CD4+ T cells (plot3 and 4). Within the CD45+, SSC-Alow lymphocytes, NK cells were 
defi ned as CD56+CD3- (plot 5).
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Supplementary figure S2: Activation of post-therapy T cells after co-culture with lysate-pulsed DCs. 
Lysate-pulsed DCs were co-cultured for 24h with autologous PBMC obtained at week 0, 2 or 7. A) 
Proportions of CD4 and CD8 T cells expressing CD69, as determined by flow cytometry. B) Proportions 
of CD4 and CD8 T cells expressing CD137, as determined by flow cytometry. C) Concentration of IFNγ 
in the culture supernatant after 24h, as determined by ELISA.
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Supplementary fi gure S3: Mesothelin peptide A-specifi c CD8 T cells in HLA-A2 positive patients. A) 
Peripheral blood samples were collected at base line (week 0) and 2 weeks after the third vaccination 
(week 6). CD8 T cells were propagated in four culture cycles with mesothelin-peptide loaded aAPC after 
which mesothelin-peptide/HLA-A2 dextramers were used to detect mesothelin specifi c CD8 T cells. 
B) Values of gated dextramer positive CD8 T cells - as shown in panel A - presented as proportions of 
mesothelin-B HLA-A2-binding cells of total CD8 T cells. Gating was based on the negative controls: 
FMO staining and the non-CD8 T cell population. All HLA-A2 positive patients are shown; patient 5 
was excluded (haplotype HLA-A3/HLA-A68).
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Supplementary fi gure S4: Additional frequencies of T cell populations or ratios, as well as expression 
of cell surface markers, showing no change between week 0, 2 and 6. A) CD4/CD8 T cell ratio, γδT 
cells and regulatory T cells (Treg) percentages (upper panels) and representative fl ow cytometry plots 
(lower panels; γδT cell and Treg). B) CD4 T cells positive for CD25, CD69, CD272 (BTLA), CD137 (4-1BB), 
CD154 (CD40L) and CD134 (OX40). C) CD8 T cells positive for CD25, CD69, CD272 (BTLA), CD137 (4-
1BB), CD154 (CD40L) and CD134 (OX40)
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Chapter 8
REVERSE TRANSLATIONAL RESEARCH AND IMMUNE 
MONITORING
The aim of translational research or translational medicine is to use fundamental scientific 
insights to develop and create new treatments to improve health. In the field of tumor 
immunology, this means that a solid understanding of tumor biology and immunology 
are needed to develop improved or novel strategies to treat and eventually cure cancer 
patients. Typically, translational research goes from bench to bedside. New drug targets 
and the effect of their modulation are first studied in vitro and subsequently tested in in 
vivo studies, using animal models that increasingly reflect the physiological situation in 
patients. Finally, new treatments are tested in clinical trials in patients. Unfortunately, no 
model fully reflects the complexity of the situation in the patient, and consequently new 
therapies may fail during development. Moreover, as each patient’s condition is different, 
we do not know on forehand which patients will respond to certain therapies and which 
patients will not. Besides efficacy of a certain drug, the right patient population should be 
determined for optimal treatment.
Whereas translation from bench to bedside is common practice in the field, less attention 
is given to translation the other way around: from bedside to bench. Much is to be learned 
by studying patient data from clinical trials; knowledge that can be used in improving the 
therapies in development. Immune monitoring in patients is an important part in this reverse 
translational research, providing insights in the mechanisms of action of certain therapies or 
defining patient groups with a differential sensitivity to certain treatments. Moreover, it can 
increase our understanding of the role of the several components of the immune system 
in cancer progression and prognosis.
The research described in this thesis focusses on monitoring immune cells and components 
in the peripheral blood of patients with thoracic malignancies. Immune monitoring can 
serve a clinical or a more fundamental objective:
1. From a clinical perspective, we aimed to predict an individual patient’s response to 
treatment or chance of (long-term) survival in a way that can be implemented in 
clinical practice.
2. From a translational perspective, we aimed to increase our knowledge about the 
mechanism of action of several cancer therapies, which will benefit the design and 
improvement of novel treatment strategies, the discovery of drug targets, or a 
rationale for potential combination strategies.
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Our main fi ndings are that in early stage non-small cell lung cancer (NSCLC), radiotherapy 
induces an activation of T cells in the majority of patients, characterized by increased 
proportions of PD1+ and Ki67+ T cells. Furthermore, we showed that chemotherapy is able 
to induce activation markers on T cells, although this does not translate to an increased 
clinical response. Surgery does not increase T cell activation in early stage NSCLC patient. 
In malignant pleural mesothelioma (MPM) patients, we showed that dendritic cell (DC) 
immunotherapy is a promising treatment and induces immune responses accompanied by 
an increase in activation markers on CD4 T cells in peripheral blood.
IMMUNE MODULATORY EFFECT OF CANCER TREATMENT
In chapters 3, 4 and 7 we studied the immune modulatory eff ects of diff erent treatments 
in patients with thoracic malignancies during conventional or experimental treatments. An 
overview of the immune modulatory eff ects of the diff erent treatments studied in these 
chapters is presented in Table 1. All these measurements were performed in peripheral 
blood, as this is an ideal source for serial sample collection that is minimally invasive to 
the patient. The limitation is, however, that we do not know how well this refl ects immune 
populations in the tumor and thus these data only inform us on systemic immune responses.
Conventional therapy
In early stage lung cancer, patients are treated generally with surgery or ablative 
radiotherapy. Radiotherapy is mainly used in patients unfi t for treatment or with a tumor 
on a location that is diffi  cult to reach. In chapter 3 we showed that in a subset of patients 
receiving stereotactic ablative body radiation (SABR), T cell activation is induced in the 
peripheral blood. This was characterized by increased proportions of proliferating T cells 
and increased PD1+ T cells. Patients receiving surgery did not show T cell activation. Instead, 
we observed that surgery induced a temporal increase in myeloid derived suppressor cells 
(MDSC) (additional data, not discussed in chapter 3). These fi ndings may have implications 
for the use of immunotherapy in these patients. Currently, PD-1/PD-L1 inhibition has 
been EMA/FDA approved for NSCLC only at an advanced stage, but presently, in several 
large randomized phase III studies, the role of adjuvant PD-1/PD-L1 is being established, 
and consequently these treatments might be administered also at an earlier stage in the 
future [1]. As a pre-existing anti-tumor immune response is required for PD-1 blockade to 
reinvigorate T cells, we hypothesize that radiotherapy might increase sensitivity to PD-1 
blockade by inducing immunogenic cell death and thereby priming this immune response. 
Current clinical trials are investigating this hypothesis [2, 3]. Another question for further 
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research, is whether the increase in T cell activation after SABR is predictive of a response 
to checkpoint inhibition.
In chapter 4, we monitored immune dynamics in patients with an advanced stage of 
NSCLC that were treated with chemotherapy and anti-VEGF combination. This combination 
treatment is an approved regimen in stage IV NSCLC. In these patients, an increase in 
proliferating CD8+ T cells was observed in the first six weeks after treatment. The increased 
proliferation occurred in T cells of the effector subtype that expressed PD-1. Similar to SABR-
treated patients, this chemotherapy anti-VEGF combination might increase sensitivity to 
PD-1/PD-L1 inhibition, because increased CD8 proliferation in peripheral blood is associated 
with a better response [4, 5]. As with SABR, chemotherapy might therefore be combined 
with immunotherapy to increase efficacy.
We cannot conclude from our data to which of the components of the PCB treatment – 
paclitaxel, carboplatin or bevacizumab – these immune modulatory effects can be ascribed. 
Moreover, several studies have shown that different types of chemotherapy have a variable 
capacity to induce immunogenic cell death, capable of inducing an immune response 
[6-8]. Therefore, a direct comparison between the different chemotherapeutic regimens 
in combination with immunotherapy would be useful. The combination of paclitaxel 
and carboplatin as studied in this thesis, is one of the most frequently used regimens 
for advanced stage NSCLC. Interestingly, an indirect comparison of PD-1/PD-L1 inhibition 
treatment, chemotherapy treatment and the combinations thereof in a meta-analysis, 
suggested improved clinical outcomes of the combination therapy compared to PD-1/
PD-L1 inhibition alone, indicating an additional benefit of chemotherapy [9]. Whether this is 
due to synergy of the two treatment effects in the same patients or separate patient groups 
that respond to either of the treatments and thus an increased response rate, remains to 
be elucidated.
Dendritic cell Immunotherapy
Whereas the main mechanism of action of the conventional treatments radiotherapy and 
chemotherapy relies on the direct killing of tumor cells by interfering with their capacity 
to proliferate, immunotherapy is designed to induce or enhance the anti-tumor immune 
response. New insights into the role of the immune system in cancer progression and 
response to cancer treatment has led to the development of novel immunotherapeutic 
strategies. DC-based immunotherapy has been one of these strategies. Preclinical 
development of DC immunotherapy and subsequent development of MesoPher treatment 
for mesothelioma, an autologous DC treatment consisting of DCs pulsed with an allogeneic 
tumor cell lysate, has been described in chapter 6. MesoPher DC immunotherapy has 
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shown clinical promise with low toxicity and two clinical responses in patients with malignant 
mesothelioma.
In chapter 7, we studied the immune modulatory eff ects of MesoPher, as determined in 
peripheral blood. We studied various molecules on T cells to assess their activation. Classical 
T cell activation markers include CD25 and HLA-DR [10]. Furthermore, many co-inhibitory 
receptors such as PD-1, CTLA4 and LAG3 are also upregulated upon activation. However, 
upon prolonged antigen exposure, T cells can accumulate multiple inhibitory receptors 
and turn into a dysfunctional state called T cell exhaustion [11]. Interestingly, the immune 
modulatory eff ect of DC immunotherapy was most pronounced for CD4 T cells, with an 
increase in expression of HLA-DR, PD1 and ICOS. The upregulation of these markers – 
the activation marker HLA-DR, the co-inhibitory molecule PD-1 that is upregulation upon 
activation, and ICOS, a co-stimulatory molecule on T cells – together indicate activation of 
CD4 T cells after therapy. On CD8 T cells on the other hand, only a small increase in LAG3 
expression was observed. As PD-1 was the only upregulated co-inhibitory molecule on 
CD4 T cells and LAG-3 the only co-inhibitory molecule upregulated on CD8 T cells, these 
changes are unlikely to refl ect an exhausted state. Unfortunately, with the small number of 
patients in this study, we could not correlate these changes to clinical outcome. The value 
of these markers as biomarkers and predictors of clinical outcome will be investigated in 
subsequent clinical trials for this therapy. Another immunological outcome in this study was 
the delayed-type hypersensitivity (DTH) skin test, in which an immune reaction – redness 
and thickening – of the skin is assessed upon injection in the skin, in this case of the lysate-
pulsed DCs. Six weeks after the fi rst vaccination, all patients had a positive response on 
this skin test, showing a functional immune reaction against the vaccine (chapter 6). The 
timing of the response, 48h after injection, is indicative of a T cell response. Moreover, we 
detected specifi city to the mesothelioma-related antigen mesothelin these skin-infi ltrating 
T cells. However, this fi nding does not guarantee that these T cells reach the tumor.
These studies may guide the further development of DC immunotherapy for instance 
towards the optimal combination immunotherapy. We are currently eagerly awaiting clinical 
and translational results of the ongoing phase III clinical trial that will show whether the 
treatment is effi  cacious in pleural mesothelioma patients. Nevertheless, we can already 
speculate on ways to further improve the treatment. For example, pre-clinical studies 
show that depletion of immune suppressive cells in the tumor microenvironment can 
improve effi  cacy of DC immunotherapy, and another logical combination would be DC 
immunotherapy and anti-PD1/PDL-1 checkpoint inhibition [12]. The latter might be eff ective 
because DC immune therapy induces increased PD-1 expression on CD4 T cells but might 
also boost CD8 T cells simultaneously for an optimal immune response.
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In vivo experiments in mice with allogeneic lysate-pulsed autologous DC showed induction 
of a tumor-specific CD8 T cell response (chapter 6), but immune monitoring of patient 
blood showed mainly activation of CD4 T cells. While this might be due to differences 
between the preclinical and clinical setting, it would be of interest to further investigate 
the contribution of CD4 T cell activation in DC immunotherapy efficacy. Depletion of either 
CD4 or CD8 T cells in animal models could show the contribution of these subsets in the 
efficacy of DC immunotherapy. Furthermore, it would be of interest to investigate to which 
extent the individual CD4 T cell subsets (Th1, Th2, Th17, Tfh, Treg) are activated by DC 
immunotherapy, for example by studying the cytokine profile of these T cells. The cytokine 
IFNγ plays a key role in the anti-tumor immune response [13], therefore activation of the 
Th1 subset is expected to be most beneficial.
Table 1. Overview of main results of longitudinal immune monitoring data as reported in chapters 
3, 4 and 7 of this thesis.
Ch. Cancer Treatment Cell numbers CD4 T cells CD8 T cells Immune 
suppressive 
cells
3 NSCLC early 
stage
Surgery N.D. No changes No changes Temporary 
increase in MDSC
3 NSCLC early 
stage
SABR N.D. Increased 
proliferation
Increased 
proliferation
No changes
4 NSCLC late 
stage
Chemotherapy 
+ anti-VEGF
N.D. No changes Increased 
proliferation
Temporary 
increase in MDSC
7 Mesothelioma DC immuno-
therapy
Increase in total 
B cells, CD4 T 
cells, CD8 T cells
Upregulation 
of PD1, HLA-
DR, ICOS
Upregulation 
of LAG3 
expression
No change in 
MDSC
Immune monitoring in peripheral blood
Altogether, we showed that several immunological changes can be measured in the 
peripheral blood of cancer patients, whereby these changes are different across treatment 
strategies. Overall, there is a large variation between patients, but samples of an individual 
patient taken at different time points are strongly correlated. Proportions of the immune 
subsets (B cells, monocytes, T cells, CD4/CD8 T cell ratio and the various differentiation 
stages of T cells) remain surprisingly stable over time. However, changes in the activation 
status of T cells can be detected by increased proportions of T cells positive for markers 
such as Ki67 (associated with cell division), PD-1, HLA-DR and ICOS. In recent years, changes 
in peripheral blood Ki67+ CD8 T cells have shown to be a marker of clinical response 
to checkpoint inhibition, which has been corroborated by several studies [4, 5, 14]. We 
have observed an increase in Ki67+ CD8 T cells after both SABR and chemotherapy, which 
indicates that this is a more common response to cancer treatment. Unfortunately, Ki67 
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expression was not measured in the immune monitoring of the DC immunotherapy clinical 
trial, so whether this extends also to other immunotherapies remains to be determined.
In chapter 7, we monitored the specifi city of T cells (i) by assessing the diversity in the 
length of complementarity-determining region 3 (CDR3) of the T cell receptor (TCR), which 
is the region that is responsible for recognizing antigens, and (ii) by assessing changes in the 
number of mesothelin-specifi c T cells, in which mesothelin was chosen as a model antigen 
for mesothelioma. However, no signifi cant changes were observed in these patients after 
treatment. The used method of determining CDR3 length diversity is suitable to detect 
prominent clonal expansions. In addition, others have found that DC or whole tumor cell 
vaccination increases the diversity of T cells clones [15, 16]. Expansion of specifi c T cell 
clones after therapy is mainly reported in combination with clones identifi ed in the tumor 
[17-19]. Immunotherapy using DCs that are pulsed with whole-cell lysates is not designed 
to induce a mono- or oligoclonal T cell response. Therefore, monitoring alterations in the 
repertoire of T cells is not recommended for immune monitoring in peripheral blood in 
future studies. However, more sensitive techniques such as next-generation sequencing will 
be useful to compare the T cell receptor repertoire in blood and tumor T cells or to explore 
changes induced by DC immunotherapy. Instead of monitoring T cell receptor repertoires, 
a general picture of the activation state of the immune system can be obtained by studying 
the diff erent subpopulations and their activation markers in peripheral blood.
THE IMMUNE PROFILE AS BIOMARKER FOR CLINICAL 
OUTCOME
Myeloid-derived suppressor cells in advanced stage NSCLC
The NVALT 12 study was a Dutch national study investigating the role of adding a 
nitroglycerin patch to a standard chemotherapy regimen in a non-blinded randomized 
setting. The chemotherapy regimen carboplatin paclitaxel was combined with the anti-
VEGF antibody bevacizumab, and the additional eff ect of the nitroglycerin patch on 
progression free survival was studied. The hypothesis that the vascular dilation caused by 
the nitroglycerin would improve chemotherapy delivery to the tumor potentiating its eff ect 
was not confi rmed in this study. Within the NVALT12 study, blood samples were collected 
from a cohort of over 200 NSCLC patients, which allowed for analysis the immune profi le 
in relation to the survival of these patients. We have shown in chapter 2 that elevated 
numbers of MDSC are associated with worse survival in NSCLC patients. This means that 
in general, MDSC are disadvantageous for (lung) cancer patients, which is in line with 
other published research. Furthermore, we investigated expression of immunoglobulin-
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like transcript 3 (ILT3), also called LILRB4. This molecule is expressed on monocytes 
and professional antigen-presenting cells (APCs) and confers an inhibitory signal via its 
immunoreceptor tyrosine-based inhibitory motif (ITIM) domain. We showed that ILT3 is 
expressed by MDSC and correlates with a worse survival. ILT3 expression might signify 
an even more suppressive state of MDSC and might thereby be an interesting target for 
therapy. Besides tolerogenic DCs and MDSC, recent literature has shown that ILT3 can also 
be expressed on tumor cells. For example, ILT3 is expressed on acute myeloid lymphoma 
(AML) cells and negatively impacts T cells [20]. Furthermore, colorectal carcinoma cells 
can express ILT3, which is negatively correlated with immune infiltration and survival [21]. 
This makes ILT3 an interesting target for therapy, which might affect tumor cells and MDSC 
simultaneously. In fact, a chimeric antigen receptor (CAR) T cell therapy against ILT3 for 
treatment of AML is currently being developed [22].
Combining multiple markers
Accumulating evidence exists for a prognostic and/or predictive role for various immune 
cells either in the tumor microenvironment or in the peripheral blood (see also chapter 
1 of this thesis). In chapter 2 we provided additional evidence for the negative impact of 
elevated MDSC proportions on survival of NSCLC patients. As the immune system involves 
many specialized cells each having their effect on the tumor, we hypothesized that the 
combination of immunological markers as a more complete immune profile would be a 
better predictor of clinical outcome than a single cell marker.
In chapter 5 we used the flow cytometry data of the MDSC staining from chapter 2 and 
the T cell stainings from chapter 4, to create a prediction model for clinically meaningful 
outcome, such as progression free and overall survival based on all possible marker 
combinations in these stainings, using the FloReMi pipeline [23]. Semi-automatic gating 
could be used to create a huge number of features for the model, encompassing all possible 
combinations of markers and thus immune subsets, given the markers that were measured. 
With advancing technology, the need for bioinformatic analysis methods is increasing. 
Multidimensional data such as flow cytometry and mass cytometry data require more 
sophisticated analysis than the two-dimensional plots that can be analyzed manually. 
(Semi)-automatic gating can be very useful for data sets with a large number of samples, 
such as clinical trials. Although reliable populations were extracted with automatic gating, 
the performance of the final prediction model was only moderate. Importantly however, 
usage of features extracted with the FloReMi pipeline resulted in a better prediction of 
survival compared to manually gated populations. In future research, the FloReMi, or other 
comparable approaches could be applied to other clinical cohorts in which a stronger 
effect of the peripheral blood immune profile on clinical outcome is expected, for example 
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immunotherapy trials. The selected features of the model can hold valuable information on 
immune populations and their eff ect on clinical outcome and may be hypothesis-generating.
Biomarkers - Correlation versus prediction
As described, a statistical diff erence in survival between patients with normal or elevated 
proportions of MDSC has been observed in the NVALT12 study. Sensitivity and specifi city are 
not high enough with this diff erence in median survival time to be used in clinical practice 
to predict an individual patient’s survival chance. Similarly, with a concordance index of 
0.67, the prediction model derived from the FloReMi pipeline is not robust enough to be 
used in clinical practice, although it does correlate signifi cantly with the observed overall 
survival. In the search for biomarkers for response to (immuno)therapy, often correlations 
with overall clinical outcome are reported. Yet, a biomarker that can be used for clinical 
decision making requires a much greater sensitivity and specifi city. PD-L1 expression in 
the tumor is currently the only approved biomarker available for PD1 blockade therapy, 
although also here specifi city is not high enough to really guide clinical decision making 
[24], because patients with PD-L1 negative tumors can still respond to therapy, albeit with a 
lower response rate. Therefore, in most cases patients with PD-L1-negative tumors will still 
be treated with this therapy. With the present knowledge, to improve prediction of clinical 
outcome in cancer patients during certain treatments a combination of multiple factors 
should be employed. These may include clinical characteristics, immunological biomarkers 
in peripheral blood and in the tumor microenvironment, as well as tumor characteristics 
such as mutational burden.
IMPLICATIONS FOR FUTURE RESEARCH AND TRIAL DESIGN
In the era of emerging immunotherapies, studying clinical parameters and molecular 
characteristics of the tumor is not suffi  cient for a full understanding of treatment response. 
When the immune system is actively targeted and is therefore the main mode of action 
of a treatment, immunological responses should be evaluated. On the other hand, the 
immune modulatory eff ects of conventional therapy might be more indirect and should 
be considered as well, especially when designing combination treatments. Furthermore, 
monitoring anti-tumor immune responses may provide information on the response 
status earlier after treatment. For example, an anti-tumor immune response can prevent 
recurrences which only become apparent after years. However, further research is needed 
to confi rm this hypothesis in clinical settings, for example in the patient cohort of chapter 
3, when recurrences have occurred. A discussion issue remains how to study the immune 
activation induced by these therapies. Is it essential to study the eff ects in the tumor tissue, 
8
Pauline_Proefschrift.indd   157 29/11/2019   09:10:52
158
Chapter 8
which is hampered by the limited availability of tissue both before the start of treatment and 
during or after treatment? Does peripheral blood, being easily accessible for longitudinal 
follow up, serve as a surrogate for tumor tissue or does the peripheral blood have a function 
on its own in the anti-tumor immune response? Evidence for the latter has been provided 
by Spitzer and colleagues, who studied the role of a systemic immune response during 
effective or ineffective treatment in murine tumor models and showed that a systemic 
immune response is crucial for tumor rejection [25]. This systemic immune response was 
characterized by sustained T cell proliferation in blood; a finding which is at least partly 
translated to the human setting, since increased T cell proliferation is correlated to response 
to checkpoint blockade in patients [4, 5, 26]. Some factors obviously cannot be studied in 
peripheral blood, such as tissue-resident immune cells and spatial localization of immune 
cells. However, given the limitations of studying tumor samples – inter-organ differences 
when studying primary tumor and metastases, intra- and inter-tumor heterogeneity within 
a patient – peripheral blood may be a suitable source to study, especially to capture the 
complete dynamics of the response by assessing multiple time points.
Based on the results presented in this thesis, the following marker combinations are advised 
to be included in future immune monitoring efforts. First, markers to define the major 
immune cell subsets (monocytes, B cells, CD4 and CD8 T cells, NK cells) in peripheral 
blood mononuclear cells (PBMC) should be included. Furthermore, markers to distinguish 
Treg from T helper cells (e.g. FoxP3, CD45RA, CD25, CD127) should be included. For T cell 
activation, PD-1, Ki67, HLA-DR and ICOS can be included. CD69, TIM3 and CTLA4 had a very 
low expression on peripheral blood T cells and determination of these markers is therefore 
only recommended when combined with other markers to specifically analyze a subset 
with higher expression, for example Tregs. MDSC are a population that is clinically relevant 
in peripheral blood and can be monitored, as well as classical and non-classical monocyte 
subsets that can be distinguished with the same set of markers. To avoid complex staining 
panels, the combination of HLA-DR and CD33 may be used.
There is an increasing number of anti-cancer drugs on the market and in (pre)clinical 
development. However, although these treatments improve survival rates of cancer 
patients, many of these will not lead to cure in an advanced stage disease. To improve 
cancer treatments, different therapies may be combined, but with the number of possible 
combinations there is a need for rational design. It would be simply too much to test 
all combinations in clinical trials. A proper rationale and preclinical evidence for certain 
combination is needed. Furthermore, with reverse translation we can make use of very 
valuable insights gained from clinical practice and clinical trials to shape and redesign our 
treatments, select the appropriate patient groups or combination strategies. Therefore, it is 
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crucial to implement patient sample collection for immune monitoring in future clinical trials. 
Despite its limitations, peripheral blood has proven to be a valuable source for immune 
monitoring, especially for the markers as discussed above. Taking into account the rapid 
developments in technologies such as multi-color fl ow cytometry, mass cytometry and 
single cell RNA sequencing and the bioinformatic data analysis methods, as well as our 
rapidly expanding knowledge in the tumor immunology and immune monitoring fi eld, this 
will greatly benefi t reverse translation and is expected to lead to substantial improvement 
of patient-centered cancer therapy.
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Chapter 9
ENGLISH SUMMARY
Cancer develops when normal cells of the body acquire mutations that lead to uncontrolled 
cell division and invasion of surrounding tissues. In the early stages of cancer, the tumor 
is confined to one local site, but it can progress to advanced stage, metastatic disease in 
which other organs are affected. Survival rates decrease drastically with an advancing stage 
of cancer. Various types of cancer exist, depending on the cell of origin. This thesis focuses 
on the thoracic malignancies non-small cell lung cancer (NSCLC) and mesothelioma. Non-
small cell lung cancer has the higher cancer mortality world-wide and derives from cells 
in the lung. Mesothelioma is a cancer of the pleural lining of the lungs and is induced by 
asbestos exposure. Although several effective cancer treatments have been developed over 
the last century, most patients are still incurable.
The immune system plays a very important role in the protection against cancer. Described as 
the cancer immunity cycle, tumor antigens that are released in the tumor microenvironment 
are taken up by dendritic cells (DC) and presented to T cells in the lymph nodes. T cells 
specific for these tumor antigens are then activated and expand, upon which they travel to 
the tumor, recognize the tumor and are able to induce tumor cell death. However, cancer 
cells employ several mechanisms to evade or suppress this anti-tumor immune response.
Immunotherapy aims to enhance this anti-tumor immune response, for example by blocking 
inhibitory receptors on T cells (checkpoint inhibition) or by administering autologous immune 
cells (DCs or T cells) that are modulated and/or expanded ex vivo. Over the last decade, 
immunotherapy has revolutionized cancer treatment and showed unprecedented clinical 
responses. Checkpoint inhibitors have quickly moved to first- or second-line treatment in 
several cancer types, and many more immunotherapeutic strategies are showing promise 
in clinical trials. In addition, conventional cancer treatments such as radiotherapy and 
chemotherapy, may also have immune modulatory effects that play an important role in 
their efficacy.
Not all patients respond equally well to cancer treatment, and there is still a large fraction 
of patient that does not respond. Currently, a great challenge in cancer treatment is to 
determine the right therapy for the right patient. Biomarkers for response and solid data 
for rational combination strategies are highly needed to improve outcomes. In this thesis 
we aimed to increase our understanding of the role of the immune system and its clinical 
value in patients with thoracic malignancies during treatment (chapter 1).
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We used fl ow cytometry to examine the immune profi le in the peripheral blood of cancer 
patients. In chapter 2 we studied a cohort of over 200 stage IV NSCLC patients from a 
randomized controlled trial that were treated with paclitaxel, carboplatin and bevacizumab 
(PCB) with or without additional nitroglycerin patch (the NVALT12 study). There was no 
diff erence in progression-free survival (PFS) or overall survival (OS) between the two 
treatment arms. In these patients, we assessed proportions of myeloid-derived suppressor 
cells (MDSC) and the expression of the inhibitory receptor immunoglobulin-like transcript 
(ILT) 3. MDSCs are a heterogeneous population of immune cells that play an important role 
in immune suppression and are elevated in many cancer patients. ILT3 may be expressed 
on DCs, where it plays a role in immune tolerance. It can interact with a still unidentifi ed 
ligand on T cells and thereby induce T cell anergy, regulatory T cells or T suppressor cells. 
We showed that pretreatment proportions of circulating MDSCs are correlated to worse 
survival. Moreover, we showed for the fi rst time that ILT3 is expressed by a subset of MDSCs, 
and that this expression is correlated with reduced overall survival in patients with increased 
proportions of MDSCs. Expression of ILT3 indicates an additional immune suppressive 
mechanism employed by MDSCs, that is relevant for clinical outcomes in stage IV NSCLC 
patients and may be an attractive target for treatment.
In early stage NSCLC, patients are mostly treated with surgery or stereotactic ablative body 
radiotherapy (SABR). We hypothesized that these diff erent treatments would have a distinct 
eff ect on the immune system. In chapter 3, we compared T cell activation in peripheral 
blood of 13 patients that were treated with surgery and ten patients treated with SABR. We 
collected blood samples before treatment, and 1, 2, 3 and 6 weeks after start of treatment. 
In the fl ow cytometry analysis, several activation markers of T cells were included, as well as 
markers to defi ne T cell subsets (CD8, CD4, FoxP3). Patients treated with surgery showed a 
small and temporary increase in proliferating T cells (characterized by Ki67 expression). In 
SABR treated patients, we observed a signifi cant increase in proliferation of CD4 and CD8 
T cells that remained up to week 6 and was accompanied by an increase in programmed 
death receptor-1 (PD-1) expression, which is a co-inhibitory surface molecule upregulated 
on T cells upon antigen recognition. Interestingly, within the SABR group, the majority of 
patients showed T cell activation, while other patients did not. It remains to be investigated 
whether this is related to recurrence-free survival in these patients. The increase in T cell 
activation and in particular PD-1 expression after treatment with SABR provides a rationale 
to combine radiotherapy with PD-1 blockade, to further enhance or prolong T cell activation.
In chapter 4 we assessed the immune modulatory eff ect of the PCB combination in the 
NVALT12 study. This treatment is a standard treatment for stage IV non-squamous NSCLC 
patients. With immunotherapy as a new treatment modality for this group of patients 
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and the possibility of combination of the different treatment modalities, it is important 
to understand the immune modulatory effect of this chemotherapeutic regimen. We 
interrogated the peripheral blood immune profile of these patients before and during 
treatment at week 0, 3 and 6. We assessed proportions of T cells, B cells and monocytes, and 
measured several activation markers on T cells by flow cytometry. We observed a significant 
increase in Ki67-expressing, proliferating CD8 T cells after treatment. These proliferating CD8 
T cells were mainly of the effector memory phenotype and had an increased expression of 
the inhibitory receptors PD-1 and CTLA4. Interestingly, a similar subset of proliferating CD8 
T cells has been shown to be induced by PD-1/ PD-1 ligand 1 (PD-L1) inhibitors in NSCLC and 
melanoma patients. In melanoma, the ratio of proliferating CD8 T cells over tumor burden, 
was positively associated with a response to treatment. Increases in proliferating T cells in 
our study, did not correlate to improved overall survival, but may increase sensitivity to 
checkpoint inhibition.
Most immune monitoring efforts focus on the relation of a specific immune subset to 
response to therapy or patient survival. In chapter 5, we hypothesized that the combination 
of several of these factors would improve prediction of clinical outcome. Flow cytometry is 
the most frequently used technique to investigate immune populations and this technique 
is continuously improving, for example with an increasing number of markers that can be 
measured simultaneously on a single cell. To use the flow cytometry data to study the 
relation between the pretreatment immune profile and survival of NSCLC patients, a suitable 
data analysis pipeline should be used. We used the FloReMi pipeline, which is a recently 
developed semi-automatic analysis pipeline that extracts features from flow cytometry data 
and uses machine learning to build a prediction model using the most relevant features. 
From three flow cytometry panels with 12-16 markers each, over 60 thousand features were 
extracted from the raw data, reflecting frequencies and mean fluorescence intensity values 
(MFIs) of each possible subset based on the available markers. Automatically extracted 
populations were highly correlated to manually gated populations. A random-forest survival 
(RFS) model with the selected non-redundant features was trained and evaluated using 
five-fold cross-validation. The RFS model derived from the FloReMi pipeline showed a better 
performance than a model trained with manually obtained features, and its prediction was 
significantly associated with actual overall survival. The top feature that was associated with 
survival, was the frequency of HLA-DR-CD33+ myeloid cells. We showed that FloReMi is a 
useful method to extract large numbers of reliable features from flow cytometric data that 
can be used to predict survival. However, the accuracy of prediction is too low to be used 
in clinical practice. Rather, this method may be used for more exploratory purposes and 
identify novel immune subsets with clinical relevance.
Pauline_Proefschrift.indd   166 29/11/2019   09:10:59
167
English Summary
In chapter 6 of this thesis we set out to improve immunotherapy for patients with malignant 
pleural mesothelioma (MPM). In the past, our research group has developed DC vaccination 
as a novel treatment for MPM. Autologous ex vivo cultured DCs pulsed with tumor cell lysate 
can activate tumor-specifi c T cells leading to an eff ective anti-tumor immune response. This 
treatment has been shown to be safe in patients. However, one of the main limitations of 
this treatment was the limited amount or quality of tumor material that could be obtained, 
which led a majority of patients being excluded for treatment. In chapter 6 we used 
allogeneic tumor cell lysates derived from cell lines as an alternative source for pulsing 
the DCs. Using two mesothelioma mouse models, we studied survival and induction of a 
tumor-specifi c T cell response and showed comparable effi  cacy between allogeneic and 
autologous tumor cell lysates. Subsequently, a fi rst-in-human clinical trial was initiated in 
which nine patients were treated with increasing doses of MesoPher treatment, consisting 
of autologous monocyte-derived DCs pulsed with lysate of fi ve human mesothelioma cell 
lines. No dose-limiting toxicities were identifi ed in any of the cohorts treated with 10, 25 
or 50 million DCs. Median PFS was 8.8 months and median (OS) was not reached with a 
median follow up of 22.8 months. Two patients in the 25 million DC cohort showed a partial 
response. These fi ndings show the safety and feasibility of MesoPher treatment. The next 
step will be the evaluation of effi  cacy in a subsequent phase III clinical trial.
In chapter 7 we monitored immune responses in the peripheral blood of MPM patients 
treated with MesoPher during the fi rst-in-human clinical trial to increase our understanding 
of the mechanism of action of DC immunotherapy and to identify markers that are suitable 
for immune monitoring in upcoming clinical trials. Peripheral blood was collected before 
start of treatment, and after each of the fi rst three doses of DC immunotherapy. We 
determined the number and relative proportions of T cells, B cells and monocytes, and 
further characterized T cell subsets with several activation markers, and expression of co-
stimulatory and co-inhibitory molecules. Furthermore, mesothelin-specifi c T cells were 
monitored as an indicator of tumor-reactive T cells and T cell receptor (TCR) diversity was 
evaluated by TCRb gene PCR assays. An increase in the number of total B cells, CD4 and 
CD8 T cells was observed in patients six weeks after the start of treatment. No changes 
were seen in mesothelin-specifi c T cells or TCRb diversity. CD4 T cells showed increased 
expression of human leukocyte antigen (HLA)-DR and PD-1 after two weeks, and increased 
expression of inducible T cell co-stimulator (ICOS) after 6 weeks, indicating an induction of T 
cell activation. CD8 T cells showed a slightly increased expression of lymphocyte-activation 
gene (LAG)-3 after two weeks. Our fi ndings indicate that systemic immune activation is 
induced by DC immunotherapy, which is mainly refl ected by an increased activation of CD4 
T cells. These markers may be incorporated in immune monitoring eff orts in future clinical 
trials to evaluate their predictive potential and use as biomarker for response.
9
Pauline_Proefschrift.indd   167 29/11/2019   09:10:59
168
Chapter 9
Immune monitoring in peripheral blood provides insights in the immune modulatory effects 
of cancer treatment. There are considerable differences in the immune modulatory effects 
of surgery, radiotherapy, chemotherapy and immunotherapy and various immune subsets 
impact clinical outcomes in patients with thoracic malignancies, as described in chapters 
2-7. While peripheral blood as a source for immune monitoring certainly has limitations, it 
provides a relatively non-invasive approach for serial collection of immune cells to study 
immune activation. Immune monitoring should be implemented as much as possible in 
future clinical trials to allow for reverse translation with a focus on the role of the immune 
system, which is needed to design and improve novel treatment strategies and combination, 
especially in the current era of emerging immunotherapies (chapter 8).
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Kanker ontwikkelt zich als normale cellen van het lichaam mutaties ondergaan die leiden tot 
ongecontroleerde celdeling en invasie van de omliggende weefsels. In vroege stadia van 
kanker bevindt de tumor zich nog slecht op één locatie, maar kan zich verder ontwikkelen 
tot een verder stadium met metastaseringen waarbij de kanker zich ook naar andere 
organen verspreidt. De overlevingskansen van een patiënt verminderen drastisch naarmate 
de kanker in een verder stadium komt. Er bestaan verschillende types kanker, afhankelijk 
van de oorsprong van de in kanker veranderde cel. Dit proefschrift focust zich op de 
thoracale maligniteiten niet-kleincellig longcarcinoom en mesothelioom. Niet-kleincellig 
longcarcinoom zorgt wereldwijd voor de hoogste kanker-gerelateerde sterfte en komt voort 
uit cellen van de long. Mesothelioom is een kanker van het longvlies en wordt veroorzaakt 
door blootstelling aan asbest. Ondanks de verscheidene behandelingen die over de laatste 
decennia zijn ontwikkeld, kunnen de meeste patiënten met longkanker en mesothelioom 
niet genezen worden.
Het immuunsysteem speelt een erg belangrijke rol bij de bescherming tegen kanker. 
Tumor-antigenen die vrijkomen in het tumor micromilieu kunnen opgenomen worden door 
dendritische cellen (DCs) en gepresenteerd aan T-lymfocyten in de lymfeklieren. De T-cellen 
die specifi ek deze tumorantigenen kunnen herkennen worden hierdoor geactiveerd en gaan 
zich vermeerderen om vervolgens naar de tumor te reizen waar zij deze kunnen herkennen 
en celdood kunnen induceren. Kanker gebruikt echter verschillende methoden om aan 
het immuunsysteem te ontsnappen of deze anti-tumor immuunrespons te onderdrukken.
Het doel van immuuntherapie is om deze anti-tumor immuunrespons te versterken, 
bijvoorbeeld door remmende moleculen op de T-cellen te blokkeren (ook wel ‘checkpoint 
inhibitie’ genoemd) of door autologe immuuncellen (DCs of T-cellen) die buiten het 
lichaam zijn gemodifi ceerd, terug te geven aan een patiënt. In de laatste decennia heeft 
immuuntherapie een revolutie teweeggebracht in de behandeling van kanker, met nog 
niet eerder vertoonde klinische responsen. Checkpoint inhibitors hebben zich in rap tempo 
een weg gebaand naar eerste- of tweedelijns therapie bij verscheidene soorten kanker, en 
nog veel meer immunotherapeutische strategieën laten veelbelovende resultaten zien in 
klinische studies. Daarnaast hebben de conventionele kankertherapieën zoals radiotherapie 
en chemotherapie ook een eff ect op het immuunsysteem wat een belangrijke rol kan spelen 
in hun eff ectiviteit.
Niet elke patiënt reageert even goed op kankertherapie en er is nog steeds een grote groep 
patiënten die niet reageert. Momenteel is een grote uitdaging in de behandeling van kanker 
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het kiezen van de juiste therapie voor de juiste patiënt. Biomarkers voor respons en solide 
data voor het rationeel combineren van verschillende medicijnen zijn hard nodig voor het 
verbeteren van de behandelingsuitkomst voor patiënten. In dit proefschrift hebben we als 
doel gesteld beter te begrijpen wat de rol van het immuunsysteem en de klinische waarde 
hiervan is in patiënten met thoracale maligniteiten tijdens hun behandeling (Hoofdstuk 1).
We hebben flowcytometrie gebruikt om het immuunprofiel te bestuderen in het bloed van 
kankerpatiënten. In hoofdstuk 2 onderzochten we een cohort van meer dan 200 patiënten 
met stadium IV niet-kleincellig longcarcinoom van een gerandomiseerd gecontroleerde 
studie, waarbij de patiënten behandeld waren met paclitaxel, carboplatine en bevacizumab 
(PCB) met of zonder additionele nitroglycerinepleister (de NVALT12 studie). Er was geen 
verschil in progressievrije overleving of algehele overleving tussen de behandelarmen. In 
deze patiënten hebben we de relatieve aantallen van myeloïde suppressorcellen (MDSC) 
bepaald, en de expressie van de inhibitoire receptor immunoglobulin-like transcript (ILT) 
3. MDSCs zijn een heterogene groep immuuncellen die een belangrijke rol spelen in 
immuunsuppressie en verhoogd zijn in veel kankerpatiënten. ILT3 kan tot expressie komen 
op DCs waarbij het een rol speelt in immuuntolerantie. Het kan een interactie aangaan 
met een nog onbekende ligand op T-cellen waarbij het T-cel anergie, regulatoire T-cellen 
of T suppressorcellen kan stimuleren. We hebben laten zien dat de relatieve aantallen 
circulerende MDSCs voor de start van behandeling gecorreleerd zijn met een verminderde 
overleving. Daarnaast hebben we voor het eerst aangetoond dat ILT3 tot expressie gebracht 
wordt door een subset van MDSCs en dat deze expressie gecorreleerd is aan verminderde 
overleving, in de patiënten met verhoogde aantallen MDSCs. Expressie van ILT3 wijst op een 
additioneel immunosuppressief mechanisme dat gebruikt wordt door MDSCs en relevant 
is voor de klinische uitkomst in stadium IV longkankerpatiënten. ILT3 zou een aantrekkelijk 
target kunnen zijn voor een nieuwe therapie.
Vroeg stadium niet-kleincellig longcarcinoom wordt meestal behandeld met een operatie of 
met stereotactische bestraling (radiotherapie). Onze hypothese was dat deze behandelingen 
een verschillend effect hebben op het immuunsysteem. In hoofdstuk 3 vergeleken we 
de activatie van T-cellen in bloed van dertien patiënten die geopereerd werden en tien 
patiënten die bestraald werden. We verzamelden bloed voor de start van behandeling 
en 1, 2, 3 en 6 weken na start van de behandeling. In de analyses middels flowcytometrie 
werden verschillende markers van T-cel activatie meegenomen, naast de markers die T-cel 
subsets definiëren (CD8, CD4, FoxP3). Bij de patiënten die geopereerd waren, was een 
kleine en tijdelijke stijging in delende T-cellen (gekarakteriseerd door Ki67 expressie) te 
zien. In de bestraalde patiënten zagen we een significante toename in deling van CD4 
en CD8 T cellen die stabiel bleef tot week 6 en die samenging met een toegenomen 
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expressie van programmed death receptor-1 (PD-1), een co-inhibitoir oppervlaktemolecuul 
dat opgereguleerd wordt nadat de T-cel een antigen herkent. Binnen de groep van 
bestraalde patiënten liet de meerderheid van patiënten T cel activatie zien, terwijl dit in 
een aantal andere patiënten niet geobserveerd werd. Het moet nog onderzocht worden 
of dit gerelateerd is aan het ontstaan van recidieven in deze patiënten. De toename in 
T-cel activatie en met name de expressie van PD-1 na bestraling biedt een motivering om 
radiotherapie te combineren met PD-1 remmers, om deze T-cel activatie te versterken of 
te verlengen.
In hoofdstuk 4 bestudeerden we het immunomodulerende effect van de 
combinatiebehandeling PCB in de NVALT12 studie. Deze behandeling is een 
standaardbehandeling voor patiënten met stadium IV niet-kleincellig longcarcinoom dat niet 
van het plaveiselcelsubtype is. Nu er met immuuntherapie een nieuwe behandelmodaliteit 
beschikbaar is gekomen en daarbij meer mogelijkheden tot combinatietherapie, is het 
belangrijk om de immunomodulerende eigenschappen van deze chemotherapie te 
begrijpen.
We bestudeerden het immuunprofi el van deze patiënten in bloed vooraf en gedurende 
de behandeling op week 0, 3 en 6. We bepaalden relatieve aantallen T cellen, B-cellen en 
monocyten en verscheidene activatiemarkers op T-cellen door middel van fl owcytometrie. 
We observeerden een signifi cante toename in delende (Ki67-positieve) CD8 T cellen na 
behandeling. Deze delende CD8 T cellen waren met name van het eff ector memory subtype 
en hadden verhoogde expressie van de co-inhibitoire receptoren PD-1 en CTLA-4. Het 
is eerder aangetoond dat een vergelijkbare subset van delende CD8 T cellen toeneemt 
na behandeling met PD-1 en PD-1 ligand 1 (PD-L1) remmers in longkanker en melanoom 
patiënten. Bij melanoom is een verhoogde ratio van delende CD8 T cellen over tumorgrootte, 
geassocieerd met betere respons op therapie. De toegenomen delende T-cellen in onze 
studie waren niet gecorreleerd met een verbeterde overleving, maar zou hierdoor wel de 
gevoeligheid voor checkpointremmers kunnen verhogen.
De meeste immunomonitorstudies concentreren zich op de relatie tussen een specifi eke 
immuunsubset en de respons op therapie of overleving van de patiënt. In hoofdstuk 
5 hadden we de hypothese dat een combinatie van meerdere van deze factoren een 
verbeterde voorspelling zou kunnen geven op de klinische uitkomst. Flowcytometrie 
is de meest gebruikte techniek om immuunpopulaties te bestuderen en deze techniek 
ontwikkelt zich snel, wat zich onder andere uit in een toenemende hoeveelheid markers 
die tegelijkertijd gemeten kunnen worden op een individuele cel. Om fl owcytometriedata 
te gebruiken om de relatie tussen het immuunprofi el voor behandeling en de overleving 
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van longkankerpatiënten te onderzoeken is een geschikte data-analysemethode nodig. 
We gebruikten de recent ontwikkelde FloReMi methode, wat een semiautomatische 
analysemethode is waarbij variabelen uit flowcytometriedata geëxtraheerd worden en 
machine learning wordt toegepast om een predictiemodel te genereren die gebruik maakt 
van de meest relevante variabelen. Van drie sets ruwe flowcytometriedata met elk 12-16 
markers, werden meer dan 60 duizend variabelen verkregen, die een afspiegeling waren 
van de percentages en gemiddelde fluorescentie-intensiteiten (MFIs) van elke mogelijke 
subset gebaseerd op de beschikbare markers. Deze automatisch verkregen variabelen 
waren sterk gecorreleerd met de handmatig geanalyseerde variabelen. Een random-forest 
survival (RFS) model met geselecteerde niet-overlappende variabelen werd getraind en 
geëvalueerd met een vijfvoudige crossvalidatie. Het RFS-model uit de FloReMi methode 
presteerde beter dan een RFS-model getraind met handmatig verkregen variabelen en 
de predictie was significant gecorreleerd aan de daadwerkelijke algehele overleving van 
patiënten. De meest voorspellende variabele was het percentage HLA-DR-CD33+ myeloïde 
cellen. We hebben laten zien dan FloReMi een bruikbare methode is om grote aantallen 
betrouwbare variabelen uit flowcytometriedata te halen, die gebruikt kunnen worden voor 
de predictie van overleving. De accuraatheid van deze predictie is echter te laag om in de 
klinische praktijk gebruikt te worden. Deze methode kan dus beter gebruikt worden voor 
exploratieve doeleinden en het identificeren van nog onbekende immuunpopulaties met 
klinische relevantie.
In hoofdstuk 6 van dit proefschrift stelden we ons tot doel om immuuntherapie voor 
patiënten met maligne pleuraal mesothelioom (MPM) te verbeteren. In het verleden heeft 
onze onderzoeksgroep een DC-vaccinatie ontwikkeld als nieuwe therapie voor MPM. 
Autologe gekweekte DCs die zijn beladen met tumorcellysaat kunnen tumor-specifieke 
T-cellen activeren en daarbij zorgen voor een effectieve anti-tumor immuunrespons. Het is 
aangetoond dat deze behandeling veilig is voor patiënten. Eén van de grootste limitaties van 
deze behandeling was echter de beperkte hoeveelheid of kwaliteit van het tumormateriaal 
dat verkregen kon worden, waardoor veel patiënten uitgesloten werden voor behandeling. 
In hoofdstuk 6 gebruikten we allogeen tumorcellysaat afkomstig van cellijnen als een 
alternatieve bron om de DCs mee te beladen. We onderzochten de overleving en het 
ontstaan van een tumor-specifieke T-celrespons in twee verschillende muismodellen voor 
mesothelioom, en lieten hierbij zien dat het gebruik van allogeen materiaal voor een 
vergelijkbare effectiviteit zorgde als het gebruik van autologe cellysaten.
Vervolgens startten we een fase I klinische studie waarbij de therapie MesoPher voor het 
eerst getest werd in mensen. Negen patiënten werden behandeld met een toenemende 
dosis MesoPher, bestaande uit autologe, vanuit monocyt gekweekte, DCs beladen met de 
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lysaten van vijf humane mesothelioomcellijnen. Er werden in geen van de cohorten van 10, 
25 en 50 miljoen DCs dosis-limiterende toxiciteit gevonden. De mediaan van progressievrije 
overleving was 8,8 maanden, en de mediaan van algehele overleving werd niet bereikt met 
een gemiddelde opvolging van 22,8 maanden. Twee patiënten die een dosis van 25 miljoen 
DCs ontvingen, ondergingen een partiele respons. Deze resultaten bevestigen de veiligheid 
en haalbaarheid van behandeling met MesoPher. De volgende stap zal zijn de eff ectiviteit 
van deze behandeling te bepalen in een opvolgende fase III klinische studie.
In hoofdstuk 7 monitorden we de immuunresponsen in bloed van de MPM-patiënten 
die behandeld waren met MesoPher in de fase I klinische studie om tot een beter begrip 
te komen van het werkingsmechanisme van DC-immuuntherapie en om markers te 
identifi ceren die geschikt zijn om te monitoren in de toekomstige klinische studies. Perifeer 
bloed werd verzameld voorafgaand aan de behandeling, en na de eerste drie doses van 
DC-immunotherapie. We bepaalden de absolute en relatieve aantallen T cellen, B-cellen 
en monocyten, en karakteriseerden de verschillende T-cel subsets door de expressie van 
verschillende activatiemarkers en co-stimulatoire en co-inhibitoire receptoren. Daarnaast 
monitorden we de aanwezigheid van mesotheline-specifi eke T-cellen als een indicator 
van tumor-reactieve T-cellen, en bepaalden we T-cel receptor (TCR) diversiteit door een 
TCRb PCR-analyse. Zes weken na de start van de behandeling zagen we een toename 
in de absolute aantallen B cellen en CD4 en CD8 T cellen. Er waren geen veranderingen 
in de mesotheline-specifi eke T-cellen en de TCRb diversiteit. Er was een toegenomen 
expressie van human leukocyte antigen (HLA)-DR en PD-1 na twee weken en een 
toegenomen expressie van inducible T cell co-stimulator (ICOS) na zes weken, wat wijst op 
toegenomen T-cel activatie. CD8 T cellen lieten een lichte verhoging zien in de expressie 
van lymphocyte-activation gene (LAG)-3 na twee weken. Deze bevindingen duiden erop 
dat DC-immunotherapie zorgt voor een systemische immuunactivatie die zich met name 
uit in activatie van CD4 T cellen. Deze markers zouden gebruikt kunnen worden voor 
het immunomonitoren in toekomstige klinische studies om hun voorspellende waarde en 
bruikbaarheid als biomarker voor respons te evalueren.
Immunomonitoren in bloed kan inzichten geven in de immunomodulerende eff ecten van 
kankerbehandeling. Er bestaan aanmerkelijke verschillen tussen de immunomodulerende 
eff ecten van operatie, radiotherapie, chemotherapie en immuuntherapie en de verschillende 
immuunpopulaties hebben een eff ect op de klinische uitkomst van patiënten met thoracale 
maligniteiten, zoals beschreven in de hoofdstukken 2-7. Al kent perifeer bloed als bron voor 
immunomonitoren zeker zijn beperkingen, het biedt ook een relatief niet-invasieve manier 
om op meerdere momenten in de tijd immuuncellen te verkrijgen om immuunactivatie 
te bestuderen. Immunomonitoren moet daarom zo veel mogelijk geïmplementeerd 
Nederlandse Samenvatting
9
Pauline_Proefschrift.indd   173 29/11/2019   09:11:00
174
Chapter 9
worden in klinische studies om ervoor te zorgen dat we, met een focus op de rol van het 
immuunsysteem, klinische gebeurtenissen kunnen vertalen naar wetenschappelijke kennis 
die nodig is om nieuwe en verbeterde (combinatie)therapieën te ontwikkelen, vooral in het 
huidige tijdperk van opkomende immuuntherapieën.
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